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ABSTRACT	  
Transcatheter	  cardiovascular	  interventions	  are	  an	  increasingly	  attractive	  alternative	  to	  open-­‐
chest	  surgery.	  Fluoroscopy,	  historically	  the	  cornerstone	  of	  imaging	  guidance	  for	  
transcatheter	  procedures,	  has	  fundamental	  limitations	  when	  operating	  in	  three-­‐dimensions	  
and	  cannot	  visualise	  soft	  tissue.	  Structural	  heart	  and	  electrophysiology	  interventions	  require	  
precise	  device	  localisation	  in	  space	  and	  direct	  visualization	  of	  anatomic	  structures.	  
Cardiovascular	  magnetic	  resonance	  imaging	  (CMR)	  offers	  a	  number	  of	  tools	  that	  may	  be	  
ideally	  suited	  to	  these	  advanced	  applications:	  excellent	  soft	  tissue	  visualization	  in	  unlimited	  
imaging	  planes,	  real-­‐time	  procedural	  guidance,	  three-­‐dimensional	  imaging,	  quantification	  of	  
blood	  flow	  and	  tissue	  characterization	  techniques.	  
In	  this	  thesis	  we	  describe	  four	  original	  interventions	  and	  explore	  the	  role	  of	  CMR	  at	  each	  
stage	  of	  the	  development	  process:	  defining	  the	  clinical	  problem,	  designing	  potential	  
solutions,	  building	  and	  testing	  prototypes,	  and	  evaluating	  device	  performance	  in	  pre-­‐clinical	  
experiments.	  The	  first	  structural	  heart	  intervention,	  transatrial	  intrapericardial	  tricuspid	  
annuloplasty,	  is	  a	  percutaneous	  therapy	  for	  functional	  tricuspid	  regurgitation.	  CMR	  was	  used	  
to	  determine	  device	  configuration	  and	  evaluate	  device-­‐imparted	  geometric	  change	  to	  the	  
heart.	  The	  second	  structural	  heart	  intervention,	  intentional	  right	  atrial	  exit	  and	  pericardial	  
CO2	  insufflation,	  facilitates	  easy	  and	  safe	  subxiphoid	  access	  to	  the	  naïve	  pericardial	  space.	  
CMR	  was	  used	  to	  quantify	  pericardial	  effusion	  volume	  over	  time,	  a	  key	  parameter	  that	  is	  
impossible	  to	  measure	  with	  fluoroscopy	  or	  echocardiography.	  The	  third	  structural	  heart	  
intervention,	  fully	  percutaneous	  transthoracic	  left	  atrial	  entry	  and	  closure,	  is	  a	  potential	  
access	  route	  to	  deliver	  large	  transcatheter	  prostheses	  to	  the	  mitral	  valve.	  Transthoracic	  
trajectories	  to	  the	  left	  atrium	  were	  planned	  and	  the	  procedure	  was	  performed	  using	  real	  
time	  CMR	  guidance	  and	  active	  visualization	  devices.	  The	  fourth	  electrophysiology	  
intervention,	  transcatheter	  myocardial	  needle	  chemoablation	  was	  also	  performed	  under	  
CMR	  guidance,	  enabling	  arrhythmic	  substrate	  and	  ablation	  lesion	  visualization	  in	  real	  time.	  
The	  purpose	  of	  this	  thesis	  is	  to	  explore	  the	  role	  of	  CMR	  in	  the	  development	  of	  each	  of	  these	  
novel	  transcatheter	  interventions.	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Chapter	  1. Summary	  
1.1 Background	  
Multimodality	  imaging	  has	  enabled	  procedures	  that	  were	  historically	  performed	  through	  
open	  chest	  surgery	  to	  be	  accomplished	  using	  transcatheter	  techniques.	  Fluoroscopy	  and	  
echocardiography	  are	  the	  most	  commonly	  used	  modalities	  in	  catheterization	  laboratories	  
today,	  but	  increasingly	  complex	  interventions	  require	  more	  advanced	  capabilities.	  The	  
development	  of	  new	  cardiovascular	  interventions	  requires	  at	  a	  minimum	  (1)	  understanding	  
of	  normal	  and	  abnormal	  anatomy	  in	  order	  to	  design	  novel	  devices;	  (2)	  real-­‐time	  three-­‐
dimensional	  imaging	  for	  procedural	  guidance;	  and	  (3)	  post-­‐procedural	  evaluation	  of	  the	  
results	  of	  therapy.	  CMR	  offers	  a	  number	  of	  unique	  capabilities	  that	  could	  facilitate	  novel	  
cardiovascular	  interventions,	  including	  3D,	  flow,	  real-­‐time	  and	  late	  gadolinium	  enhancement	  
CMR.	  Feasibility	  of	  real-­‐time	  CMR	  to	  guide	  diagnostic	  cardiac	  catheterization,	  
electrophysiology	  studies	  and	  simple	  structural	  interventions	  has	  been	  demonstrated	  in	  the	  
last	  decade.	  Innovative	  real-­‐time	  CMR	  pulse	  sequences	  and	  active	  and	  passive	  visualization	  
MRI-­‐conditional	  devices	  should	  enable	  more	  complex	  interventions.	  Even	  if	  fluoroscopy	  
remains	  the	  preferred	  modality	  for	  procedural	  guidance,	  CMR	  can	  offer	  additional	  
information	  to	  plan	  interventions	  and	  evaluate	  the	  results.	  
In	  this	  thesis,	  the	  role	  of	  CMR	  is	  explored	  in	  the	  development	  of	  four	  different	  novel	  
transcatheter	  cardiovascular	  interventions.	  These	  four	  interventions	  address	  clinical	  
problems	  for	  which	  there	  is	  currently	  no	  or	  unsatisfactory	  transcatheter	  solutions:	  (1)	  the	  
treatment	  of	  tricuspid	  regurgitation;	  (2)	  access	  to	  the	  naïve	  pericardium	  for	  structural	  or	  
electrophysiology	  procedures;	  (3)	  wide-­‐bore	  access	  to	  the	  left	  atrium	  to	  deliver	  large	  mitral	  
prostheses;	  and	  (4)	  ablation	  in	  the	  thick	  ventricular	  myocardium	  for	  rhythm	  disorders.	  
It	  is	  important	  to	  recognise	  the	  limitations	  of	  interventional	  CMR,	  in	  terms	  of	  feasibility	  of	  
clinical	  translation	  of	  these	  novel	  interventions.	  While	  CMR	  may	  offer	  advantages	  during	  the	  
design,	  testing	  and	  refinement	  process,	  the	  limited	  availability	  of	  interventional	  CMR	  cath	  
labs	  and	  lack	  of	  commercially	  available	  MRI-­‐conditional	  guidewires	  and	  catheters	  remains	  a	  
serious	  obstacle.	  Therefore	  it	  is	  important	  to	  distinguish	  the	  benefit	  of	  CMR	  during	  the	  
development	  process	  and	  the	  reality	  of	  clinical	  translation	  using	  widely	  available	  imaging	  
modalities	  such	  as	  echocardiography	  and	  X-­‐ray	  fluoroscopy.	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1.2 Overview	  of	  thesis	  and	  chapter	  description	  
This	  thesis	  is	  submitted	  as	  a	  ‘thesis	  incorporating	  publication’	  in	  accordance	  with	  the	  
King’s	  College	  guidelines.	  
Clinical	  roll	  out	  of	  real-­‐time	  MRI	  guidance	  for	  interventional	  cardiovascular	  procedures	  
remains	  limited	  by	  availability	  of	  guidewires,	  catheters	  and	  other	  interventional	  devices.	  
Nonetheless,	  CMR	  may	  offer	  unique	  capabilities	  in	  the	  development	  process	  even	  if	  CMR	  is	  
not	  the	  imaging	  modality	  of	  choice	  for	  eventual	  clinical	  translation,	  particularly	  for	  more	  
complex	  interventions	  that	  disrupt	  traditional	  vascular	  boundaries.	  To	  explore	  the	  role	  of	  
CMR	  in	  this	  process,	  we	  selected	  three	  novel	  cardiovascular	  interventions	  that	  require	  the	  
operator	  to	  intentionally	  exit	  the	  heart	  to	  access	  the	  pericardium,	  navigate	  within	  the	  
pericardium	  to	  encircle	  the	  heart,	  and	  traverse	  the	  thorax	  to	  access	  the	  left	  atrium.	  Finally	  
we	  selected	  a	  procedure	  that	  simply	  could	  not	  be	  performed	  safely	  and	  effectively	  using	  X-­‐
ray	  fluoroscopy	  or	  echocardiography	  guidance	  to	  highlight	  how	  CMR	  could	  be	  a	  truly	  
disruptive	  technology	  in	  the	  future.	  
Chapter	  2	  comprises	  an	  overview	  and	  literature	  review	  of	  interventional	  CMR.	  This	  is	  word	  
for	  word	  the	  chapter	  to	  be	  published	  in	  the	  forthcoming	  2nd	  edition	  of	  ‘Cardiovascular	  
Magnetic	  Resonance	  Imaging’	  (Humana	  Press,	  New	  York)	  edited	  by	  Dr	  Kwong,	  Dr	  Heydari	  
and	  Dr	  Jerosch-­‐Herold	  due	  for	  publication	  in	  2016.	  
Chapter	  3	  describes	  a	  transcatheter	  device	  and	  methods	  to	  treat	  functional	  tricuspid	  
regurgitation.	  The	  original	  research	  manuscript	  is	  presented	  as	  published	  in	  the	  ‘Journal	  of	  
the	  American	  College	  of	  Cardiology:	  Cardiovascular	  Interventions’	  in	  2015.	  Two	  related	  
patent	  applications	  covering	  devices	  and	  methods	  for	  tricuspid	  annuloplasty	  can	  be	  found	  in	  
the	  appendices.	  CMR	  played	  a	  critical	  role	  in	  understanding	  the	  anatomy	  of	  the	  
atrioventricular	  valves,	  quantitatively	  assessing	  device	  tensioning,	  and	  measuring	  the	  
treatment	  effect	  in	  naïve	  and	  porcine	  animal	  models.	  Most	  procedure	  steps	  were	  performed	  
using	  X-­‐ray	  fluoroscopy	  guidance	  and	  for	  clinical	  translation,	  we	  expect	  tensioning	  could	  be	  
performed	  using	  echocardiography	  guidance,	  titrating	  tension	  to	  the	  degree	  of	  tricuspid	  
regurgitation.	  
Chapter	  4	  describes	  a	  technique	  for	  facilitating	  sub-­‐xiphoid	  access	  to	  the	  naïve	  pericardial	  
space	  that	  involves	  right	  atrial	  appendage	  exit	  with	  a	  microcatheter	  and	  insufflation	  of	  the	  
pericardial	  space	  with	  CO2	  to	  separate	  pericardial	  layers.	  The	  original	  pre-­‐clinical	  research	  
manuscript	  is	  presented	  as	  published	  in	  ‘Catheterization	  and	  Cardiovascular	  Interventions’	  in	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2014.	  Our	  report	  of	  the	  first	  human	  experience	  of	  this	  technique	  is	  presented	  as	  published	  in	  
the	  ‘Journal	  of	  the	  American	  College	  of	  Cardiology:	  Clinical	  Electrophysiology’	  in	  2015.	  In	  
order	  to	  assure	  safety	  of	  the	  technique	  before	  clinical	  translation,	  we	  needed	  to	  confirm	  in	  
pre-­‐clinical	  experiments	  that	  pericardial	  bleeding	  was	  negligible.	  This	  required	  serial	  non-­‐
invasive	  accurate	  measurements	  of	  pericardial	  fluid	  volume.	  CMR	  is	  an	  ideal	  imaging	  
modality	  for	  this	  application.	  Once	  safety	  was	  assured,	  such	  measurements	  were	  no	  longer	  
required	  for	  clinical	  translation,	  as	  a	  pericardial	  drain	  was	  left	  in	  place	  after	  each	  procedure.	  
Chapter	  5	  describes	  an	  alternative	  wide-­‐bore	  access	  route	  to	  the	  mitral	  valve	  to	  deliver	  large	  
transcatheter	  prostheses	  using	  real-­‐time	  MRI	  guidance.	  The	  original	  research	  manuscript	  is	  
presented	  as	  published	  in	  ‘Circulation:	  Cardiovascular	  Interventions’	  in	  2015.	  The	  procedure	  
was	  developed	  using	  real-­‐time	  CMR,	  because	  it	  permits	  imaging	  in	  unlimited	  planes	  and	  full	  
visualization	  of	  all	  soft	  tissue	  structures.	  However,	  once	  optimal	  trajectories	  were	  
established	  and	  procedure	  steps	  refined,	  we	  were	  able	  to	  replicate	  the	  procedure	  using	  X-­‐
ray	  fluoroscopy	  augmented	  with	  rotational	  angiography,	  which	  should	  enable	  easier	  clinical	  
implementation.	  
Chapter	  6	  described	  a	  completely	  new	  approach	  to	  myocardial	  ablation	  to	  treat	  ventricular	  
arrhythmias	  by	  chemoablation	  using	  acetic	  acid	  rather	  than	  radiofrequency	  energy.	  The	  
procedure	  is	  performed	  under	  real-­‐time	  MRI	  guidance	  enabling	  instantaneous	  depiction	  of	  
irreversible	  necrosis	  and	  overcomes	  the	  major	  limitations	  of	  contemporary	  VT	  ablation.	  This	  
procedure	  exploits	  the	  unique	  tissue	  characterization	  capability	  of	  CMR	  and	  cannot	  be	  
replicated	  using	  X-­‐ray	  or	  echocardiography	  for	  guidance.	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Chapter	  2. Interventional	  cardiovascular	  magnetic	  resonance	  
2.1 Introduction	  
Interventional	  cardiovascular	  MRI	  (or	  “iCMR”)	  is	  potentially	  revolutionary	  because	  of	  the	  
exquisite	  tissue	  and	  blood	  imaging	  afforded	  to	  guide	  therapeutic	  procedures.	  By	  making	  
small	  compromises	  in	  spatial	  or	  temporal	  resolution,	  and	  with	  little	  or	  no	  modifications	  to	  
commercial	  high	  performance	  MRI	  systems,	  images	  can	  be	  acquired	  and	  displayed	  almost	  
instantaneously	  to	  operators.	  This	  may	  be	  useful	  simply	  to	  avoid	  ionizing	  radiation	  during	  
conventional	  catheter-­‐based	  procedures,	  especially	  in	  children.	  Perhaps	  more	  important,	  
iCMR	  promises	  to	  enable	  more	  advanced	  procedures	  not	  otherwise	  possible	  without	  open	  
surgical	  exposure.	  
X-­‐Ray	  fluoroscopy	  is	  widely	  available	  and	  is	  used	  to	  drive	  a	  wealth	  of	  catheter-­‐based	  and	  
minimally	  invasive	  cardiovascular	  and	  non-­‐cardiovascular	  interventions.	  Other	  procedures	  
are	  guided	  by	  external	  or	  invasive	  ultrasound	  (i.e.	  transesophageal	  or	  intravascular),	  or	  
electromagnetic	  position	  mapping	  (Carto,	  Biosense	  Webster;	  Ensite	  NavX,	  St	  Jude	  Medical),	  
alone	  or	  in	  tandem	  with	  X-­‐Ray.	  To	  change	  the	  primary	  image	  guidance	  modality	  away	  from	  
X-­‐Ray	  would	  require	  a	  more	  favourable	  risk-­‐benefit	  profile	  or	  would	  require	  applications	  not	  
otherwise	  possible	  with	  X-­‐Ray.	  For	  certain	  applications,	  iCMR	  is	  likely	  to	  meet	  these	  
requirements.	  
iCMR	  does	  not	  expose	  patients	  or	  operators	  to	  ionizing	  radiation.	  Children	  with	  congenital	  
cardiovascular	  disease	  suffer	  excess	  risk	  of	  late	  malignancy	  after	  exposure	  to	  ionizing	  
radiation	  1.	  They	  also	  are	  prone	  to	  multiple	  catheter-­‐based	  treatments,	  subjecting	  them	  to	  
higher	  cumulative	  radiation	  exposure.	  Cumulative	  exposure	  is	  also	  a	  risk	  to	  operators	  and	  
staff	  2.	  Lead	  aprons	  worn	  during	  X-­‐Ray	  procedures	  are	  associated	  with	  career-­‐threatening	  
musculoskeletal	  injuries.	  
iCMR,	  by	  virtue	  of	  imaging	  soft	  tissue,	  blood	  spaces,	  and	  catheter	  devices	  simultaneously,	  
may	  enable	  novel	  procedures.	  In	  preclinical	  experiments,	  iCMR	  has	  been	  shown	  to	  guide	  and	  
track	  targeted	  cell	  delivery	  into	  or	  around	  myocardial	  infarctions,	  to	  guide	  atrial	  septal	  
puncture,	  to	  drain	  pericardial	  effusions,	  and	  to	  obtain	  direct	  transthoracic	  access	  to	  the	  
heart.	  iCMR	  is	  being	  developed	  in	  preclinical	  systems	  to	  guide	  cardiac	  valve	  repair	  and	  
replacement,	  and	  extra-­‐anatomic	  bypass,	  procedures	  that	  in	  the	  past	  would	  have	  required	  
surgical	  exposure.	  In	  some	  settings,	  iCMR	  may	  provide	  a	  safety	  advantage	  over	  conventional	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image	  guidance,	  by	  revealing	  complications	  such	  as	  vascular	  perforation	  or	  rupture	  more	  
rapidly,	  and	  enabling	  more	  rapid	  treatment.	  
In	  recent	  years,	  iCMR	  in	  humans	  has	  become	  a	  clinical	  reality.	  Several	  institutions	  now	  
perform	  MR-­‐guided	  diagnostic	  right	  heart	  catheterization,	  and	  first-­‐in-­‐man	  MR-­‐guided	  
arrhythmia	  ablation	  and	  structural	  cardiac	  interventions	  have	  performed	  recently.	  In	  this	  
chapter,	  we	  discuss	  the	  technical	  challenges	  of	  iCMR	  and	  evaluate	  the	  potential	  solutions,	  
describe	  how	  to	  equip	  an	  iCMR	  suite	  for	  clinical	  applications,	  and	  review	  the	  published	  pre-­‐
clinical	  and	  clinical	  experience	  to	  date.	  
2.2 Technical	  issues	  
2.2.1 Pulse	  sequence	  and	  image	  reconstruction	  
iCMR	  is	  possible	  because	  of	  the	  same	  technical	  advances	  that	  enable	  MRI	  of	  moving	  cardiac	  
structures.	  Newer	  hardware	  with	  homogeneous	  magnetic	  fields	  and	  with	  rapidly	  switching	  
magnetic	  gradients	  permit	  repetition	  times	  (TR)	  shorter	  than	  3ms.	  The	  most	  widely	  used	  
pulse	  sequences	  are	  steady-­‐state	  free	  precession	  (SSFP,	  also	  known	  as	  balanced	  fast	  field	  
echo,	  trueFISP,	  and	  FIESTA),	  because	  of	  the	  relatively	  high	  signal-­‐to-­‐noise	  ratio	  (SNR)	  
generated	  with	  short	  TRs.	  Gradient	  echo	  techniques,	  used	  especially	  to	  enhance	  magnetic	  
susceptibility	  artefacts,	  can	  be	  equally	  fast	  but	  usually	  have	  inferior	  SNR.	  	  
During	  “interventional”	  MRI,	  pulse	  sequences	  are	  often	  adjusted	  interactively	  to	  change	  
image	  contrast	  and	  to	  adjust	  the	  compromise	  between	  temporal	  and	  spatial	  resolution	  in	  
favour	  of	  speed	  3.	  Compared	  with	  X-­‐Ray	  imaging,	  which	  typically	  uses	  1024x1024	  pixel	  
images	  at	  15	  frames	  per	  second,	  a	  typical	  iCMR	  image	  will	  be	  192x160	  pixels	  at	  10	  frames	  
per	  second.	  Because	  of	  enhanced	  tissue	  imaging,	  the	  relative	  information	  content	  in	  these	  
small-­‐matrix	  iCMR	  images	  is	  comparable	  to	  larger-­‐matrix	  X-­‐Ray	  images.	  	  
We	  define	  “real-­‐time”	  imaging	  as	  acquisition-­‐to-­‐display	  latency	  (or	  delay)	  of	  250ms	  or	  less,	  
which	  is	  at	  the	  border	  of	  perceptibility	  by	  catheter	  operators,	  and	  at	  a	  frame	  rate	  sufficient	  
for	  the	  specific	  application,	  generally	  5–15	  frames/second.	  Imaging	  speed	  is	  adjusted	  
through	  a	  combination	  of	  acquisition	  and	  post-­‐processing	  techniques.	  	  
Under-­‐sampling	  refers	  to	  image	  creation	  with	  less-­‐than-­‐complete	  data	  sets.	  iCMR	  
acquisitions	  can	  be	  under-­‐sampled	  further	  to	  increase	  temporal	  resolution,	  often	  combining	  
multiple	  methods	  including	  interleaving	  echos	  (analogous	  to	  alternating	  even	  and	  odd	  lines	  
on	  older	  television	  sets),	  incomplete	  phase	  sampling	  of	  frequency	  space	  (“k-­‐space”),	  and	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sampling	  of	  incomplete	  echoes.	  Alternative	  frequency-­‐space	  sampling	  trajectories	  also	  can	  
employ	  under-­‐sampling.	  For	  example,	  frequency	  space	  can	  be	  sampled	  radially	  so	  that	  each	  
echo	  intersects	  the	  centre	  frequency	  4,	  which	  are	  attractive	  because	  they	  intrinsically	  over-­‐
sample	  the	  centre	  of	  frequency	  space	  and	  under-­‐sample	  the	  outer	  frequencies.	  Others	  
advocate	  “spiral”	  sampling	  of	  frequency	  space	  to	  combine	  advantages	  both	  of	  conventional	  
rectilinear	  and	  radial	  sampling.	  
Parallel	  imaging	  techniques	  exploit	  the	  fact	  that	  differently	  located	  receiver	  coils	  each	  have	  
different	  “perspectives.”	  This	  is	  analogous	  to	  the	  enhanced	  imaging	  afforded	  by	  binoculars	  
compared	  with	  monocular	  telescopes.	  Such	  techniques,	  bearing	  monikers	  such	  as	  SENSE	  and	  
GRAPPA,	  require	  multiple	  hardware	  receiver	  channel	  systems,	  special	  receiver	  coils	  with	  
reduced	  crosstalk,	  and	  increased	  computational	  horsepower.	  In	  practice	  they	  readily	  
increase	  frame	  rate	  2–4-­‐fold	  or	  more	  at	  an	  acceptable	  cost	  of	  image	  noise.	  
2.2.2 MRI	  features	  especially	  useful	  for	  iCMR	  
Most	  commercial	  MRI	  systems	  provide	  rtMRI	  functionality	  using	  SSFP	  with	  interactive	  
graphics	  slice	  prescription	  during	  continuous	  scanning.	  Additional	  functionality	  may	  be	  
available	  using	  external	  computer	  workstations	  to	  control	  the	  scanner	  during	  iCMR	  
procedures	  and	  display	  rtMRI	  images.	  
Our	  labs	  have	  found	  several	  additional	  features	  to	  be	  valuable	  in	  preclinical	  and	  clinical	  
iCMR.	  Perhaps	  most	  important	  is	  the	  ability	  independently	  to	  process	  signals	  from	  individual	  
receiver	  channels,	  especially	  those	  attached	  to	  intravascular	  devices	  (see	  next	  section).	  
Specifically,	  this	  permits	  signals	  from	  device	  channels,	  such	  as	  intravascular	  guidewires	  or	  
endocardial	  injection	  needles,	  to	  be	  displayed	  in	  colour	  (Figure	  2-­‐1).	  This	  simple	  modification	  
provides	  high	  user	  confidence	  in	  device	  location	  during	  rtMRI	  procedures.	  It	  has	  proven	  
helpful	  also	  to	  be	  able	  to	  alter	  gain	  settings	  for	  each	  channel	  interactively,	  much	  as	  
operators	  adjust	  gain	  on	  intravascular	  or	  transthoracic	  ultrasound	  devices.	  
Other	  features	  we	  have	  found	  useful	  include	  the	  ability	  to	  alter	  slice	  thickness,	  or	  toggle	  on	  
and	  off	  saturation	  pre-­‐pulse	  to	  enhance	  the	  appearance	  of	  gadolinium-­‐filled	  balloons	  and	  to	  
highlight	  areas	  of	  gadolinium-­‐enhanced	  myocardium.	  Image-­‐acceleration,	  such	  as	  with	  
GRAPPA,	  is	  also	  toggled	  interactively.	  The	  interaction	  also	  can	  be	  automated.	  For	  example,	  
investigators	  at	  Case	  Western	  Reserve	  University	  automatically	  reduces	  the	  field	  of	  view	  or	  
increases	  temporal	  resolution	  during	  rapid	  device	  motion;	  the	  pictures	  may	  be	  fast-­‐but-­‐
blurry	  during	  coarse	  device	  movements	  but	  slow-­‐and-­‐sharp	  during	  fine	  device	  positioning	  5.	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Similarly	  the	  field	  of	  view	  may	  be	  large	  during	  rapid	  movement,	  or	  small	  during	  fine	  
positioning.	  
Multiple	  slices	  acquired	  and	  displayed	  in	  rapid	  succession	  guide	  our	  investigational	  
interventional	  procedures.	  Updates	  of	  individual	  slices	  can	  be	  paused	  or	  reactivated	  to	  
speed	  the	  frame	  rate	  of	  other	  slices.	  This	  type	  of	  display	  also	  can	  be	  enhanced	  by	  interactive	  
user	  point-­‐marking	  to	  identify	  important	  anatomic	  features	  or	  targets,	  the	  ability	  to	  make	  
measurements	  on-­‐line,	  and	  the	  ability	  to	  combine	  with	  prior	  roadmap	  images	  to	  make	  rapid	  
before	  and	  after	  comparisons	  (Figure	  2-­‐1).	  
iCMR	  operators	  have	  two	  general	  imaging	  strategies.	  For	  some	  applications,	  rtMRI	  is	  
directed	  at	  target	  pathology,	  while	  devices	  are	  manipulated	  in	  or	  out	  of	  the	  desired	  target	  
slice.	  Alternatively,	  the	  rtMRI	  slice	  can	  automatically	  track	  catheter	  movements	  and	  alter	  the	  
slice	  prescription	  so	  as	  always	  to	  keep	  the	  desired	  catheter-­‐device	  in	  view,	  while	  changing	  
the	  view	  of	  the	  neighbouring	  anatomy.	  Ideally,	  both	  imaging	  techniques	  should	  be	  available	  
to	  the	  operator.	  We	  have	  found	  a	  “projection-­‐mode”	  feature	  useful	  during	  catheter	  
manipulations	  within	  target	  slices.	  When	  parts	  of	  catheter	  devices	  move	  outside	  these	  
selected	  slices,	  they	  appear	  “lost.”	  By	  toggling	  projection-­‐mode	  (which	  switches	  to	  thick-­‐
slice	  or	  slice-­‐less	  imaging	  akin	  to	  X-­‐ray	  fluoroscopic	  projections),	  the	  catheter	  can	  be	  “found”	  
and	  manipulated	  back	  into	  the	  target	  slice	  (Figure	  2-­‐1).	  
2.3 Logistics	  and	  safety:	  Assembling	  a	  clinical	  interventional	  MRI	  suite	  
Constructing	  a	  clinical	  laboratory	  suitable	  for	  iCMR	  procedures	  is	  straightforward	  but	  
requires	  a	  degree	  of	  customization	  6,	  7.	  Once	  configured,	  the	  laboratory	  resembles	  
conventional	  X-­‐Ray	  fluoroscopy	  suites	  (Figure	  2-­‐2).	  
2.3.1 Infrastructure	  requirements	  
All	  major	  systems	  manufacturers	  provide	  turnkey	  installation	  of	  combined	  X-­‐Ray/MRI	  (XMR)	  
systems	  consisting	  of	  single-­‐	  or	  biplane	  X-­‐Ray	  fluoroscopy	  system,	  clinical	  1.5-­‐3T	  MRI	  system,	  
the	  capacity	  to	  transport	  patients	  rapidly	  and	  safely	  between	  the	  modalities,	  and	  X-­‐Ray	  and	  
radiofrequency	  shielded	  doors	  that	  permit	  the	  two	  imaging	  systems	  to	  be	  used	  
independently	  when	  they	  are	  not	  being	  used	  together.	  We	  believe	  XMR	  installations	  are	  
both	  useful	  and	  cost-­‐effective	  in	  providing	  adjunctive	  and	  bailout	  treatment	  environments.	  
Moreover,	  the	  incremental	  cost	  over	  two	  separate	  labs	  is	  fairly	  low,	  consisting	  only	  of	  the	  
barrier	  doors	  and	  the	  inter-­‐modality	  patient	  transport	  system.	  As	  more	  experience	  is	  gained	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and	  the	  safety	  of	  iCMR	  is	  established,	  we	  anticipate	  that	  in	  the	  future	  an	  adjacent	  X-­‐ray	  
room	  will	  no	  longer	  be	  required.	  
For	  transfemoral	  arterial	  or	  transjugular	  venous	  access,	  the	  length	  of	  conventional	  1.5T	  MRI	  
bores	  (approximately	  150cm)	  does	  not	  significantly	  interfere	  with	  catheter	  manipulations	  in	  
adults.	  Shorter-­‐bore	  (120cm)	  1.5T	  MRI	  systems	  are	  commercially	  available	  and	  may	  reduce	  
these	  obstacles	  but	  are	  certainly	  not	  a	  requirement.	  Shorter-­‐bore	  MRI	  systems	  also	  may	  
reduce	  patient	  anxiety	  and	  claustrophobia	  and	  may	  ease	  intra-­‐procedural	  nursing	  care	  and	  
observation.	  
One	  noteworthy	  logistical	  point:	  at	  present	  transfemoral	  or	  transjugular	  access	  may	  best	  be	  
obtained	  using	  X-­‐ray	  or	  ultrasound	  guidance	  for	  backup.	  In	  a	  combined	  XMR	  system,	  arterial	  
access	  is	  obtained	  under	  X-­‐Ray	  and	  the	  patient	  is	  then	  transferred	  rapidly	  into	  the	  MRI	  
system	  for	  further	  procedure	  conduct.	  
2.3.2 Communications	  
Real	  time	  MRI	  is	  loud.	  Even	  in	  newer	  “acoustically-­‐shielded”	  systems,	  the	  acoustic	  noise	  is	  
sufficiently	  loud	  that	  unassisted	  verbal	  communication	  is	  impossible,	  and	  protective	  
headsets	  are	  necessary	  to	  avoid	  occupational	  injury.	  Several	  commercial	  systems	  are	  now	  
available,	  combining	  noise-­‐suppression	  headsets,	  multiple	  channels,	  and	  wireless	  
connectivity	  to	  facilitate	  movement	  around	  the	  MRI	  room	  (Optoacoustics,	  Innovere).	  Unless	  
patients	  will	  always	  be	  under	  general	  anaesthesia,	  multiple	  communication	  channels	  are	  
valuable,	  as	  well	  as	  the	  ability	  for	  staff	  to	  switch	  between	  channels	  to	  address	  each	  other	  
and/or	  the	  patient	  separately.	  
2.3.3 Video	  display	  
At	  NIH,	  we	  customize	  a	  commercial	  rtMRI	  workstation,	  but	  similar	  systems	  are	  available	  
(Interventional	  Front	  End,	  Siemens;	  RTHawk,	  HeartVista;	  Cleartrace,	  MRI	  Intervention;	  iSuite,	  
Philips).	  We	  use	  multiple	  video	  displays:	  one	  for	  instantaneous	  hemodynamics,	  one	  
mirroring	  the	  host	  computer	  for	  scanner	  control,	  and	  one	  for	  rtMRI	  display.	  Available	  display	  
options	  include	  in-­‐lab	  shielded	  LCD	  displays,	  either	  floor-­‐	  or	  ceiling-­‐mounted.	  Commercial	  
LCD	  projectors	  can	  be	  shielded	  (Gaven	  Industries)	  against	  radiofrequency	  noise	  emissions,	  
can	  be	  positioned	  inside	  the	  lab,	  and	  can	  project	  onto	  inexpensive	  aluminium-­‐framed	  
projector	  screens.	  Digital	  signals	  are	  transmitted	  into	  the	  MRI	  room	  through	  fibre-­‐optic	  
transmission	  lines	  passed	  through	  waveguides	  (large	  conductive	  cylinders	  installed	  across	  
the	  radiofrequency	  shield	  that	  allow	  nonconductive	  materials	  to	  pass	  freely).	  Alternatively,	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projectors	  can	  project	  from	  outside	  the	  lab	  through	  waveguides	  onto	  the	  screen	  in	  the	  MRI	  
room.	  
2.3.4 Sterility	  
Sterile	  procedure	  during	  iCMR	  is	  similar	  to	  other	  procedures.	  In	  our	  laboratories,	  before	  
transfer	  from	  X-­‐Ray	  to	  MRI	  systems,	  we	  cover	  the	  sterile	  patient	  access	  site	  (usually	  groin	  or	  
neck	  area)	  with	  large	  sterile	  drapes,	  especially	  to	  protect	  that	  site	  while	  surface	  MRI	  coils	  are	  
placed.	  We	  enclose	  surface	  coils	  in	  sterile	  plastic	  bags,	  and	  interventional	  coil	  connectors	  in	  
sterile	  plastic	  sheaths	  marketed	  to	  enclose	  intravascular	  ultrasound	  connectors.	  Finally,	  we	  
line	  the	  MRI	  bore	  and	  controls	  with	  adhesive	  clear	  plastic	  sterile	  drapes.	  	  
2.3.5 Safety,	  patient	  monitoring	  and	  emergency	  evacuation	  
iCMR	  procedures	  require	  standard	  operating	  procedures	  that	  are	  an	  extension	  of	  those	  
applied	  for	  standard	  non-­‐invasive	  MRI	  procedures.	  
Suites	  need	  to	  be	  designed	  to	  minimize	  trips	  by	  “circulating”	  staff	  members	  across	  the	  RF	  
barrier	  to	  gather	  devices.	  Opening	  the	  door,	  interrupting	  the	  RF	  barrier,	  usually	  interferes	  
with	  the	  iCMR	  procedure	  by	  introducing	  excessive	  noise	  into	  images.	  This	  requires	  both	  
circulating	  staff	  and	  disposable	  devices	  to	  be	  positioned	  inside	  the	  iCMR	  room.	  
Contingency	  plans	  must	  exist	  to	  avoid	  introducing	  ferrous	  “missiles”	  into	  the	  iCMR	  suite.	  As	  
with	  standard	  non-­‐invasive	  MRI,	  the	  risk	  is	  highest	  during	  emergencies.	  Defibrillator	  
consoles	  or	  oxygen	  cylinders	  become	  missiles	  if	  inadvertently	  brought	  into	  the	  MRI	  room	  by	  
emergency	  team	  members.	  As	  during	  standard	  MRI,	  contingency	  plans	  should	  be	  in	  place	  
rapidly	  to	  evacuate	  the	  patient	  outside	  the	  field	  during	  emergencies.	  At	  NIH,	  we	  drill	  
evacuations	  regularly	  and	  are	  able	  to	  move	  a	  patient	  out	  of	  the	  scanner,	  transfer	  to	  the	  
adjacent	  X-­‐ray	  suite	  and	  defibrillate	  in	  under	  1min.	  We	  expect	  MR-­‐conditional	  defibrillators	  
to	  become	  available	  in	  the	  near	  future,	  enabling	  ‘in-­‐bore’	  therapy.	  
A	  great	  deal	  of	  biomechanical	  patient	  care	  equipment	  is	  commercially	  available	  for	  
operation	  in	  the	  MRI	  suite,	  including	  patient	  monitoring	  equipment,	  intravenous	  fluid	  
pumps,	  and	  mechanical	  ventilators.	  Such	  equipment	  still	  should	  be	  tested	  and	  marked	  as	  
being	  safe	  for	  operation	  inside	  the	  high	  magnetic	  field.	  All	  other	  ferrous	  materials	  that	  are	  
deemed	  essential	  must	  be	  tethered	  outside	  the	  high	  field	  line	  if	  they	  must	  remain	  inside	  the	  
scanning	  room.	  Nitric	  oxide	  administration	  systems	  can	  be	  modified	  with	  extended	  plastic	  
tubing	  that	  is	  passed	  through	  the	  waveguide.	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MR-­‐safe	  hemodynamic	  monitoring	  systems	  are	  available	  commercially	  (Invivo,	  GE,	  Medrad)	  
and	  are	  sufficient	  for	  basic	  monitoring.	  However,	  there	  are	  currently	  no	  high-­‐fidelity	  
hemodynamic	  recording	  systems	  sold	  commercially.	  Custom	  systems	  have	  been	  built	  for	  
research	  purposes	  using	  filters	  to	  correct	  for	  interference	  from	  the	  scanner	  and	  fibre	  optic	  
cables	  or	  wireless	  systems	  to	  transmit	  signals	  out	  of	  the	  room,	  and	  using	  research	  
acquisition	  hardware	  (National	  Instruments,	  ADInstruments,	  Biopac).	  A	  commercial	  system,	  
which	  should	  integrate	  into	  conventional	  catheterization	  laboratory	  hemodynamic	  analysis	  
systems	  (e.g.	  Siemens	  Sensis,	  GE	  Mac-­‐Lab)	  is	  currently	  under	  development	  (Pinmed).	  
A	  surprisingly	  large	  number	  of	  lines	  are	  connected	  to	  the	  patient,	  and	  their	  management	  
should	  be	  planned	  in	  advance.	  They	  are	  enumerated	  here	  for	  effect:	  (1)	  oxygen	  and	  other	  
gases;	  (2)	  mechanical	  ventilation;	  (3)	  oximetric	  detector;	  (4)	  microphone;	  (5)	  headset;	  (6)	  
multiple	  intravenous	  lines;	  (7)	  intra-­‐arterial	  pressure	  transducer	  connectors;	  (8)	  
interventional	  fluid	  manifold	  including	  contrast,	  flush,	  and	  waste	  lines;	  (9)	  urinary	  catheters;	  
(10)	  electrocardiography	  leads	  for	  MRI	  and	  for	  bailout	  X-­‐ray;	  (11)	  surface	  MRI	  coil	  
connectors;	  (12)	  intravascular	  MRI	  coil	  connectors.	  These	  should	  be	  arranged	  so	  that	  no	  
inadvertent	  loops	  are	  formed	  of	  conductive	  materials,	  and	  so	  that	  conductive	  materials	  are	  
kept	  away	  from	  the	  wall	  of	  the	  MRI	  bore,	  both	  of	  which	  can	  contribute	  to	  heating.	  The	  lines	  
also	  should	  be	  organized	  so	  that	  the	  patient	  can	  be	  evacuated	  rapidly	  without	  disrupting	  and	  
disconnecting	  them.	  
2.4 Catheter	  devices	  
X-­‐Ray	  fluoroscopic	  interventional	  devices	  are	  conspicuous	  because	  they	  attenuate	  X-­‐Ray	  
photons.	  Most	  off-­‐the-­‐shelf	  devices	  are	  intrinsically	  conspicuous	  under	  X-­‐Ray;	  others	  
incorporate	  heavy	  metals	  like	  barium	  or	  platinum.	  Catheter	  devices	  usually	  incorporate	  
ferrous	  materials	  (such	  as	  wire	  braiding)	  to	  make	  them	  rigid	  and	  torque-­‐resistant.	  By	  
contrast,	  under	  MRI,	  structures	  are	  conspicuous	  because	  they	  contain	  or	  adjoin	  excited	  
proton	  spins.	  Off-­‐the-­‐shelf	  catheter	  devices,	  designed	  for	  X-­‐Ray,	  usually	  distort	  the	  MR	  
image	  because	  the	  ferrous	  materials	  destroy	  the	  local	  magnetic	  field.	  Devices	  rendered	  
“MR-­‐compatible”	  by	  having	  ferrous	  materials	  removed	  are	  also	  rendered	  invisible	  because	  
they	  still	  don’t	  contain	  water	  protons.	  Attempts	  to	  coat	  or	  fill	  catheter	  devices	  with	  
gadolinium-­‐type	  contrast	  agents	  have	  for	  the	  most	  part	  been	  unsuccessful,	  because	  not	  
enough	  excited	  proton	  spins	  are	  able	  to	  interact	  with	  the	  gadolinium-­‐type	  “relaxation”	  
agent.	  Moreover,	  “MR-­‐compatible”	  guidewire	  materials	  such	  as	  nitinol	  are	  electrically	  
conductive	  and,	  when	  long	  enough	  to	  be	  clinically	  useful,	  they	  are	  vulnerable	  to	  rapid	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heating	  from	  the	  MRI	  radio	  energy	  excitation,	  much	  as	  they	  would	  be	  inside	  a	  microwave	  
oven.	  Table	  2-­‐1	  and	  Figure	  2-­‐3	  provide	  an	  overview	  of	  general	  approaches	  to	  making	  
catheter	  devices	  visible	  under	  MRI.	  
2.4.1 Passive	  device	  visualization	  
“Passive”	  catheter	  devices	  are	  the	  simplest,	  and	  are	  visualized	  based	  on	  their	  intrinsic	  
materials	  properties.	  Most	  passive	  devices	  are	  visible	  because	  they	  do	  not	  contain	  water	  
protons	  and	  therefore	  appear	  black	  using	  most	  MRI	  pulse	  sequences.	  Tracking	  dark	  devices	  
can	  be	  challenging	  using	  MRI,	  because	  the	  darkness	  can	  be	  difficult	  to	  spot	  when	  it	  is	  diluted	  
(or	  “volume-­‐averaged”)	  in	  a	  larger	  imaging	  slice.	  The	  dark	  spots	  can	  be	  enhanced	  by	  adding	  
small	  amounts	  of	  metal	  to	  create	  “blooming”	  or	  magnetic	  susceptibility	  artefacts	  (Figure	  
2-­‐3).	  These	  artefacts	  can	  make	  the	  passive	  device	  appear	  larger	  than	  the	  actual	  size,	  and	  can	  
even	  obscure	  surrounding	  tissue	  detail.	  Guidewires	  and	  catheters	  8-­‐10	  have	  been	  made	  out	  of	  
non-­‐metallic	  polymers	  (Figure	  2-­‐3),	  and	  clinical	  procedures	  have	  been	  conducted	  using	  
polymer	  guidewires	  11,	  passive	  CO2-­‐filled	  12-­‐14	  or	  dilute	  gadolinium-­‐filled	  balloon	  catheters	  15.	  
2.4.2 Active	  device	  visualization	  
We	  prefer	  to	  use	  MRI	  catheter	  devices	  that	  are	  modified	  to	  incorporate	  MRI	  receiver	  coils,	  
or	  antennae.	  These	  so-­‐called	  “active”	  catheter	  devices	  become	  highly	  visible	  when	  they	  are	  
attached	  to	  the	  MRI	  scanner	  hardware	  because	  they	  accentuate	  nearby	  excited	  water	  
protons.	  Early	  designs	  were	  intended	  for	  high-­‐resolution	  tissue	  imaging	  or	  spectroscopy	  16-­‐22	  
of	  nearby	  tissue.	  In	  their	  simplest	  designs,	  the	  entire	  length	  or	  “profile”	  of	  active	  catheters	  
are	  made	  conspicuous	  23-­‐29.	  In	  addition,	  these	  profile-­‐design	  active	  catheters	  can	  help	  
visualize	  the	  devices	  even	  if	  they	  move	  outside	  the	  selected	  scanning	  plane	  (Figure	  2-­‐1).	  
Profile-­‐design	  active	  catheters	  generally	  are	  imaged	  along	  with	  target	  tissue,	  and	  require	  no	  
modification	  of	  imaging	  pulse	  sequences.	  Active	  catheter	  coils	  can	  be	  attached	  to	  separate	  
receiver	  channels	  in	  the	  MRI	  system,	  analogous	  to	  separate	  audio	  channels	  in	  a	  stereo	  audio	  
system,	  and	  images	  deriving	  from	  catheters	  can	  be	  assigned	  colours	  that	  help	  to	  distinguish	  
them	  from	  surrounding	  structures	  in	  2D	  or	  3D	  space	  30	  (Figure	  2-­‐3).	  When	  active	  guidewires	  
are	  combined	  with	  passive	  catheters	  or	  balloons	  filled	  with	  dilute	  gadolinium	  MRI	  contrast,	  
the	  pair	  becomes	  readily	  visible.	  
Another	  type	  of	  active	  catheter	  design,	  embedding	  tracking-­‐microcoils,	  is	  used	  to	  track	  
individual	  points	  on	  the	  catheter	  during	  MRI	  21,	  31-­‐33.	  Tracking-­‐microcoil	  catheters	  require	  a	  
slight	  modification	  of	  the	  MRI	  pulse	  sequences,	  a	  small	  number	  of	  intermittent	  non-­‐selective	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excitations	  to	  localize	  the	  microcoils	  in	  space	  and	  calculate	  their	  position	  on	  the	  image.	  The	  
microcoil	  location	  usually	  is	  depicted	  as	  a	  cross	  hair	  overlaid	  on	  the	  image	  (Figure	  2-­‐3).	  These	  
tracking-­‐microcoil	  systems	  are	  simple	  and	  effective,	  but	  unfortunately	  cannot	  depict	  the	  full	  
length	  of	  catheter	  devices	  unless	  the	  catheter	  contains	  dozens	  of	  them.	  
Active	  catheter	  designs	  require	  conductive	  connections	  to	  the	  MRI	  scanner.	  These	  tend	  to	  
heat	  if	  longer	  than	  10–15cm.	  MRI	  pulse	  sequence	  techniques	  can	  reduce	  the	  energy	  
deposited	  per	  image	  and	  therefore	  heating	  34,	  at	  an	  acceptable	  penalty	  in	  image	  quality.	  
These	  include	  radial	  sampling,	  spiral	  sampling	  and	  echo	  planar	  imaging	  which	  use	  fewer	  
excitation	  pulses	  and	  longer	  repetition	  times,	  variable	  flip	  angle	  sequences	  35	  and	  parallel	  
imaging.	  Methods	  being	  developed	  to	  reduce	  specific	  absorption	  rate	  (SAR)	  at	  high	  fields,	  
such	  as	  adaptive	  parallel	  transmission,	  may	  also	  prove	  helpful	  at	  lower	  fields	  to	  reduce	  
heating	  during	  MRI-­‐guided	  interventions	  36.	  
Several	  teams	  have	  developed	  circuitry	  for	  detuning	  or	  decoupling	  conductive	  transmission	  
lines	  37-­‐41,	  or	  have	  developed	  alternative	  transmission	  lines	  such	  as	  fibre	  optics	  42-­‐45.	  Using	  
loopless	  antennae,	  existing	  interventional	  devices	  such	  as	  nitinol	  occluder	  delivery	  cables	  
can	  be	  modified	  and	  tuned	  to	  indicate	  device	  deployment	  state	  (for	  example,	  open	  versus	  
closed)	  46.	  One	  profile-­‐design,	  loopless	  active	  decoupled	  and	  detuned	  guidewire,	  the	  
SurgiVision	  0.030”	  x	  100cm	  guidewire,	  briefly	  obtained	  US	  FDA	  marketing	  clearance	  for	  
invasive	  intravascular	  MRI	  in	  humans	  6,	  47,	  48.	  The	  limitation	  of	  this	  device	  was	  that	  the	  
receiver	  sensitivity	  fell	  to	  zero	  at	  the	  distal	  tip,	  which	  was	  difficult	  to	  visualize	  and	  
insufficient	  to	  navigate	  vasculature	  under	  rtMRI.	  Improved	  designs	  have	  not	  yet	  been	  
commercialized	  28.	  
MR-­‐conditional	  guidewires	  would	  facilitate	  numerous	  interventions	  using	  otherwise	  
intrinsically	  MR-­‐safe	  devices	  (e.g.	  angioplasty	  balloons	  or	  non-­‐braided	  catheters).	  To	  date	  
polymeric	  guidewires	  do	  not	  afford	  the	  requisite	  mechanical	  properties	  (i.e.	  stiffness	  and	  
torquability)	  but	  metallic	  (non-­‐ferromagnetic)	  guidewires	  risk	  heating.	  Our	  lab	  designed	  an	  
alternative	  strategy	  to	  address	  the	  issue	  of	  device	  heating	  by	  embedding	  a	  fibre	  optic	  
temperature	  probe	  into	  a	  0.035”	  active	  guidewire	  with	  similar	  mechanical	  properties	  to	  
commercial	  X-­‐ray	  guidewires	  29.	  Heating	  was	  monitored	  continuously	  during	  in	  vivo	  use	  and	  
was	  negligible	  under	  normal	  operating	  conditions.	  Importantly,	  the	  whole	  shaft	  is	  active	  and	  
the	  tip	  has	  a	  distinct	  signal	  which	  is	  critical	  when	  navigating	  the	  vasculature	  49.	  We	  plan	  to	  
test	  this	  guidewire	  in	  human	  subjects	  once	  US	  FDA	  approval	  is	  granted	  (Figure	  2-­‐4).	  
Several	  teams	  have	  reported	  “wireless”	  active	  catheters	  or	  stents	  50-­‐53,	  which	  are	  inductively	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coupled	  with	  the	  MRI	  system	  (Figure	  2-­‐3).	  Theoretically	  these	  can	  be	  exploited	  to	  enhance	  
later	  non-­‐invasive	  imaging,	  for	  example,	  of	  restenosis	  or	  of	  captured	  thromboemboli.	  
Of	  note,	  multiple	  approaches	  to	  enhance	  device	  visibility	  can	  be	  combined.	  For	  example	  an	  
interventional	  MRI	  system	  could	  include	  an	  active-­‐profiling	  guidewire	  that	  incorporates	  
tracking-­‐microcoils	  near	  the	  tip	  to	  enhance	  distal	  visibility;	  a	  passive	  balloon	  incorporating	  
passive	  platinum	  marker	  bands	  when	  deflated	  and	  filled	  with	  dilute	  gadolinium	  when	  
inflated;	  used	  together	  to	  deliver	  an	  inductively-­‐coupled	  stent-­‐graft	  device.	  
The	  main	  barrier	  to	  further	  clinical	  translation	  of	  iCMR	  remains	  the	  limited	  commercial	  
availability	  of	  clinical-­‐grade	  active	  and	  devices.	  Nevertheless,	  a	  wide	  range	  of	  prototype	  
applications	  has	  been	  demonstrated	  in	  animals.	  
2.5 iCMR	  applications	  
Certain	  applications	  lend	  themselves	  to	  iCMR	  development.	  Target	  anatomic	  structures	  that	  
are	  relatively	  immobile	  or	  slow	  moving	  (such	  as	  peripheral	  arteries)	  are	  attractive	  because	  
MR	  images	  can	  be	  updated	  slowly	  and	  therefore	  can	  have	  higher	  SNR	  or	  spatial	  resolution.	  
Large	  or	  thick-­‐walled	  structures	  (such	  as	  heart	  or	  aorta)	  are	  attractive	  because	  they	  contain	  
many	  proton	  spins,	  can	  be	  imaged	  with	  high	  SNR,	  and	  contrast	  mechanisms	  might	  be	  
available	  readily	  to	  distinguish	  them	  from	  neighbouring	  structures.	  Structures	  that	  can	  be	  
contained	  within	  a	  single	  imaging	  plane	  (such	  as	  straight	  segments	  of	  iliac	  arteries)	  can	  be	  
imaged	  rapidly,	  compared	  with	  tortuous	  smaller	  structures	  such	  as	  coronary	  arteries,	  which	  
are	  difficult	  to	  image	  in	  real-­‐time.	  
The	  myocardium	  is	  an	  attractive	  target	  despite	  its	  high	  degree	  of	  cardiac	  and	  respiratory	  
motion	  because	  it	  is	  a	  large,	  thick-­‐walled	  structure	  that	  is	  readily	  depicted	  (using	  SSFP	  MRI)	  
in	  high	  contrast	  compared	  with	  the	  blood	  space.	  Even	  thin-­‐walled	  structures,	  such	  as	  the	  
myocardial	  atria,	  are	  visible	  with	  current	  rtMRI.	  
2.5.1 Coronary	  artery	  disease	  
The	  SNR	  of	  proton	  MRI	  is	  too	  low	  to	  provide	  temporal	  resolution	  (33–66	  ms)	  at	  anywhere	  
near	  the	  spatial	  resolution	  (200	  μm)	  currently	  enjoyed	  by	  X-­‐Ray	  fluoroscopy	  operators	  
conducting	  complex	  coronary	  interventions	  in	  heavily	  diseased,	  even	  occluded,	  coronary	  
arteries	  using	  0.014”	  (0.35mm)	  guidewires.	  Barring	  unforeseen	  technical	  breakthroughs,	  
meaningful	  coronary	  artery	  interventions	  are	  not	  likely	  to	  be	  conducted	  using	  MRI.	  
Page	  31	  of	  242	  
That	  said,	  Speuntrup	  et	  al	  54	  demonstrated	  navigation	  and	  delivery	  of	  passively-­‐visualized	  
stainless	  steel	  stents	  in	  the	  coronary	  arteries	  of	  healthy	  swine.	  The	  devices	  and	  target	  
proximal	  coronary	  arteries	  were	  readily	  visible	  using	  SSFP	  at	  1.5T	  despite	  cardiac	  motion	  and	  
the	  small	  size	  of	  these	  structures.	  Nonetheless,	  we	  do	  not	  believe	  that	  coronary	  artery	  
intervention	  is	  suited	  for	  iCMR,	  because	  the	  imaging	  is	  inferior	  and	  there	  is	  no	  clear	  benefit	  
compared	  with	  X-­‐ray	  fluoroscopy.	  
2.5.2 Peripheral	  vascular	  disease	  
The	  most	  straightforward	  iCMR	  applications,	  transluminal	  angioplasty	  55-­‐59	  and	  stent	  
deployment	  60-­‐65,	  have	  been	  conducted	  in	  numerous	  animal	  models.	  Similarly,	  investigators	  
have	  reported	  placement	  of	  vena	  cava	  filters	  66-­‐68	  and	  even	  transcatheter	  visceral	  
embolization	  of,	  for	  example,	  renal	  or	  hepatic	  parenchyma	  69-­‐71.	  These	  are	  important	  proofs	  
of	  concept	  toward	  clinical	  development.	  Indeed	  a	  few	  human	  examples	  of	  peripheral	  artery	  
angioplasty	  and	  stenting	  have	  been	  reported.	  For	  the	  most	  part,	  these	  represent	  
straightforward	  axial	  displacement	  of	  devices	  requiring	  little	  interactive	  image	  guidance.	  	  
iCMR	  also	  offers	  the	  convenience	  of	  using	  a	  single	  imaging	  modality	  to	  determine	  reference	  
vessel	  size,	  whereas	  X-­‐ray	  guided	  angioplasty	  requires	  adjunctive	  intravascular	  ultrasound	  to	  
determine	  arterial	  wall	  characteristics	  (including	  media-­‐to-­‐media	  diameter).	  However,	  even	  
in	  simple	  angioplasty	  and	  stenting,	  iCMR	  offers	  a	  potential	  safety	  advantage	  over	  
conventional	  X-­‐Ray.	  Raval	  et	  al	  65	  conducted	  iCMR-­‐guided	  stenting	  of	  aortic	  coarctation	  in	  a	  
pig	  model.	  Continuous	  imaging	  both	  of	  target	  pathology	  and	  devices	  immediately	  revealed	  
catastrophic	  aortic	  rupture	  when	  deliberately	  oversized	  devices	  were	  employed.	  Early	  
recognition	  offers	  the	  only	  opportunity	  effectively	  to	  treat	  this	  life-­‐threatening	  complication.	  	  
Perhaps	  more	  compelling	  are	  applications	  that	  exploit	  the	  ability	  of	  MRI	  to	  visualize	  vascular	  
spaces	  not	  conspicuous	  using	  X-­‐ray.	  In	  a	  pig	  model	  of	  chronic	  total	  occlusion	  of	  peripheral	  
arteries,	  Raval	  et	  al	  72,	  used	  iCMR	  to	  navigate	  a	  recanalizing	  guidewire.	  These	  trajectories	  
cannot	  be	  determined	  using	  X-­‐ray	  because	  the	  occluded	  lumen	  cannot	  fill	  with	  contrast.	  
iCMR	  permitted	  the	  operators	  to	  traverse	  complex	  occlusions	  while	  remaining	  within	  the	  
walls	  of	  the	  target	  operator.	  This	  can	  be	  especially	  important	  in	  recanalization	  of	  tortuous	  
peripheral	  artery	  occlusions,	  such	  as	  those	  found	  in	  the	  pelvis.	  
Aortic	  aneurysm	  disease	  often	  entails	  complex	  tortuous	  three-­‐dimensional	  structures	  that	  
are	  difficult	  to	  visualize	  using	  projection	  X-­‐ray.	  iCMR	  might	  provide	  a	  single-­‐modality	  
solution	  to	  procedure	  planning,	  device	  deployment,	  and	  anatomic	  and	  hemodynamic	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assessment	  of	  catheter-­‐based	  (endograft)	  treatment	  of	  aortic	  aneurysm.	  In	  a	  simple	  pig	  
model,	  Raman	  et	  al	  73	  demonstrated	  all	  of	  the	  above	  steps	  using	  custom	  “active”	  stent	  graft	  
devices.	  Endograft	  treatment	  under	  MRI	  restored	  a	  normal	  lumen	  contour	  and	  restored	  
laminar	  flow.	  Moreover,	  MRI	  demonstrated	  device	  apposition	  to	  the	  target	  aortic	  wall	  and	  
allowed	  interrogation	  for	  endoleak.	  
The	  team	  at	  University	  Hospital	  Essen	  has	  elegantly	  applied	  iCMR	  to	  guide	  the	  placement	  of	  
stent	  grafts	  in	  an	  animal	  model	  of	  thoracic	  aortic	  dissection	  74.	  They	  used	  unmodified,	  
passive	  stent	  graft	  devices.	  MRI	  clearly	  revealed	  the	  true	  and	  false	  lumens	  of	  the	  dissected	  
aorta,	  guided	  stent-­‐graft	  deployment,	  and	  demonstrated	  stent-­‐graft	  obliteration	  of	  the	  false	  
lumen.	  This	  was	  another	  excellent	  example	  of	  the	  intrinsic	  value	  of	  simultaneous	  tissue	  and	  
device	  imaging	  using	  real-­‐time	  MRI	  (Figure	  2-­‐7).	  
2.5.3 Cardiac	  catheterization	  and	  structural	  heart	  interventions	  
The	  UCSF	  group	  75	  reported	  a	  comprehensive	  diagnostic	  cardiac	  catheterization	  procedure	  in	  
a	  porcine	  model	  of	  atrial	  septal	  defect	  using	  iCMR.	  They	  used	  catheters	  containing	  catheters	  
containing	  tracking	  microcoils	  embedded	  near	  the	  tip.	  They	  were	  easily	  able	  to	  accomplish	  
left	  and	  right	  heart	  catheterization	  including	  continuous	  intra-­‐cavitary	  pressure	  monitoring	  
and	  blood	  sampling.	  They	  also	  incorporated	  phase-­‐contrast	  MRI	  into	  their	  procedures	  for	  
the	  determination	  of	  shunt	  ratios.	  Other	  groups	  have	  reported	  rtMRI	  catheter	  manipulation	  
using	  selective	  arteriography	  using,	  for	  example,	  tracking-­‐microcoil-­‐based	  catheters	  for	  
selective	  carotid	  artery	  catheterization	  76,	  passive	  catheters	  over	  active	  guidewires	  for	  
selective	  coronary	  arteriography	  77,	  or	  active	  catheters	  for	  selective	  visceral	  artery	  
catheterization	  78	  in	  swine.	  
Several	  groups	  have	  deployed	  passively-­‐visualized	  nitinol	  occluder	  devices	  to	  treat	  porcine	  
models	  of	  atrial	  septal	  defect	  79	  and	  thereafter	  to	  assess	  hemodynamics	  using	  phase-­‐
contrast	  MRI	  80,	  81.	  
Kuehne	  et	  al	  82	  have	  reported	  preliminary	  experience	  deploying	  a	  passively-­‐visualized	  
nitinol-­‐based	  aortic	  valve	  prosthesis	  from	  a	  transfemoral	  approach	  in	  healthy	  swine.	  Theirs	  is	  
a	  good	  demonstration	  of	  the	  value	  of	  combined	  tissue	  and	  device	  imaging	  for	  the	  precise	  
placement	  of	  critical	  prosthetic	  devices.	  
Our	  lab	  83,	  84	  and	  others	  85-­‐88	  have	  used	  iCMR	  to	  deliver	  cells	  and	  other	  materials	  into	  
specified	  targets	  in	  normal	  and	  infarcted	  animal	  hearts.	  We	  have	  found	  it	  particularly	  useful	  
to	  interleave	  multiple	  slices	  during	  iCMR,	  and	  to	  render	  them	  in	  3D	  to	  represent	  their	  true	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geometric	  relationship.	  This	  technology	  provides	  “exposure”	  of	  the	  inside	  of	  the	  beating	  
heart	  even	  better	  than	  does	  open-­‐chest	  surgery.	  Targeting	  can	  be	  based	  on	  wall	  motion,	  late	  
gadolinium	  enhancement	  (infarction),	  perfusion	  defects,	  strain	  maps,	  or	  any	  other	  contrast	  
mechanism	  selected.	  When	  the	  injectate	  includes	  a	  contrast	  agent,	  real-­‐time	  MRI	  can	  
interactively	  depict	  the	  intramyocardial	  dispersion	  of	  the	  injected	  materials.	  This	  can	  be	  
valuable	  for	  confirming	  successful	  delivery,	  for	  assuring	  confluence	  of	  treated	  volumes,	  and	  
for	  avoiding	  inadvertently	  overlapping	  injections.	  
2.5.4 Cardiac	  electrophysiology	  
Cardiac	  electrophysiology	  procedures	  are	  currently	  conducted	  using	  catheter	  techniques	  
without	  compelling	  image	  guidance.	  Endocardial	  surface	  maps	  are	  generated	  using	  
electromagnetic	  mapping	  techniques,	  but	  these	  provide	  only	  “roadmaps”	  that	  do	  not	  
account	  for	  respiratory	  and	  other	  dynamic	  changes.	  Most	  catheter-­‐based	  ablation	  
procedures	  are	  ultimately	  guided	  by	  multichannel	  intracardiac	  electrograms.	  Alternatively,	  
ablation	  is	  conducted	  under	  direct	  surgical	  exposure	  89.	  iCMR	  might	  provide	  similar	  
“exposure”	  for	  image-­‐guided	  transcatheter	  ablation	  of	  cardiac	  arrhythmia	  and	  visualization	  
of	  ablation	  lesions.	  
Several	  groups	  have	  performed	  pre-­‐clinical	  catheter	  tracking	  experiments	  using	  active	  
catheters	  that	  acquire	  filtered	  local	  intracardiac	  electrograms	  90	  and	  have	  characterized	  
ablated	  myocardium	  over	  time	  91.	  The	  team	  at	  Massachusetts	  General	  Hospital	  positioned	  
electrophysiology	  catheters	  in	  an	  MRI	  system	  and	  overlaid	  these	  positions	  onto	  high-­‐
resolution	  cardiac	  images	  92.	  More	  recently,	  they	  performed	  left	  ventricular	  mapping	  in	  a	  
porcine	  model	  of	  chronic	  infarction	  93.	  Others	  have	  used	  similar	  systems	  to	  ablate	  the	  
cavotricuspid	  isthmus	  or	  pulmonary	  veins	  94-­‐96.	  
2.5.5 Extra-­‐anatomic	  communications	  
iCMR	  may	  even	  enable	  interventions	  outside	  normal	  lumen	  spaces.	  Arepally	  et	  al	  97	  
conducted	  image-­‐guided	  puncture	  of	  the	  cardiac	  interatrial	  septum,	  a	  procedure	  usually	  
conducted	  primarily	  using	  tactile	  feedback	  under	  X-­‐ray.	  Our	  lab	  conducted	  similar	  septal	  
puncture	  followed	  by	  balloon	  septostomy	  and	  MRI	  assessment	  of	  the	  resulting	  small	  
intracardiac	  shunts	  98.	  While	  similarly	  guidance	  is	  afforded	  by	  intracardiac	  or	  
transesophageal	  ultrasound,	  these	  are	  important	  preclinical	  steps	  toward	  more	  elaborate	  
procedures	  guided	  by	  MRI.	  
With	  the	  advent	  of	  trans-­‐catheter	  valvular	  interventions,	  alternative	  access	  routes	  to	  deliver	  
Page	  34	  of	  242	  
large	  devices	  to	  the	  heart	  are	  required.	  iCMR	  facilitates	  development	  of	  novel	  approaches	  
that	  are	  not	  feasible	  under	  X-­‐ray	  guidance,	  for	  example	  direct	  transthoracic	  access	  to	  the	  left	  
ventricle	  through	  the	  cardiac	  apex	  99	  or	  right	  ventricle	  100.	  Ratnayaka	  et	  al	  101	  demonstrated	  
that	  a	  direct	  transthoracic	  approach	  could	  be	  used	  to	  close	  ventricular	  septal	  defects	  in	  an	  
animal	  model	  (Figure	  2-­‐5).	  An	  added	  advantage	  is	  the	  ability	  to	  monitor	  for	  and	  manage	  
complications	  early,	  for	  example	  pericardial	  effusion	  102.	  
Using	  a	  unique	  double-­‐doughnut	  MRI	  configuration	  containing	  an	  integrated	  flat-­‐panel	  X-­‐
Ray	  fluoroscopy	  system,	  Kee	  et	  al	  have	  conducted	  preclinical	  103	  and	  clinical	  104	  transjugular	  
intrahepatic	  porto-­‐systemic	  shunt	  (TIPS)	  procedures.	  Even	  in	  this	  proof-­‐of-­‐concept	  
experiment,	  MRI	  reduced	  the	  number	  of	  trans-­‐hepatic	  needle	  punctures	  compared	  with	  
historical	  controls.	  Arepally	  et	  al	  conducted	  even	  more	  adventurous	  preclinical	  experiments	  
in	  creating	  a	  catheter-­‐based	  mesocaval	  shunt	  outside	  the	  liver	  capsule	  105.	  Ratnayaka	  et	  al	  
recently	  created	  percutaneous	  bidirectional	  Glenn	  shunts	  in	  swine,	  connecting	  the	  superior	  
vena	  cava	  and	  right	  pulmonary	  artery,	  using	  rtMRI	  guidance	  and	  an	  “active”	  needle	  (Figure	  
2-­‐6).	  This	  sort	  of	  extra-­‐anatomic	  bypass,	  once	  made	  available	  to	  non-­‐surgeons,	  has	  the	  
potential	  to	  revolutionize	  mechanical	  revascularization.	  
2.6 Human	  iCMR	  procedures	  
2.6.1 Diagnostic	  cardiac	  catheterization	  
Razavi	  et	  al	  13	  at	  Kings	  College	  in	  London	  conducted	  the	  first	  diagnostic	  cardiac	  
catheterization	  in	  children	  using	  a	  combined	  XMR	  environment.	  The	  same	  group	  conducted	  
X-­‐ray	  Fused	  with	  MRI	  (XFM)	  procedures,	  in	  which	  prior	  MRI	  datasets	  were	  combined	  with	  
real-­‐time	  XRF	  to	  conduct	  therapeutic	  procedures.	  Kuehne	  et	  al	  also	  conducted	  diagnostic	  
cardiac	  catheterization	  procedures	  using	  passive	  catheter	  devices	  under	  rtMRI	  14.	  Three	  
groups	  have	  reported	  invasive	  imaging	  of	  peripheral	  artery	  atheromata	  using	  profile-­‐design	  
active	  guidewire	  receiver	  coils	  6,	  47,	  48.	  In	  the	  report	  by	  Dick	  et	  al	  6,	  we	  concluded	  this	  
guidewire	  design	  adds	  little	  to	  surface	  coils	  for	  diagnostic	  MRI	  of	  atherosclerosis,	  but	  might	  
have	  value	  in	  delivering	  interventional	  devices	  using	  iCMR.	  A	  team	  in	  Regensburg,	  Germany,	  
conducted	  high	  quality	  selective	  intra-­‐arterial	  MR	  angiography	  106	  and	  reported	  preliminary	  
revascularization	  procedures	  using	  passive	  devices	  in	  the	  iliac	  107	  and	  femoral	  108	  arteries.	  
The	  Stanford	  team	  conducted	  iCMR-­‐assisted	  TIPS	  procedures	  in	  patients	  104.	  
At	  NIH	  15	  we	  perform	  MR-­‐guided	  right	  heart	  catheterization	  using	  MR-­‐safe	  catheters	  with	  
gadolinium-­‐filled	  balloons	  (Figure	  2-­‐10).	  The	  procedure	  has	  been	  re-­‐classified	  as	  a	  standard	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medical	  procedure	  in	  our	  hospital	  and	  to	  date	  we	  have	  performed	  over	  80	  clinical	  cases	  in	  
adults	  with	  a	  wide	  range	  of	  diseases,	  including	  pulmonary	  hypertension,	  heart	  failure,	  and	  
intra-­‐cardiac	  shunt.	  We	  have	  also	  opened	  an	  interventional	  MRI	  suite	  at	  Children’s	  National	  
Medical	  Center	  in	  Washington	  DC	  to	  provide	  ‘radiation-­‐free’	  catheterization	  to	  paediatric	  
and	  adult	  patients	  with	  congenital	  heart	  disease.	  
Importantly,	  MR-­‐guided	  catheterization	  promises	  to	  provide	  hemodynamic	  and	  functional	  
information	  that	  X-­‐ray	  fluoroscopy	  cannot	  109.	  Cardiac	  chamber	  volumes	  and	  function,	  and	  
large	  vessel	  dimensions	  can	  be	  assessed	  using	  cine	  imaging.	  In	  many	  diseases,	  for	  example	  
pulmonary	  hypertension	  or	  advanced	  heart	  failure,	  right	  ventricular	  mass,	  volume	  and	  
function	  have	  independent	  prognostic	  value	  110,	  111.	  Phase	  contrast	  MRI	  permits	  
measurement	  of	  flow	  through	  major	  vessels	  (e.g.	  pulmonary	  arteries	  and	  aorta)	  and	  
calculation	  of	  Qp	  and	  Qs.	  Muthurangu	  elegantly	  demonstrated	  that	  important	  hemodynamic	  
parameters	  such	  as	  pulmonary	  vascular	  resistance	  112	  or	  pulmonary	  artery	  compliance	  113	  
were	  more	  accurately	  assessed	  by	  combining	  MR	  phase	  contrast-­‐derived	  cardiac	  output	  and	  
invasive	  pressure	  measurements,	  compared	  with	  traditional	  cath	  lab	  techniques	  (e.g.	  Fick	  or	  
thermodilution),	  particularly	  during	  pulmonary	  vasoreactivity	  testing	  with	  high	  flow	  oxygen	  
and	  inhaled	  nitric	  oxide.	  
By	  adding	  sequences	  such	  as	  lung	  perfusion	  to	  screen	  for	  chronic	  pulmonary	  
thromboemboli,	  T1	  mapping	  or	  delayed	  contrast	  enhancement	  to	  screen	  for	  diffuse	  of	  
regional	  myocardial	  fibrosis,	  a	  comprehensive	  ‘one-­‐stop’	  cardiopulmonary	  assessment	  can	  
be	  obtained	  114,	  115.	  By	  repeating	  imaging	  and	  invasive	  hemodynamic	  measurements	  under	  
different	  physiological	  provocations,	  for	  example	  with	  exercise,	  saline	  challenge	  or	  inhaled	  
nitric	  oxide,	  iCMR	  catheterization	  could	  help	  unmask	  latent	  symptoms	  and	  pathology	  not	  
apparent	  at	  rest	  and	  provide	  useful	  prognostic	  information	  109,	  116-­‐118.	  We	  now	  routinely	  
perform	  functional	  imaging,	  phase	  contrast	  to	  measure	  cardiac	  output	  and	  invasive	  
hemodynamic	  measurements	  at	  baseline	  and	  repeated	  with	  up	  to	  two	  physiological	  
provocations	  in	  all	  patients,	  all	  within	  less	  than	  two	  hours.	  We	  have	  also	  streamlined	  
scanning	  protocols	  to	  eliminate	  the	  need	  for	  patient	  breath	  holding,	  using	  investigational	  
realtime	  sequences	  and	  free-­‐breathing	  phase	  contrast	  with	  averaging	  119,	  120.	  This	  is	  critical	  
because	  many	  patients	  with	  advanced	  disease	  struggle	  to	  breath	  hold,	  particularly	  if	  they	  
receive	  sedation	  for	  the	  catheterization	  procedure.	  
2.6.2 Structural	  heart	  interventions	  
Some	  structural	  iCMR	  procedures	  have	  already	  been	  performed	  in	  humans,	  including	  aortic	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coarctation	  angioplasty	  121,	  femoral	  and	  popliteal	  artery	  angioplasty	  108	  and	  pulmonary	  
valvuloplasty	  11.	  But	  widespread	  clinical	  adoption	  has	  been	  delayed	  by	  the	  unavailability	  of	  
commercial	  MR-­‐safe	  guidewires,	  catheters	  and	  devices	  that	  meet	  the	  mechanical	  standards	  
expected	  of	  conventional	  catheters	  and	  devices	  used	  in	  X-­‐ray.	  
2.6.3 Cardiac	  electrophysiology	  
Several	  manufacturers	  (Imricor,	  MRI-­‐Interventions)	  have	  developed	  MR-­‐conditional	  
electrophysiology	  ablation	  systems	  and	  catheters,	  using	  passive	  or	  active	  tracking	  to	  
navigate	  the	  cardiac	  chambers	  (Figure	  2-­‐9).	  Using	  these	  systems,	  ablation	  of	  simple	  atrial	  
arrhythmias	  has	  been	  reported	  in	  early	  human	  studies	  122,	  123	  (Figure	  2-­‐8).	  Extensive	  work	  is	  
on	  going	  to	  optimize	  ablation	  lesions	  visualization,	  which	  has	  the	  potential	  to	  improve	  
arrhythmia	  termination	  rates	  by	  enabling	  the	  operator	  to	  verify	  adequate	  ablation	  depth	  
and	  continuity	  of	  ablation	  lines	  in	  realtime	  124-­‐129.	  There	  is	  evidence	  that	  procedural	  success	  
defined	  by	  rates	  of	  arrhythmia	  recurrence	  after	  ablation	  correlates	  with	  the	  extent	  of	  late	  
gadolinium	  enhancement	  130.	  
2.7 Conclusion	  
Advocates	  promote	  the	  development	  of	  iCMR	  for	  the	  sake	  of	  reduction	  of	  radiation	  
exposure	  to	  patients,	  especially	  young	  patients	  who	  are	  anticipated	  to	  require	  a	  large	  
cumulative	  radiation	  exposure	  during	  diagnostic	  and	  therapeutic	  procedures;	  reduction	  of	  
radiation	  exposure	  to	  operators	  and	  staff,	  who	  endure	  a	  large	  cumulative	  radiation	  exposure	  
during	  their	  careers;	  reduction	  of	  patient	  exposure	  to	  nephrotoxic	  iodinated	  contrast,	  which	  
is	  important	  in	  patients	  with	  moderate-­‐severe	  renal	  disease;	  and	  to	  eliminate	  the	  
requirement	  that	  staff	  wear	  heavy	  protective	  lead	  garments,	  which	  are	  associated	  with	  a	  
high	  incidence	  of	  chronic	  musculoskeletal	  injury.	  Detractors	  argue	  that	  iCMR	  represents	  a	  
costly	  and	  cumbersome	  alternative	  to	  procedures	  that	  otherwise	  are	  conducted	  rapidly	  and	  
efficiently	  under	  X-­‐ray	  guidance	  and	  occasionally	  enhanced	  with	  adjunctive	  ultrasound.	  
Detractors	  also	  argue	  that	  despite	  any	  potential	  benefit,	  the	  large	  capital	  outlays	  and	  
expected	  higher	  marginal	  cost	  of	  disposable	  (catheter)	  equipment	  are	  simply	  unjustifiable.	  
These	  arguments	  are	  less	  tenable.	  Existing	  XMR	  facilities	  are	  constructed	  to	  permit	  each	  
imaging	  system	  to	  be	  used	  independently	  of	  the	  other.	  The	  only	  incremental	  expense	  over	  
separate	  angiography	  and	  MRI	  systems	  is	  the	  cost	  of	  the	  inter-­‐modality	  transfer	  table	  and	  
the	  barrier	  doors	  connecting	  the	  systems.	  
	  As	  described	  above,	  the	  chief	  obstacle	  to	  further	  development	  of	  iCMR	  is	  the	  limited	  
Page	  37	  of	  242	  
availability	  of	  clinical	  grade	  catheters	  and	  devices	  suitable	  for	  use	  in	  the	  MR	  environment.	  
This	  in	  turn	  discourages	  wider	  deployment	  of	  XMR	  or	  iCMR	  systems.	  That	  said,	  clinical	  iCMR	  
for	  simple	  diagnostic	  cardiac	  catheterization	  is	  feasible	  using	  existing	  technology	  and	  off-­‐the-­‐
shelf	  catheters,	  and	  is	  in	  routine	  clinical	  use	  in	  institutions	  in	  the	  US	  and	  Europe.	  iCMR	  
electrophysiology	  is	  expected	  to	  be	  an	  area	  of	  particular	  interest	  and	  technical	  development,	  
now	  that	  MR-­‐conditional	  electrophysiology	  mapping	  and	  ablation	  systems	  are	  available	  and	  
first-­‐in-­‐man	  arrhythmia	  ablation	  has	  been	  demonstrated.	  
However,	  iCMR	  may	  prove	  superior	  because	  using	  a	  single	  modality,	  3D	  anatomy,	  
composition,	  function,	  and	  hemodynamics	  can	  be	  combined.	  iCMR	  can	  provide	  surgical-­‐
grade	  exposure	  to	  guide	  non-­‐surgical	  minimally-­‐invasive	  procedures	  and	  could	  enable	  
completely	  new	  procedures	  to	  be	  developed.	  This	  has	  the	  potential	  to	  revolutionize	  the	  
conduct	  of	  minimally	  invasive	  image-­‐guided	  treatments.	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2.8 Figures	  
	  
Figure	  2-­‐1:	  Demonstration	  of	  multi-­‐slice	  imaging	  
Two	  slices	  are	  acquired	  together	  and	  displayed	  in	  their	  true	  3-­‐dimensional	  relationship.	  This	  
also	  demonstrates	  the	  problem	  of	  out-­‐of-­‐plane	  catheters.	  On	  the	  left,	  the	  heart	  is	  visualized	  
in	  multiple	  concurrent	  imaging	  planes	  while	  a	  transaortic	  myocardial	  injection	  needle	  is	  
manipulated.	  The	  guiding	  catheter	  is	  coloured	  green.	  The	  distal	  end	  of	  the	  catheter	  is	  
outside	  the	  selected	  imaging	  plane,	  and	  is	  therefore	  not	  visible.	  On	  the	  right,	  ‘projection	  
mode’	  is	  activated	  in	  the	  coronal	  view	  so	  that	  the	  entire	  length	  of	  the	  guiding	  catheter	  can	  
be	  visualized.	  This	  functionality	  is	  possible	  with	  catheters	  incorporated	  ‘active’	  receiver	  coils.	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Figure	  2-­‐2:	  iCMR	  suite	  
A	  view	  of	  the	  NIH	  XMR	  suite	  during	  a	  procedure	  –	  (A)	  Conventional	  X-­‐ray	  fluoroscopy	  is	  used	  
for	  coronary	  artery	  catheterization.	  (B-­‐C)	  The	  patient	  is	  transferred	  to	  MRI	  on	  the	  transfer	  
table.	  (D)	  Diagnostic	  right	  heart	  catheterization	  is	  performed	  using	  realtime	  MR-­‐guidance.	  
The	  operators	  wear	  fibre	  optic	  noise-­‐suppression	  headsets	  with	  microphones,	  and	  watch	  
realtime	  MR	  images	  and	  hemodynamics	  projected	  from	  shielded	  projectors.	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Figure	  2-­‐3:	  A	  comparison	  of	  representative	  catheter	  designs	  for	  iCMR	  
(A)	  Shows	  a	  traditional	  X-­‐ray	  catheter,	  which	  incorporates	  stainless	  steel	  braid	  for	  strength.	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The	  steel	  distorts	  the	  MR	  image	  and	  has	  the	  potential	  to	  heat,	  as	  it	  would	  in	  a	  microwave	  
oven.	  (B)	  Shows	  the	  same	  passive	  catheter	  without	  steel	  braids,	  rendering	  it	  nearly	  invisible	  
even	  in	  vitro.	  (C)	  Shows	  the	  same	  catheter	  shape	  in	  an	  ‘active-­‐profile’	  design,	  incorporating	  
an	  MRI	  receiver	  coil	  to	  make	  it	  visible.	  (D)	  Shows	  a	  tracking-­‐microcoil-­‐design	  catheter	  
incorporating	  a	  microcoil	  near	  the	  tip.	  The	  3D	  position	  of	  the	  microcoil	  can	  be	  tracked	  
rapidly	  and	  indicated	  using	  computer-­‐synthesized	  cross-­‐hairs	  (green)	  as	  it	  is	  moved	  into	  the	  
right	  ventricle	  of	  the	  animal	  shown	  in	  (E),	  Courtesy	  of	  Michael.	  Bock,	  DKFZ	  Heidelberg,	  
Germany).	  The	  rest	  of	  the	  catheter	  is	  not	  visible	  under	  MRI.	  (F)	  Shows	  a	  catheter	  
incorporating	  a	  ‘wireless’	  inductively-­‐coupled	  receiver	  coil	  (Courtesy	  of	  Harald	  H.	  Quick,	  
University	  Essen,	  Germany)	  that	  can	  be	  visualized	  as	  a	  bright	  signal	  using	  MRI131.	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Figure	  2-­‐4:	  Left	  heart	  catheterization	  in	  a	  pig	  using	  the	  NHLBI	  active	  iCMR	  guidewire	  
The	  whole	  shaft	  of	  the	  guidewire	  is	  active	  and	  the	  tip	  has	  a	  separate	  and	  distinct	  signal	  
(arrow).	  The	  guidewire	  is	  navigated	  to	  the	  (A)	  aortic	  arch,	  (B)	  aortic	  valve	  and	  (C)	  through	  the	  
aortic	  valve	  into	  the	  left	  ventricle	  under	  realtime	  MR-­‐guidance.	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Figure	  2-­‐5:	  iCMR	  direct	  transthoracic	  ventricular	  septal	  defect	  closure	  
The	  right	  ventricle	  is	  accessed	  directly	  through	  the	  chest	  wall	  using	  an	  MR	  ‘active’	  needle	  
under	  realtime	  MR-­‐guidance.	  The	  ventricular	  septal	  defect	  (VSD)	  is	  crossed	  anterogradely	  
and	  then	  closed	  using	  an	  Amplatz	  muscular	  VSD	  occluder.	  The	  delivery	  cable	  for	  the	  closure	  
device	  is	  also	  active.	  (A)	  The	  left	  ventricular	  disk	  (arrow)	  is	  deployed	  and	  pulled	  back	  against	  
the	  septum.	  The	  right	  ventricular	  disk	  is	  then	  deployed	  and	  pushed	  forward	  against	  the	  
septum	  to	  close	  the	  defect.	  The	  right	  ventricle	  free	  wall	  puncture	  is	  closed	  using	  an	  off-­‐the-­‐
shelf	  vascular	  closure	  plug.	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Figure	  2-­‐6:	  iCMR	  percutaneous	  bi-­‐directional	  Glenn	  shunt	  
Central	  venous	  access	  is	  obtained	  via	  the	  right	  internal	  jugular	  vein.	  (A)	  An	  active	  needle	  is	  
used	  to	  puncture	  from	  the	  superior	  vena	  cava	  in	  to	  the	  right	  pulmonary	  artery	  under	  
realtime	  MR-­‐guidance	  (arrow).	  A	  guidewire	  is	  then	  positioned	  into	  the	  distal	  left	  pulmonary	  
artery.	  (B)	  A	  covered	  stent	  is	  then	  deployed	  from	  the	  SVC	  into	  the	  right	  pulmonary	  artery.	  
The	  stent	  balloon	  is	  filled	  with	  gadolinium.	  (C)	  The	  SVC	  and	  right	  pulmonary	  artery	  are	  now	  
connected	  with	  a	  conduit	  (i.e.	  ‘Glenn’	  shunt).	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Figure	  2-­‐7:	  Endograft	  treatment	  of	  thoracic	  aortic	  dissection	  in	  a	  pig	  model,	  using	  a	  
commercially	  available	  passive	  device	  
(A)	  Baseline	  aortic	  dissection.	  The	  dissection	  is	  depicted	  with	  arrowheads.	  (B)	  The	  endograft	  
is	  advanced	  retrograde	  from	  the	  iliac	  artery.	  The	  tip	  of	  the	  endograft	  (arrows)	  approaches	  
the	  inferior	  aspect	  of	  the	  dissection,	  inside	  the	  true	  lumen.	  (C)	  The	  endograft	  is	  in	  final	  
position	  before	  deployment.	  (D)	  Most	  of	  the	  false	  lumen	  is	  obliterated	  after	  endograft	  
delivery.	  (Courtesy	  of	  Holger	  Eggebrecht,	  MD	  and	  Harald	  H.	  Quick,	  PhD,	  University	  Hospital	  
Essen,	  Germany).	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Figure	  2-­‐8:	  Cavo-­‐tricuspid	  isthmus	  ablation	  in	  a	  human	  subject	  
(A)	  The	  passively	  tracked	  tip	  of	  the	  ablation	  catheter	  is	  positioned	  above	  the	  cavo-­‐tricuspid	  
isthmus	  (arrow).	  Post-­‐ablation	  T2	  weighted	  (B)	  and	  late	  gadolinium	  enhancement	  (C)	  images	  
of	  the	  cavo-­‐tricuspid	  isthmus	  show	  the	  newly	  created	  ablation	  lesion	  (arrows).	  AA:	  
ascending	  aorta;	  MV:	  mitral	  valve;	  RA:	  right	  atrium;	  RV:	  right	  ventricle.	  (Courtesy	  of	  M.	  
Gutberlet,	  M.	  Grothoff	  and	  G.	  Hindricks,	  University	  of	  Leipzig,	  Germany).	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Figure	  2-­‐9:	  Catheter	  ablation	  of	  typical	  right	  atrial	  flutter	  under	  MR	  guidance	  
The	  intracardiac	  electrogram	  is	  acquired	  at	  several	  locations	  with	  a	  first	  actively	  tracked	  
catheter	  (red,	  Imricor	  Vision	  MR-­‐EP	  catheter)	  while	  pacing	  with	  a	  second	  actively	  tracked	  
catheter	  (green)	  located	  in	  the	  coronary	  sinus.	  The	  Interventional	  MR	  iSuite	  (Philips	  
Research	  Hamburg)	  uses	  the	  position	  tracking	  data	  of	  the	  green	  catheter	  and	  corresponding	  
activation	  time	  data	  to	  update	  a	  color-­‐coded	  activation	  time	  map	  for	  each	  new	  mapped	  
point.	  The	  colours	  represent	  the	  interpolation	  of	  previously	  acquired	  activation	  times	  on	  the	  
right	  atrial	  endocardial	  shell.	  Red	  indicates	  early	  and	  blue	  late	  activation.	  The	  shell	  has	  been	  
derived	  from	  the	  segmentation	  of	  a	  3d	  cardiac	  scan	  acquired	  immediately	  before	  the	  
intervention	  (Courtesy	  of	  R.	  Rezavi,	  M.	  O’Neill	  and	  T.	  Schaeffter,	  King’s	  College	  London,	  UK;	  
S.	  Weiss	  and	  S.	  Krueger,	  Philips	  Research,	  Hamburg,	  Germany;	  S.	  Wedan,	  G.	  Stenzel,	  T.	  Lloyd	  
and	  D.	  Sunnarborg,	  Imricor,	  Minnesota,	  US).	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Figure	  2-­‐10:	  MRI	  guided	  right	  heart	  catheterization	  
The	  gadolinium-­‐filled	  balloon	  wedge	  end	  hole	  catheter	  is	  navigated	  through	  the	  right	  heart	  
using	  realtime	  MR-­‐guidance.	  The	  balloon	  appears	  as	  a	  white	  ball	  on	  the	  images	  (arrows).	  
Catheter	  tip	  positioned	  in	  (A)	  Inferior	  vena	  cava,	  (B)	  superior	  vena	  cava,	  (C)	  right	  ventricle,	  
and	  (D)	  right	  pulmonary	  artery.	  At	  key	  positions,	  for	  example	  main	  pulmonary	  artery,	  
simultaneous	  invasive	  pressures	  and	  MR	  phase	  contrast	  flow	  measurements	  are	  acquired.	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2.9 Table	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Table	  2-­‐1:	  General	  approaches	  to	  make	  catheter	  devices	  conspicuous	  under	  MRI	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Chapter	  3. Transatrial	  intrapericardial	  tricuspid	  annuloplasty	  
(publication)	  
3.1 Introduction	  
The	  tricuspid	  valve	  is	  often	  referred	  to	  as	  the	  ‘forgotten	  valve’.	  Surgery	  for	  lone	  tricuspid	  
regurgitation	  is	  rarely	  performed	  due	  to	  high	  mortality	  and	  morbidity.	  Persistent	  tricuspid	  
regurgitation	  after	  aortic	  or	  mitral	  valve	  surgery	  is	  associated	  with	  poor	  prognosis.	  As	  more	  
and	  more	  patients	  undergo	  transcatheter	  treatment	  for	  aortic	  and	  mitral	  valve	  disease,	  a	  
transcatheter	  solution	  for	  the	  tricuspid	  valve	  is	  needed.	  While	  transcatheter	  solutions	  to	  
treat	  aortic,	  mitral	  and	  pulmonary	  valve	  disease	  are	  now	  commercially	  available,	  there	  are	  
none	  for	  the	  tricuspid	  valve.	  
Most	  tricuspid	  regurgitation	  is	  ‘functional’	  or	  ‘secondary’,	  i.e.	  the	  leaflets	  are	  normal	  but	  the	  
annulus	  is	  dilated,	  usually	  due	  to	  dilation	  of	  the	  right	  ventricle.	  Surgical	  treatment	  almost	  
always	  involves	  implantation	  of	  an	  annuloplasty	  ring	  to	  correct	  the	  geometry	  of	  the	  annulus.	  
Transatrial	  intrapericardial	  tricuspid	  annuloplasty	  is	  a	  fully	  percutaneous	  alternative	  that	  
effects	  geometric	  change	  to	  the	  lateral	  tricuspid	  annulus	  from	  a	  circumferential	  extra-­‐
cardiac	  device	  positioned	  along	  the	  atrioventricular	  groove	  in	  the	  pericardial	  space.	  
3.2 The	  role	  of	  CMR	  
Understanding	  the	  complex	  geometry	  of	  the	  atrioventricular	  plane	  and	  the	  morphology	  of	  
the	  tricuspid	  annulus	  in	  health	  and	  in	  disease	  requires	  a	  truly	  three-­‐dimensional	  imaging	  
modality	  with	  excellent	  soft	  tissue	  visualization.	  Three-­‐dimensional	  echocardiography	  is	  
limited	  by	  field	  of	  view	  and	  was	  therefore	  not	  ideal	  for	  this	  application.	  CMR	  is	  better	  suited	  
to	  this	  application	  because	  it	  affords	  unlimited	  imaging	  planes	  and	  excellent	  soft	  tissue	  
characterization.	  During	  this	  project,	  CMR	  was	  used	  to	  determine	  anatomical	  parameters	  for	  
device	  design	  during	  the	  prototyping	  phase,	  to	  assess	  the	  effect	  of	  the	  device	  on	  dynamic	  
cardiac	  geometry	  in	  vivo	  post-­‐implantation	  and	  at	  different	  tension	  levels,	  to	  monitor	  for	  
acute	  complications	  (specifically	  tricuspid	  valve	  obstruction	  and	  pericardial	  effusion),	  and	  to	  
assess	  for	  short-­‐term	  results	  in	  survival	  experiments.	  Evaluating	  the	  differential	  effect	  of	  
tensioning	  on	  the	  tricuspid	  and	  mitral	  annuli	  was	  particularly	  important	  in	  order	  to	  
determine	  the	  optimal	  geometry	  of	  the	  permanent	  implant.	  
The	  actual	  device	  implantation	  procedure	  was	  performed	  using	  X-­‐ray	  fluoroscopy	  guidance	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and	  CMR	  is	  unlikely	  to	  be	  needed	  for	  clinical	  translation.	  Tensioning	  would	  be	  performed	  
under	  echocardiography	  guidance	  focussed	  on	  the	  tricuspid	  annulus	  and	  titrated	  to	  reduce	  
tricuspid	  regurgitation.	  The	  TRAIPTA	  device	  would	  ideally	  be	  constructed	  from	  MRI-­‐
conditional	  materials	  so	  that	  patients	  could	  undergo	  CMR	  to	  assess	  position	  and	  device	  
interaction	  with	  other	  structures	  (e.g.	  mitral	  annulus,	  right	  ventricular	  outflow	  tract)	  
throughout	  the	  cardiac	  cycle,	  although	  dynamic	  cardiac	  CT	  would	  also	  be	  feasible.	  
3.3 Candidate’s	  contribution	  
I	  performed	  all	  of	  the	  pre-­‐clinical	  TRAIPTA	  experiments,	  including	  creation	  of	  the	  animal	  
model.	  I	  worked	  with	  our	  in-­‐house	  engineering	  team	  to	  develop	  and	  build	  the	  TRAIPTA	  
implant.	  I	  analysed	  the	  MRI	  images,	  collected	  the	  haemodynamic	  data	  and	  performed	  the	  
statistical	  analysis.	  I	  drafted	  the	  manuscript	  and	  prepared	  the	  figures,	  tables	  and	  
supplementary	  materials.	  
3.4 Creation	  of	  a	  porcine	  model	  of	  tricuspid	  regurgitation	  
There	  are	  several	  published	  animal	  models	  of	  functional	  tricuspid	  regurgitation.	  None	  use	  
percutaneous	  techniques;	  rather	  all	  are	  invasive	  surgical	  procedures.	  Otaki	  first	  described	  a	  
surgical	  model	  in	  which	  multiple	  small	  incisions	  were	  made	  around	  the	  circumference	  of	  the	  
tricuspid	  annulus	  on	  cardiopulmonary	  bypass133.	  Walter	  described	  a	  similar	  technique	  
performed	  off-­‐pump	  with	  a	  video-­‐assisted	  endoscope	  through	  a	  thoracotomy134.	  Bai	  
reported	  a	  percutaneous	  technique	  of	  tearing	  the	  chordae	  tendineae,	  but	  this	  is	  a	  model	  of	  
organic	  and	  not	  functional	  regurgitation135.	  
We	  hypothesized	  that	  serial	  insults	  to	  the	  right	  heart	  could	  cause	  accelerated	  right	  ventricle	  
and	  tricuspid	  annular	  dilation	  resulting	  in	  secondary	  (or	  ‘functional’)	  tricuspid	  regurgitation.	  
We	  tested	  a	  combination	  of	  the	  following	  approaches	  in	  swine:	  (1)	  right	  ventricle	  myocardial	  
injury	  through	  right	  ventricle	  marginal	  artery	  infarction;	  (2)	  right	  heart	  volume	  overload	  
through	  atrial	  septal	  defect	  creation	  (atrial	  septostomy);	  (3)	  right	  ventricle	  pressure	  overload	  
through	  pulmonary	  artery	  micro-­‐particle	  embolization;	  (4)	  right	  ventricle	  volume	  overload	  
through	  pulmonary	  valve	  disruption	  inducing	  free-­‐flowing	  pulmonary	  regurgitation;	  and	  (5)	  
targeted	  ethanol	  needle	  injection	  into	  the	  right	  ventricular	  papillary	  muscle.	  Importantly,	  all	  
are	  transcatheter	  techniques	  rather	  than	  open	  surgery.	  
3.4.1 Right	  ventricular	  free	  wall	  infarction	  
Animals	  were	  pre-­‐medicated	  with	  oral	  Amiodarone	  400mg	  daily	  for	  5	  days	  prior	  to	  and	  after	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the	  procedure	  and	  a	  further	  300mg	  intravenous	  bolus	  was	  given	  at	  the	  time	  of	  procedure.	  
The	  animals	  were	  anticoagulated	  with	  150IU/kg	  of	  unfractionated	  Heparin.	  A	  biphasic	  
cardiac	  defibrillator	  was	  connected.	  A	  temporary	  pacing	  wire	  was	  positioned	  in	  the	  right	  
ventricular	  apex	  and	  set	  to	  pace	  at	  60bpm	  on	  demand.	  The	  right	  coronary	  artery	  was	  
engaged	  with	  an	  8Fr	  multipurpose	  catheter	  and	  angiograms	  were	  taken	  in	  multiple	  
projections.	  If	  the	  right	  coronary	  artery	  was	  dominant	  and	  the	  posterior	  descending	  artery	  
diameter	  was	  >2mm	  then	  a	  190cm	  hi-­‐torque	  balance	  middleweight	  universal	  0.014”	  
guidewire	  (Abbott	  Vascular,	  Santa	  Clara,	  CA)	  was	  positioned	  in	  the	  posterior	  descending	  
artery.	  A	  short	  (8-­‐12mm)	  monorail	  compliant	  balloon,	  sized	  to	  occlude	  the	  vessel,	  was	  
positioned	  as	  a	  distal	  protection	  device	  in	  the	  right	  coronary	  artery	  just	  proximal	  to	  the	  crux.	  
A	  second	  300cm	  hi-­‐torque	  balance	  middleweight	  universal	  0.014”	  guidewire	  was	  positioned	  
in	  the	  mid	  right	  coronary	  artery	  and	  a	  short	  (8-­‐12mm)	  over-­‐the-­‐wire	  balloon,	  sized	  to	  
occlude	  the	  proximal	  right	  coronary	  artery.	  If	  the	  vessel	  was	  non—dominant	  or	  the	  posterior	  
descending	  artery	  diameter	  was	  ≤2mm	  then	  the	  distal	  protection	  balloon	  was	  not	  used.	  
Intravenous	  fluid	  bolus	  of	  500mL	  was	  given.	  The	  distal	  balloon	  was	  inflated	  first	  and	  an	  
angiogram	  was	  taken	  to	  confirm	  occlusion	  of	  the	  distal	  vessel.	  The	  proximal	  balloon	  was	  
then	  inflated	  and	  an	  angiogram	  was	  taken	  to	  confirm	  occlusion	  of	  the	  proximal	  vessel.	  The	  
proximal	  balloon	  guidewire	  was	  withdrawn	  and	  1mL	  of	  Ethanol	  100%	  doped	  with	  iodinated	  
contrast	  was	  injected	  slowly	  through	  the	  over-­‐the-­‐wire	  balloon	  guidewire	  lumen	  into	  the	  
space	  between	  the	  two	  inflated	  balloons.	  Both	  balloons	  were	  kept	  inflated	  for	  at	  least	  5min	  
and	  12-­‐lead	  electrocardiogram	  was	  monitored	  to	  confirm	  ischemic	  ST	  segment	  changes.	  The	  
proximal	  balloon	  was	  deflated	  first	  to	  allow	  antegrade	  flow	  to	  flush	  any	  remaining	  Ethanol	  
down	  the	  right	  coronary	  artery.	  After	  30sec	  the	  distal	  balloon	  was	  deflated.	  In	  4	  animals,	  
reperfusion	  was	  complicated	  by	  ventricular	  fibrillation	  requiring	  DC	  cardioversion	  and	  
catecholamines.	  4	  animals	  developed	  severe	  right	  heart	  failure	  and/or	  intractable	  
ventricular	  fibrillation	  and	  were	  euthanized.	  Final	  angiograms	  in	  the	  4	  surviving	  animals	  
confirmed	  slow	  or	  absent	  flow	  in	  the	  acute	  marginal	  branches	  of	  the	  right	  coronary	  artery	  
but	  normal	  flow	  in	  the	  posterior	  descending	  artery.	  Follow	  up	  imaging	  with	  magnetic	  
resonance	  late	  gadolinium	  enhancement	  imaging	  confirmed	  subendocardial	  scar	  in	  the	  right	  
ventricular	  free	  wall.	  There	  was	  no	  evidence	  of	  scar	  in	  the	  inferior	  wall	  of	  the	  left	  ventricle.	  
This	  finding	  confirms	  that	  safeguarding	  the	  posterior	  descending	  artery	  with	  a	  distal	  
protection	  balloon	  effectively	  limits	  the	  delivery	  of	  ethanol	  to	  right	  ventricular	  myocardium.	  
However,	  the	  high	  mortality	  from	  right	  ventricle	  infarction	  was	  not	  acceptable	  and	  so	  this	  
technique	  is	  not	  ideal.	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3.4.2 Atrial	  septostomy	  
A	  5Fr	  multipurpose	  catheter	  was	  positioned	  in	  the	  right	  atrium.	  Probing	  of	  the	  inter-­‐atrial	  
septum	  for	  a	  patent	  foramen	  ovale	  was	  performed	  with	  a	  260cm	  0.035”	  hydrophilic-­‐coated	  
guidewire	  (Terumo,	  Somerset,	  NJ).	  If	  the	  wire	  was	  able	  to	  cross	  into	  the	  left	  atrium	  then	  the	  
catheter	  was	  advanced	  through	  the	  foramen	  ovale	  into	  the	  left	  atrium.	  If	  resistance	  was	  met	  
then	  the	  catheter	  was	  exchanged	  for	  a	  5Fr	  hydrophilic-­‐coated	  catheter	  (Terumo).	  If	  no	  PFO	  
was	  found	  then	  trans-­‐septal	  puncture	  was	  performed	  under	  intra-­‐cardiac	  echocardiographic	  
guidance	  (AcuNav,	  Siemens)	  using	  a	  Brockenbrough	  trans-­‐septal	  needle	  and	  Mullins	  sheath	  
(Medtronic,	  Minneapolis,	  MN).	  An	  exchange-­‐length	  0.035”	  Rosen	  guidewire	  was	  positioned	  
in	  the	  left	  upper	  pulmonary	  vein	  and	  the	  catheter/sheath	  was	  then	  removed.	  An	  18-­‐22mm	  
diameter	  (length	  4cm)	  balloon	  was	  then	  advanced	  over	  the	  guidewire	  and	  positioned	  across	  
the	  inter-­‐atrial	  septum.	  The	  balloon	  was	  inflated,	  first	  at	  low	  pressure	  to	  confirm	  a	  waist	  at	  
the	  level	  of	  the	  septum	  and	  then	  up	  to	  the	  rated	  pressure	  (usually	  2-­‐3atm)	  until	  the	  waist	  
disappeared.	  The	  balloon	  was	  then	  deflated	  and	  re-­‐inflated	  twice.	  Flow	  across	  the	  inter-­‐
atrial	  septum,	  was	  confirmed	  with	  intracardiac	  echocardiography	  and/or	  angiography.	  No	  
significant	  hemodynamic	  compromise	  and	  no	  peri-­‐procedural	  complications	  were	  observed	  
in	  any	  animal.	  However,	  right	  ventricle	  dilation	  was	  very	  slow	  to	  develop	  and	  therefore	  this	  
technique	  is	  not	  ideal.	  
3.4.3 Pulmonary	  arterial	  microsphere	  embolization	  
A	  7Fr	  balloon-­‐tip	  Berman	  catheter	  (Arrow,	  Reading,	  PA)	  was	  positioned	  in	  the	  main	  
pulmonary	  monitoring	  of	  pulmonary	  arterial	  pressure.	  Pulmonary	  hypertension	  was	  induced	  
by	  infusion	  of	  non-­‐bioresorbable	  600-­‐1200μm	  diameter	  microspheres	  (Embospheres,	  Merit	  
Medical,	  South	  Jordan,	  UT)	  into	  the	  left	  and	  then	  right	  pulmonary	  arteries	  sequentially	  in	  
2mL	  aliquots	  every	  15	  minutes.	  After	  each	  administration,	  pulmonary	  and	  systemic	  arterial	  
pressures	  were	  measured.	  Microspheres	  were	  administered	  until	  target	  pulmonary	  pressure	  
was	  reached	  (defined	  as	  ≥30%	  increase	  from	  baseline)	  without	  systemic	  pressure	  
compromise	  (<10%	  reduction	  from	  baseline).	  The	  average	  volume	  of	  microspheres	  
administered	  was	  8mL	  split	  equally	  between	  left	  and	  right	  pulmonary	  arteries.	  Infusion	  of	  
microspheres	  was	  well	  tolerated	  with	  no	  hemodynamic	  compromise	  and	  no	  peri-­‐procedural	  
complications.	  Right	  ventricle	  dilation	  occurred	  rapidly	  and	  without	  complication,	  therefore	  
this	  approach	  appears	  to	  be	  a	  good	  option	  to	  induce	  functional	  tricuspid	  regurgitation.	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3.4.4 Pulmonary	  valve	  disruption	  
Disruption	  of	  the	  pulmonary	  valve	  results	  in	  free	  pulmonary	  regurgitation,	  which	  in	  turn	  
results	  in	  volume	  overload	  of	  the	  right	  ventricle.	  Pulmonary	  valve	  disruption	  was	  achieved	  
by	  deploying	  a	  large	  custom-­‐built	  self-­‐expandable	  Nitinol	  stent	  within	  the	  valve,	  pinning	  the	  
leaflets	  open.	  Stent	  implantation	  was	  well	  tolerated	  although	  positioning	  large	  sheath	  in	  the	  
right	  ventricular	  outflow	  tract	  to	  deliver	  the	  stent	  was	  very	  arrhythmogenic	  in	  swine.	  Right	  
ventricle	  dilation	  occurred	  rapidly;	  therefore	  this	  approach	  appears	  to	  be	  a	  good	  option	  to	  
induce	  functional	  tricuspid	  regurgitation.	  One	  animal	  developed	  a	  pericardial	  effusion,	  which	  
upon	  necropsy	  was	  caused	  by	  erosion	  of	  a	  sharp	  end	  of	  the	  stent	  braid	  through	  the	  right	  
ventricular	  outflow	  tract.	  Stents	  with	  smooth,	  atraumatic	  ends	  should	  prevent	  this	  
complication.	  
3.4.5 Right	  ventricular	  papillary	  muscle	  ethanol	  injection	  
Under	  intracardiac	  echocardiography	  guidance,	  a	  Brockenbrough	  needle	  was	  advanced	  into	  
the	  right	  ventricle	  and	  into	  the	  base	  of	  the	  right	  ventricular	  papillary	  muscle.	  A	  small	  amount	  
of	  100%	  ethanol	  was	  injected	  (approximately	  0.5-­‐1mL)	  and	  the	  needle	  withdrawn.	  Although	  
visible	  using	  intracardiac	  echocardiography,	  the	  right	  ventricular	  papillary	  muscle	  was	  small	  
in	  swine	  and	  therefore	  was	  difficult	  to	  target	  accurately.	  In	  addition,	  this	  technique	  causes	  
tricuspid	  regurgitation	  through	  restriction	  of	  the	  papillary	  muscle	  and	  chords,	  which	  is	  a	  
primary	  rather	  than	  secondary	  mechanism	  of	  regurgitation.	  For	  this	  reason,	  this	  technique	  
was	  not	  considered	  useful	  and	  was	  abandoned.	  
3.4.6 Combination	  of	  techniques	  
For	  the	  purposes	  of	  the	  TRAIPTA	  experiments,	  we	  used	  animals	  with	  tricuspid	  regurgitation	  
caused	  through	  a	  number	  of	  different	  combinations	  of	  the	  above	  techniques	  (as	  detailed	  in	  
the	  Section	  3.5).	  For	  future	  experiments,	  in	  order	  to	  minimize	  complications	  and	  mortality,	  
the	  preferred	  technique	  would	  be	  to	  create	  functional	  tricuspid	  regurgitation	  via	  
simultaneous	  pressure	  and	  volume	  overload	  of	  the	  right	  ventricle,	  by	  pulmonary	  artery	  
microsphere	  embolization	  and	  stenting	  open	  the	  pulmonary	  valve.	  We	  expect	  mortality	  and	  
morbidity	  from	  these	  two	  procedures	  to	  be	  low.	  Right	  ventricular	  dilation	  appears	  to	  occur	  
rapidly	  (within	  approximately	  2	  weeks)	  resulting	  in	  tricuspid	  annular	  dilation	  and	  
development	  of	  tricuspid	  regurgitation.	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3.5 Transatrial	  intrapericardial	  tricuspid	  annuloplasty	  
An	  original	  research	  manuscript	  published	  in	  the	  ‘Journal	  of	  the	  American	  College	  of	  
Cardiology:	  Cardiovascular	  Interventions’	  in	  2015.	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ABSTRACT
OBJECTIVES This study sought to demonstrate transcatheter deployment of a circumferential device within
the pericardial space to modify tricuspid annular dimensions interactively and to reduce functional tricuspid regurgitation
(TR) in swine.
BACKGROUND Functional TR is common and is associated with increased morbidity and mortality. There are no
reported transcatheter tricuspid valve repairs. We describe a transcatheter extracardiac tricuspid annuloplasty device
positioned in the pericardial space and delivered by puncture through the right atrial appendage. We demonstrate acute
and chronic feasibility in swine.
METHODS Transatrial intrapericardial tricuspid annuloplasty (TRAIPTA) was performed in 16 Yorkshire swine, including
4 with functional TR. Invasive hemodynamics and cardiac magnetic resonance imaging (MRI) were performed at baseline,
immediately after annuloplasty and at follow-up.
RESULTS Pericardial access via a right atrial appendage puncture was uncomplicated. In 9 naïve animals, tricuspid
septal-lateral and anteroposterior dimensions, the annular area and perimeter, were reduced by 49%, 31%, 59%, and
24% (p < 0.001), respectively. Tricuspid leaﬂet coaptation length was increased by 53% (p < 0.001). Tricuspid geo-
metric changes were maintained after 9.7 days (range, 7 to 14 days). Small effusions (mean, 46 ml) were observed
immediately post-procedure but resolved completely at follow-up. In 4 animals with functional TR, severity of regur-
gitation by intracardiac echocardiography was reduced.
CONCLUSIONS Transatrial intrapericardial tricuspid annuloplasty is a transcatheter extracardiac tricuspid valve
repair performed by exiting the heart from within via a transatrial puncture. The geometry of the tricuspid annulus can
interactively be modiﬁed to reduce severity of functional TR in an animal model. (J Am Coll Cardiol Intv 2015;8:483–91)
© 2015 by the American College of Cardiology Foundation.
T ricuspid regurgitation (TR) is a predictorof mortality, increasing with regurgitationseverity and independent of age, biventricu-
lar function or dimensions, or pulmonary artery
pressure (1). In patients with mitral regurgitation (2)
or undergoing left-sided valve surgery (3), TR is asso-
ciated with heart failure and worse outcome. Persis-
tent TR after left-sided valve surgery predicts poor
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outcome (4). Isolated tricuspid valve surgery
is associated with high mortality (5,6) and,
therefore, is seldom justiﬁable.
Most clinical TR is “functional” and is
caused by dilation of the right ventricle and
tricuspid annulus (7), resulting from volume
or pressure overload. Less commonly, dila-
tion results from primary right ventricular
(RV) pathology such as RV infarction or
cardiomyopathy. The severity of TR corre-
sponds to tricuspid annulus dimension (8)
and is dependent on individual patient pre-
load and afterload conditions, which vary with time.
Surgical annuloplasty restores annular geometry
and improves leaﬂet coaptation (9). Replacement
tricuspid valves are more susceptible to thrombosis
compared with prostheses in the mitral or aortic po-
sitions. Transcatheter repairs have been developed
for functional mitral regurgitation (10–12) but not
functional TR.
Transatrial intrapericardial tricuspid annuloplasty
(TRAIPTA) is a novel transcatheter tricuspid valve
repair, guided by x-rayﬂuoroscopy. The pericardium is
accessed via a puncture of the right atrial appendage
(RAA) from within. A circumferential implant, which
exerts compressive force over the tricuspid annulus, is
delivered along the atrioventricular groove within the
pericardial space. Tension on the implant is adjusted
interactively tomodify tricuspid annular geometry and
reduce TR. The RAA puncture is sealed using off-the-
shelf nitinol closure devices.
In this study, we tested pre-clinical feasibility of
transcatheter extracardiac tricuspid annuloplasty in
swine and showed that substantial modiﬁcation of
tricuspid annular geometry is achieved and sustained
for at least 7 days. In animals with induced functional
TR, we showed that TRAIPTA effectively reduces the
severity of tricuspid regurgitation. We also explored
the feasibility of clinical translation through human
cardiac computed tomography (CT) analysis.
METHODS
Procedures were approved by the institutional animal
care and use committee. TRAIPTA was performed in
16 Yorkshire swine (mean 48 ! 14 kg) under general
anesthesia and mechanical ventilation. Of these, 9
naïve animals were survived for 7 to 14 days, 4 with
functional TR were survived for up to 48 days and 3
underwent nonsurvival characterization of TRAIPTA
tension and coronary artery protection elements.
Hemodynamics and geometry were characterized
at each time point by angiography, magnetic reso-
nance imaging (MRI) at mid-systole at 1.5-T, and/or
320-detector row CT. Selective coronary angiography
was performed before and after TRAIPTA.
TRAIPTA SYSTEM CONFIGURATION. We designed
and built a catheter system comprising a delivery
device and a permanent implant (Figure 1). The
delivery device is formed from an interrupted 0.035-
inch nitinol wire, pre-shaped into a self-expanding
loop to open inside the pericardium and encircle
the heart. The TRAIPTA implant comprises a 2.5-mm
diameter hollow tube of braided 0.005-inch nitinol
wire. The braided design allows the implant to
shorten longitudinally by more than 50%. A braided
polyester suture (Ti-Cron size 2, Covidien, Waltham,
Massachusetts) runs within the hollow implant with
a pre-tied sliding Roeder knot that allows interac-
tive tightening after deployment and that ensures
continuous myocardial apposition. The implant is
pre-mounted on the delivery device loop and is pre-
loaded into a 12-F braided sheath (Cook Medical,
Bloomington, Indiana) for deployment.
TRANSATRIAL PERICARDIAL ACCESS. The RAA was
engaged from the femoral vein with a 4-French
multipurpose catheter (Figure 2) and punctured us-
ing the back end of a 0.035-inch guidewire. The
catheter was exchanged for a 14-F sheath (Cook
Medical); 10 ml of 50% iopamidol/saline was injected
into the pericardial sheath to visualize epicardial
structures (Online Appendix, Online Figure 1).
DELIVERY AND TIGHTENING OF TRAIPTA IMPLANT.
The nitinol loop of the TRAIPTA system opened in-
side the pericardium to encircle the heart along the
atrioventricular groove (Figure 1). The delivery device
was then withdrawn, leaving the TRAIPTA implant in
place. The suture was tightened interactively during
real-time 1.5-T MRI (Aera, Siemens, Erlangen, Ger-
many) to achieve the desired tension.
In animals with functional TR, implant tension
was adjusted during intracardiac echocardiography.
In 2 naïve animals, we assessed the tension-
geometry relationship by applying progressive ten-
sion measured with a force meter, 3 times in each
animal, during real-time MRI.
CLOSURE OF THE RAA PUNCTURE. After TRAIPTA
deployment, pericardial contrast was washed out
and 2 mg/kg triamcinolone was infused to impede
pericardial adhesions (13). Alongside a 0.014-inch
“buddy” guidewire (Ironman, Abbott Vascular, Santa
Clara, California) for emergency bailout, a 5- or 6-mm
nitinol atrial septal occluder (Amplatzer, St. Jude
SEE PAGE 492
ABBR EV I A T I ON S
AND ACRONYMS
CT = computed tomography
MRI = magnetic resonance
imaging
RAA = right atrial appendage
RV = right ventricular
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Figure	  3-­‐1:	  TRAIPTA	  system	  and	  procedural	  steps	  	   	  
Medical, St. Paul, Minnesota or Lepu Medical, Bejing,
China) closed the appendage puncture site. A ﬁnal RAA
angiogram conﬁrmed hemostasis before all wires and
sheaths were withdrawn.
ANIMAL MODEL OF FUNCTIONAL TR. Ten naïve York-
shire swine underwent procedures to cause right
ventricular (RV) volume and/or pressure overload
or tricuspid papillary restriction. This included com-
binations of (1) isolated RV infarction by ethanol
infusion into the right coronary artery during balloon
protection of the posterior descending artery (n ¼ 8);
(2) interatrial septostomy with a 20-mm balloon
(n ¼ 4); (3) pulmonary artery infusion of 8 ml of
300- to 700-mm polyvinyl-alcohol spheres to induce
pulmonary hypertension (n ¼ 5); (4) ethanol needle
injection directly into the RV papillary muscles
(n ¼ 1); and (5) stenting open the pulmonary valve to
cause severe regurgitation (n ¼ 1). Of these 10 ani-
mals, 4 were euthanized for intractable ventricular
ﬁbrillation or severe right heart failure after RV
infarction. The remaining 6 developed a dilated right
ventricle, but only 4 of these developed moderate-
severe TR after a mean of 117 days. These 4 animals
underwent TRAIPTA with intracardiac echocardiog-
raphy and were survived for up to 48 days.
HUMAN IMAGING FOR SUITABILITY. We studied human
cardiac CT angiograms of patients with RV enlarge-
ment in the anonymized and delinked National
Heart, Lung, and Blood Institute database. This
does not constitute human subjects research under
US45CFRx46.102(f). Suitability criteria for transatrial
access were the presence of a discrete lobe from
which to puncture and anterior orientation. Patients
were evaluated for the presence of a clearly demar-
cated atrioventricular groove suitable for TRAIPTA.
Epicardial coronary arteries at risk of compression
were identiﬁed.
STATISTICAL ANALYSIS. Data were analyzed using
SPSS 19.0 (IBM, Armonk, New York) and reported
as mean " SD. Differences were examined by 1-way
repeated-measures analysis of variance, with Bon-
ferroni post-hoc tests as appropriate. A p # 0.05 was
considered signiﬁcant.
RESULTS
TRAIPTA was performed in a total of 16 animals
(9 naïve survived for 7 to 14 days, 4 with functional
TR survived up to 48 days, and 3 were not survived
to characterize tension-geometry and coronary pro-
tection elements). Transatrial pericardial access was
successful in a single pass, and the TRAIPTA device
was consistently delivered to the atrioventricular
groove in 16 of 16 animals. These 2 stages required
<10 min to perform (Online Video 1).
SURVIVAL EXPERIMENTS IN 9 NAÏVE ANIMALS.
Signiﬁcant tricuspid annular geometric reduction
was achieved by tightening the TRAIPTA implant
(Table 1, Figures 3 and 4), with 49% (p < 0.001)
reduction in the septal-lateral dimension and 31%
(p < 0.001) in the anteroposterior dimension. The
tricuspid annular area and perimeter were reduced
by 59% (p < 0.001) and 24% (p < 0.001), respectively.
FIGURE 1 TRAIPTA System and Procedural Steps
(A) Braided suture (packaging and spool), transatrial intrapericardial tricuspid annulo-
plasty (TRAIPTA) implant and delivery device. (B) TRAIPTA implant loaded onto delivery
device. The suture is housed within the hollow TRAIPTA implant with a pre-tied Roeder
sliding knot. (C) The system is advanced into the pericardium through the right atrial
appendage. (D) The nitinol delivery device ensures that the system opens into a loop
inside the pericardium and reaches the atrioventricular groove. (E) The delivery device is
withdrawn. (F) The implant is tightened. See Online Video 1 for demonstration of
TRAIPTA procedure. TRAIPTA ¼ transatrial intrapericardial tricuspid annuloplasty.
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Figure	  3-­‐2:	  TRAIPTA	  procedure	  in	  vivo	  	   	  
Tricuspid leaﬂet coaptation length (Figure 4) was
signiﬁcantly increased by 53% (p < 0.001). Lesser
mitral annular geometric change was observed with
a mean reduction in the septal-lateral and antero-
posterior dimensions of 15% (p < 0.05) and 15%
(p < 0.05), respectively. No signiﬁcant hemody-
namic changes and no sustained arrhythmias were
observed (Online Table 1). Coronary artery compres-
sion was not seen in any animal (Online Figure 2).
The RAA puncture was consistently closed using a
nitinol closure device in all 9 animals. Post-procedure
MRI demonstrated small pericardial effusions (mean,
46 ! 44 ml), but there was no evidence of tamponade
(Online Table 1). No animal required pericardial
drainage. At follow-up (mean, 9.7 days; range, 7 to
14 days), the TRAIPTA implant remained in place
without migration, and pericardial effusions had
resolved. On necropsy (Figure 5), the implant was
encased in ﬁbrous tissue and fused to the myocar-
dium along its entire course. There were no adhe-
sions between the visceral and parietal pericardial
layers.
SURVIVAL EXPERIMENTS IN 4 ANIMALS WITH
FUNCTIONAL TR. TRAIPTA successfully reduced the
severity of TR by intracardiac echocardiography
(Figure 4). This was maintained up to 48 days of
follow-up. After euthanasia, the TRAIPTA implant
remained intact in the correct anatomic position on
necropsy and was completely endothelialized and
fused to the myocardium (Figure 5).
NONSURVIVAL EXPERIMENTS IN 3 NAÏVE ANIMALS.
Implant tension correlated with changes in annular
geometry (Figure 3), and the feasibility of coronary
artery protection was demonstrated (Online Figure 2),
although, in fact, no coronary compression was
observed in any of these experiments.
ANATOMIC SUITABILITY IN HUMANS. We reviewed
14 cardiac CT angiograms for anatomic suitability
from patients with an intracardiac shunt and a dilated
right heart. RAA morphology and anatomic position
were consistent across subjects. All 14 met both
suitability criteria for transatrial pericardial access.
Thirteen of 14 patients (93%) had a clearly deﬁned
atrioventricular groove. Of those, all had at least
1 epicardial coronary artery that crossed the projected
course of the TRAIPTA implant.
DISCUSSION
To our knowledge, this is the ﬁrst description of a
transcatheter tricuspid valve repair and the ﬁrst
FIGURE 2 TRAIPTA Procedure In Vivo
(A) Right atrial appendage (RAA) angiogram. (B) RAA puncture with 0.035-inch guidewire.
(C) A 14-French sheath introduced into the pericardium. (D) The transatrial intrapericardial
tricuspid annuloplasty (TRAIPTA) implant is deployed around the heart within the contrast-
ﬁlled pericardial space. (E) Delivery system (arrows) withdrawal leaving the TRAIPTA
implant in the atrioventricular groove. (F) The TRAIPTA implant is tightened by a sliding
Roeder knot. (G) Closure of the RAA puncture with a nitinol closure device (arrow).
(H) RAA angiogram 7 days later (arrow indicates the closure device).
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Table	  3-­‐1:	  MRI	  findings	  	   	  
mechanical intervention accomplished via a right
atrial exit to the pericardium. In contrast with the
mitral valve, where primary leaﬂet or subvalvular
apparatus pathology often contributes to regurgita-
tion, most symptomatic TR is caused by annular
dilation with intact valvular apparatus. For this
reason, annuloplasty is the preferred surgical repair.
We showed a dose-response relationship between
TRAIPTA tension and tricuspid geometry and leaﬂet
coaptation; we showed that TRAIPTA treats func-
tional TR in a clinically relevant animal model, that
the right atrial exit port is reliably closed, that the
procedure is rapid and reproducible, and that eligible
humans appear to have suitable anatomy.
TRANSATRIAL PERICARDIAL ACCESS. Transatrial
pericardial access was ﬁrst described by Verrier et al.
(14) to sample pericardial ﬂuid, drain effusions, and
deliver drugs. A number of interventional (15) and
electrophysiology procedures require pericardial
access, which is usually obtained through a “dry”
subxiphoid puncture and which risks hemoper-
icardium from right ventricular or coronary artery
laceration.
TRAIPTA is the ﬁrst mechanical intervention per-
formed by exiting the heart from within via a trans-
atrial puncture. This approach provides direct access
to the base of the heart in the plane of the atrioven-
tricular groove. The puncture was sealed with off-
the-shelf nitinol closure devices, and hemostasis
was consistently achieved in all animals. However,
right atrial pressures were low in these animals, and
the risk of bleeding could be higher in patients with
severe TR or coagulopathy. Small post-procedural
pericardial effusions were observed but without
tamponade, whereas in patients, a temporary peri-
cardial drain would likely be placed. Complete reso-
lution of these effusions was observed in all animals
at follow-up, even with the permanent TRAIPTA
implant in situ. Our current technique requires
inversion of the appendage to ensure proper nitinol
closure device positioning. We believe that the device
redistributes force adequately to protect against
appendage injury.
INTRAPERICARDIAL TRICUSPID ANNULOPLASTY.
Aortic and mitral valve disease commonly coexist
with tricuspid valve disease. Despite the adoption of
transcatheter aortic and mitral valve interventions,
there remains an unmet need for transcatheter
tricuspid valve repair (16), particularly because un-
treated TR after aortic or mitral surgery confers a poor
outcome. Percutaneous orthotopic (17,18) or hetero-
topic (19,20) prosthetic tricuspid valve replacement
has been described, but these risk thrombosis with-
out anticoagulation. TRAIPTA would not require
anticoagulation because the implant is extravascular,
although some patients may have other indica-
tions (e.g., atrial ﬁbrillation). Transcatheter tricuspid
replacement valves are contraindicated in the pres-
ence of transvenous pacing or deﬁbrillator leads, but
TRAIPTA is possible because it is extravascular.
Transatrial exit is possible in the presence of right
atrial pacing leads because the puncture can be per-
formed distant to the lead insertion point. TRIAPTA
may also be a treatment strategy for pediatric and
adult congenital systemic single right ventricle
patients with TR.
In this study, we correlated implant tension
with reduction in tricuspid annular dimensions,
especially in the septal-lateral dimension, which is
the main axis of annular dilation (7) and the principal
target for surgical annuloplasty. The magnitude of
geometric modiﬁcation easily exceeded ranges re-
ported for surgical annuloplasty (21). We observed
lesser geometric modiﬁcation of the mitral annulus,
likely reﬂecting the higher pressures and increased
myocardial thickness of the left heart. Nevertheless,





RA area, cm2 11.8 " 1.6 12.0 " 1.2 11.4 " 2.1
RV end-diastolic volume, ml 84.5 " 12.3 65.6 " 20.9 73.9 " 20.4
RV end-systolic volume, ml 42.5 " 14.8 35.8 " 16.9 36.8 " 17.8
RV stroke volume, ml 42.0 " 7.5 29.9 " 5.9* 37.1 " 6.5
RV ejection fraction, % 50.8 " 11.6 47.6 " 10.3 52.1 " 10.4
LA area, cm2 12.3 " 2.6 11.1 " 1.1 12.1 " 1.9
LV end-diastolic volume, ml 93.3 " 14.7 66.9 " 13.3* 79.2 " 8.7
LV end-systolic volume, ml 51.5 " 13.9 36.6 " 11.3* 41.9 " 5.6
LV stroke volume, ml 41.8 " 8.8 30.3 " 5.6* 37.3 " 8.0
LV ejection fraction, % 45.3 " 9.6 46.1 " 8.3 46.8 " 6.5
TV annulus‡
TV septal-lateral, mm 24.4 " 2.1 12.6 " 2.8† 13.9 " 3.1†
TV anteroposterior, mm 32.8 " 2.4 22.6 " 4.0† 22.6 " 3.6†
TV area, cm2 11.8 " 1.9 5.3 " 1.8† 4.4 " 1.5†
TV annular perimeter, cm 13.2 " 1.1 9.6 " 2.4† 9.8 " 1.2†
TV leaﬂet coaptation length, mm 3.1 " 0.9 6.8 " 0.8† 6.1 " 0.8†
MV annulus‡
MV septal-lateral, mm 29.2 " 3.7 24.8 " 3.8* 25.2 " 2.4
MV anteroposterior, mm 31.1 " 2.5 26.3 " 2.4* 26.1 " 3.3*
MV area, cm2 9.3 " 2.0 6.0 " 1.3† 5.6 " 1.2†
MV annular perimeter, cm 11.9 " 1.1 9.3 " 1.2† 9.1 " 0.9†
Pericardium
Pericardial effusion, ml 0.0 " 0.0 45.8 " 43.7† 0.0 " 0.0
Values are mean " SD. *p < 0.05. †p < 0.001 compared with baseline. ‡Annular measurements were performed
in mid-systole.
LA ¼ left atrium; LV ¼ left ventricle; MRI ¼magnetic resonance imaging; MV ¼mitral valve; RA ¼ right atrium;
RV ¼ right ventricle; TRAIPTA ¼ transatrial intrapericardial tricuspid annuloplasty; TV ¼ tricuspid valve.
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Figure	  3-­‐3:	  Geometric	  change	  resulting	  from	  annuloplasty	  
	   	  
this technique could potentially be adapted to treat
both atrioventricular valves. Unlike surgery, TRAIPTA
can be performed in the beating heart and titrated in
real time under varying loading conditions imposed
by hemodynamic provocations such as exercise and
volume. Importantly, we found geometric change
was maintained over the follow-up period.
ANIMAL MODEL. TR has been induced in animals by
surgical annular disruption (22,23), but there are no
transcatheter large animal models of functional TR.
In this study, we found that to create TR required
multiple insults, including volume and pressure
overload, as well as considerable time to allow the
right ventricle to remodel.
STUDY LIMITATIONS AND POTENTIAL FAILURE
MODES. TRAIPTA requires the pericardial space to
be free of adhesions, which could impede implant
delivery. This likely precludes TRAIPTA in
FIGURE 3 Geometric Change Resulting From Annuloplasty
(A) Mean tricuspid valve annular dimensions in 5- and 2-chamber MRI views. (B) Mean mitral valve annular dimensions in 4- and 2-chamber
magnetic resonance imaging views. Arrows denote measured annular dimensions (A and B). (C) The transatrial intrapericardial tricuspid
annuloplasty (TRAIPTA) implant was tensioned using a force meter attached to the suture. *p < 0.05; **p < 0.001.
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Figure	  3-­‐4:	  Imaging	  of	  tricuspid	  valve	  and	  annulus	  before	  and	  after	  annuloplasty	  
	   	  
patients with previous pericardiotomy or pericarditis.
However, the technique might be useful in conjunc-
tion with transcatheter aortic valve replacement
and/or mitral valve repair. Because of its circumfer-
ential position around the heart, 1 potential com-
plication is coronary artery and coronary sinus
compression. At the level of tension exerted to
achieve 40% reduction in the tricuspid septal-lateral
dimension, we did not observe any coronary artery
or sinus compression (Online Figure 2), albeit in ani-
mals without severe RV hypertension. To address this
potential complication, we demonstrated that a pro-
tection element could be incorporated into the
TRAIPTA implant (Online Figure 2) and that its
FIGURE 4 Imaging of Tricuspid Valve and Annulus Before and After Annuloplasty
(A) Magnetic resonance imaging 5-chamber view at baseline. Arrow denotes tricuspid annulus. (B) A 5-chamber view after transatrial intra-
pericardial tricuspid annuloplasty (TRAIPTA). (C) A 2-chamber view at baseline. (D) A 2-chamber view after TRAIPTA. (E) Tricuspid leaﬂet
coaptation at baseline. Arrow denotes coaptation length. (F) Tricuspid leaﬂet coaptation after TRAIPTA. Arrow denotes coaptation length.
(G) Intracardiac echocardiography of the tricuspid valve before deployment of the TRAIPTA implant. (H) Color Doppler shows a central jet
of moderate-severe tricuspid regurgitation (peak velocity 1.8 m/s). (I) Tensioned TRAIPTA implant at the level of the tricuspid annulus (arrow).
(J) Color Doppler showing signiﬁcant reduction in tricuspid regurgitation severity after TRAIPTA. Ao ¼ aorta; LA ¼ left atrium; LV ¼ left
ventricle; RA ¼ right atrium; RV ¼ right ventricle.
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Figure	  3-­‐5:	  Necropsy	  
	   	  
position along the TRAIPTA implant was adjustable
interactively in situ. This bridgelike element, origi-
nally developed in our lab for mitral cerclage annu-
loplasty (12), directs compressive force away from an
entrapped coronary artery or sinus. Finally, in com-
mon with all permanent implants, potential failure
modes are implant migration and tissue erosion. We
did not observe any implant migration, and on nec-
ropsy, the TRAIPTA device was fully adhered to the
myocardium with no macroscopic evidence of tissue
erosion (Figure 5A). Similar macroscopic ﬁndings
were observed for the nitinol closure device at the
right atrial puncture site. No pericarditis or pericar-
dial adhesions were observed, perhaps because we
administered intrapericardial glucocorticoids after
deployment. These ﬁnding suggests a very low like-
lihood of late device migration or tissue erosion, but
this will be evaluated in a future long-term animal
study.
CLINICAL TRANSLATION AND SUITABILITY OF
HUMAN ANATOMY. RAA morphology was suitable
for transatrial pericardial access in all patients, and
most had a clearly deﬁned atrioventricular groove
suitable for TRAIPTA. Most patients also had epicar-
dial coronary arteries crossing the projected course
of the TRAIPTA implant, and we therefore anticipate
that protection elements would be required in human
implementation (Online Figure 2).
CONCLUSIONS
We report a novel transcatheter tricuspid annulo-
plasty technique using transatrial pericardial access
and pericardial deployment of a permanent implant.
We demonstrate interactive adjustment of tricuspid
annular and leaﬂet geometry in naïve swine, compa-
rable to that achieved with surgical annuloplasty.
In animals with functional tricuspid regurgitation,
this geometric adjustment reduces the severity of
regurgitation.
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  figures	  
	  
Figure	  3-­‐6:	  Epicardial	  anatomy	  revealed	  with	  intrapericardial	  iodinated	  contrast	  
(A)	  Antero-­‐posterior	  projection.	  (B)	  Lateral	  projection.	  The	  sheath	  has	  been	  introduced	  into	  
the	  pericardium	  via	  trans-­‐auricular	  puncture.	  RAA:	  right	  atrial	  appendage;	  LAA:	  left	  atrial	  
appendage;	  RVOT:	  right	  ventricular	  outflow	  tract.	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Figure	  3-­‐7:	  Atrioventricular	  plane	  anatomy	  and	  mechanism	  of	  functional	  tricuspid	  
regurgitation	  
‘Secondary’	  or	  ‘functional’	  tricuspid	  regurgitation	  is	  caused	  by	  progressive	  dilation	  of	  the	  
tricuspid	  valve	  annulus.	  This	  is	  usually	  a	  result	  of	  progressive	  right	  ventricular	  dilation.	  The	  
tricuspid	  annulus	  dilates	  towards	  the	  free	  wall.	  The	  goal	  of	  surgical	  tricuspid	  annuloplasty	  is	  
to	  bring	  the	  free	  wall	  component	  of	  the	  tricuspid	  annulus	  back	  towards	  the	  septum	  and	  
improve	  leaflet	  coaptation.	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Figure	  3-­‐8:	  TRAIPTA	  implant	  
The	  TRAIPTA	  implant	  is	  formed	  of	  braided	  nitinol	  to	  enable	  it	  to	  shorten	  during	  tensioning.	  It	  
is	  pre-­‐mounted	  on	  a	  shaped	  delivery	  catheter	  to	  facilitate	  positioning	  around	  the	  heart	  in	  
the	  atrioventricular	  groove.	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Figure	  3-­‐9:	  TRAIPTA	  procedure	  steps	  (part	  1)	  
(A)	  The	  TRAIPTA	  implant	  is	  advanced	  through	  the	  right	  atrial	  appendage	  sheath	  into	  the	  
pericardium.	  (B)	  The	  shaped	  delivery	  catheter	  opens	  up	  within	  the	  pericardium	  to	  form	  a	  
lasso.	  (C)	  The	  limbs	  of	  the	  delivery	  catheter	  are	  separated	  at	  the	  distal	  portion	  so	  that	  they	  
can	  be	  withdrawn	  once	  the	  TRAIPTA	  implant	  is	  in	  the	  correct	  position.	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Figure	  3-­‐10:	  TRAIPTA	  procedure	  steps	  (part	  2)	  
(A)	  The	  TRAIPTA	  implant	  is	  navigated	  within	  the	  pericardium	  to	  reach	  the	  desired	  position	  
around	  the	  heart	  in	  the	  atrioventricular	  groove.	  (B)	  The	  limbs	  of	  the	  delivery	  catheter	  are	  
withdrawn,	  leaving	  the	  TRAIPTA	  implant	  in	  place.	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Figure	  3-­‐11:	  Differential	  compression	  of	  tricuspid	  and	  mitral	  annuli	  by	  the	  TRAIPTA	  
implant	  band	  
By	  imparting	  different	  shapes	  to	  different	  portions	  of	  the	  TRAIPTA	  implant,	  it	  is	  possible	  to	  
direct	  compressive	  force	  to	  the	  tricuspid	  annulus,	  while	  protecting	  the	  mitral	  annulus.	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Figure	  3-­‐12:	  Coronary	  arteries	  and	  coronary	  sinus	  angiography	  following	  annuloplasty	  
(A)	  Left	  coronary	  artery	  angiogram	  with	  tensioned	  TRAIPTA	  implant	  (arrow).	  (B)	  Right	  
coronary	  artery	  angiogram	  with	  tensioned	  TRAIPTA	  implant	  (arrow).	  (C)	  Coronary	  sinus	  
angiogram	  with	  tensioned	  TRAIPTA	  implant	  (arrow).	  (D)	  Left	  coronary	  angiogram	  with	  a	  rigid	  
protection	  element	  (insert)	  mounted	  within	  the	  TRAIPTA	  implant	  (arrow)	  to	  demonstrate	  
feasibility	  of	  left	  anterior	  descending	  coronary	  artery	  protection.	  Coronary	  artery	  or	  sinus	  
compression	  was	  not	  observed	  in	  any	  animal.	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Figure	  3-­‐13:	  Coronary	  artery	  protection	  
The	  coronary	  artery	  protection	  element	  is	  positioned	  over	  a	  coronary	  artery	  to	  deflect	  
compression	  away	  from	  the	  artery	  and	  preserve	  myocardial	  perfusion.	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3.7 Supplemental	  table	  
n=9	   Baseline	   Post-­‐TRAIPTA	   Follow-­‐up	  
Heart	  rate	  (bpm)	   95±15	   106±11	   101±15	  
Ao	  systolic	  (mmHg)	   83±9	   72±7	   75±10	  
Ao	  diastolic	  (mmHg)	   50±7	   48±5	   48±7	  
IVC	  (mmHg)	   1±2	   2±1	   2±1	  
SVC	  (mmHg)	   1±2	   2±1	   2±2	  
RA	  (mmHg)	   1±2	   2±1	   2±2	  
RV	  systolic	  (mmHg)	   16±5	   16±5	   16±2	  
RV	  diastolic	  (mmHg)	   1±1	   0±0	   1±1	  
PA	  systolic	  (mmHg)	   16±5	   13±3	   14±3	  
PA	  diastolic	  (mmHg)	   5±4	   4±2	   5±2	  
PA	  mean	  (mmHg)	   10±4	   8±2	   9±2	  
PA	  wedge	  pressure	  (mmHg)	   2±2	   2±2	   3±2	  
	  
Table	  3-­‐2:	  Haemodynamic	  findings	  
No	  statistically	  significant	  differences.	  Ao:	  aorta;	  IVC:	  inferior	  vena	  cava;	  PA:	  pulmonary	  
valve;	  RA:	  right	  atrium;	  SVC:	  superior	  vena	  cava.	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Chapter	  4. Intentional	  right	  atrial	  exit	  and	  CO2	  insufflation	  to	  
facilitate	  subxiphoid	  access	  to	  the	  naïve	  pericardial	  space	  
(two	  publications)	  
4.1 Introduction	  
Access	  to	  the	  naïve	  or	  ‘dry’	  pericardium	  is	  required	  for	  a	  number	  of	  electrophysiology	  and	  
structural	  heart	  interventions.	  However,	  serious	  complications	  remain	  high	  despite	  technical	  
refinements	  (e.g.	  the	  use	  of	  micropuncture	  needles).	  Having	  demonstrated	  that	  accessing	  
the	  pericardium	  through	  the	  right	  atrial	  appendage	  appears	  safe	  for	  transatrial	  
intrapericardial	  tricuspid	  annuloplasty,	  we	  explored	  whether	  this	  approach	  could	  be	  used	  to	  
access	  the	  pericardium	  using	  much	  smaller	  transatrial	  catheters	  and	  by	  infusing	  contrast	  into	  
the	  pericardial	  space	  to	  separate	  visceral	  from	  parietal	  pericardial	  layers	  and	  create	  a	  space	  
for	  safe	  and	  easy	  access	  sub-­‐xiphoid	  access.	  
4.2 The	  role	  of	  CMR	  
The	  main	  risk	  of	  intentionally	  puncturing	  the	  right	  atrial	  appendage	  is	  bleeding	  into	  the	  
pericardium	  and	  tamponade.	  To	  assure	  safety	  of	  the	  technique	  before	  clinical	  translation,	  it	  
was	  therefore	  critical	  to	  be	  able	  to	  monitor	  for	  and	  accurately	  measure	  the	  volume	  of	  
accumulating	  pericardial	  fluid	  at	  multiple	  time	  points.	  Introducing	  a	  second	  pericardial	  
catheter	  to	  monitor	  pericardial	  fluid	  accumulation	  could	  have	  confounded	  the	  results	  by	  
causing	  additional	  bleeding	  and	  therefore	  we	  preferred	  a	  non-­‐invasive	  measurement.	  
Intercostal	  and	  subcostal	  windows	  limit	  echocardiography	  of	  the	  pericardium.	  Because	  CMR	  
can	  clearly	  differentiate	  between	  tissue	  and	  fluid,	  and	  because	  CMR	  is	  not	  constrained	  by	  
imaging	  windows	  and	  is	  therefore	  an	  ideal	  imaging	  modality	  for	  this	  application.	  For	  clinical	  
translation,	  serial	  non-­‐invasive	  measurements	  of	  pericardial	  fluid	  are	  not	  required	  and	  so	  
this	  procedure	  can	  be	  performed	  using	  X-­‐ray	  fluoroscopy	  in	  a	  conventional	  cath	  lab.	  
4.3 Candidate’s	  contribution	  
I	  performed	  all	  the	  pre-­‐clinical	  experiments,	  collected	  the	  hemodynamic	  data,	  analysed	  the	  
MRI	  images	  and	  performed	  the	  statistical	  analysis.	  I	  drafted	  the	  manuscript	  and	  prepared	  
the	  figures,	  tables	  and	  supplementary	  materials.	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4.4 Intentional	  right	  atrial	  exit	  for	  microcatheter	  infusion	  of	  pericardial	  
carbon	  dioxide	  or	  iodinated	  contrast	  to	  facilitate	  subxiphoid	  access	  
An	  original	  research	  manuscript	  published	  in	  the	  journal	  ‘Catheterization	  and	  Cardiovascular	  
Interventions’	  in	  2014.	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Basic Science
Intentional Right Atrial Exit for Microcatheter Infusion
of Pericardial Carbon Dioxide or Iodinated Contrast to
Facilitate Sub-Xiphoid Access
Toby Rogers,1 BM, BCh, MRCP, Kanishka Ratnayaka,1,2 MD, William H. Schenke,1 BA,
Anthony Z. Faranesh,1 PhD, Jonathan R. Mazal,1 MS, William W. O’Neill,3 MD,
Adam B. Greenbaum,3 MD, and Robert J. Lederman,1* MD
Objectives: We test the safety of transatrial pericardial access using small catheters, infusion
of carbon dioxide (CO2) or iodinated contrast to facilitate sub-xiphoid access, and catheter
withdrawal under full anticoagulation. Background: Sub-xiphoid pericardial access is required
for electrophysiological and structural heart interventions. If present, an effusion protects the
heart from needle injury by separating the myocardium from the pericardium. However, if the
pericardium is ‘dry’ then there is a significant risk of right ventricle or coronary artery lacera-
tion caused by the heart beating against the needle tip. Intentional right atrial exit is an alter-
native pericardial access route, through which contrast media could be infused to separate
pericardial layers. Methods: Transatrial pericardial access was obtained in a total of 30 York-
shire swine using 4Fr or 2.8Fr catheters. In 16 animals, transatrial catheters were withdrawn
under anticoagulation and MRI was performed to monitor for pericardial hemorrhage. In 14
animals, iodinated contrast or CO2 was infused before sub-xiphoid access was obtained.
Results: Small effusions (mean 18.5 ml) were observed after 4Fr (1.3 mm outer-diameter) but
not after 2.8Fr (0.9 mm outer-diameter) transatrial catheter withdrawal despite full anticoagu-
lation (mean activated clotting time 383 sec), with no hemodynamic compromise. Pericardial
CO2 resorbed spontaneously within 15 min. Conclusions: Intentional transatrial exit into the
pericardium using small catheters is safe and permits infusion of CO2 or iodinated contrast to
separate pericardial layers and facilitate sub-xiphoid access. This reduces the risk of right
ventricular or coronary artery laceration. 2.8Fr transatrial catheter withdrawal does not cause
any pericardial hemorrhage, even under full anticoagulation. VC 2014Wiley Periodicals, Inc.
Key words: pericardial access; epicardial intervention; transatrial puncture; structural
heart intervention; electrophysiology
INTRODUCTION
Access to the na€ıve or ‘dry’ pericardial space in the
absence of effusion is required for interventional proce-
dures, for example epicardial mapping and radiofre-
quency ablation for ventricular tachycardia and for left
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atrial appendage suture ligation [1–3]. Sub-xiphoid
access is usually obtained under fluoroscopic guidance.
A needle is advanced slowly towards the heart and ali-
quots of iodinated contrast are injected until the tip is
confirmed inside the pericardial space. A soft-tipped
wire is then introduced through the needle, over which
larger sheaths can be exchanged. Even though 18-
gauge (1.3 mm outer diameter) needle entry into the
right ventricle is considered benign [4], there is a risk
of laceration to the right ventricle or epicardial coro-
nary arteries. Torsional cardiac and translational respi-
ratory motion exacerbate the risk of more serious
injury by laceration as the heart beats against the sharp
needle tip. Bleeding complication rates of 4–7% have
been reported in single and multicenter studies [5–7]
but real world complication rates may be higher
[8–10].
An alternative transatrial approach for pericardial
access, by intentionally puncturing through the right
atrial appendage (RAA), was first proposed for diag-
nostic sampling and delivery of drugs [11]. A catheter
is navigated to the tip of the RAA from the inferior
vena cava. Next a needle or guidewire is used to punc-
ture through the RAA wall into the pericardial space.
Animal experiments have demonstrated that pericardial
effusions did not develop after needle withdrawal and
the puncture site healed rapidly [12]. Importantly, this
approach appeared technically easy and safe with no
evidence of injury to epicardial vessels or to the thin-
walled right ventricle. Other groups have proposed this
approach for epicardial pacing wire implantation [13]
or epicardial mapping and ablation [14]. We have
advocated transatrial access to the pericardium to
achieve other therapeutic procedures, such as intraper-
iardial tricuspid annuloplasty [15].
We hypothesized that despite aggressive anticoagula-
tion, atrial tissue recoil would avoid significant pericar-
dial hemorrhage or effusion after transatrial access
used to introduce a small catheter into the ‘dry’ peri-
cardium. Second, contrast media could then be infused
through this catheter to separate visceral and parietal
pericardial layers and enhance the safety of sub-
xiphoid access with larger sheaths for electrophysiolog-
ical or heart interventions. Third, we compared pericar-
dial infusion of carbon dioxide versus iodinated
contrast, reasoning that gas would separate the pericar-
dial walls preferentially at the anterior site of supine
sub-xiphoid access, and further that gas might sponta-
neously resorb as a margin of safety.
METHODS
Procedures were approved by the institutional animal
care and use committee. Yorkshire swine were anesthe-
tized with ketamine (25 mg/kg), midazolam (15 mg/
kg), and glycopyrrolate (0.01 mg/kg), and maintained
on sevoflurane (1–4%) with mechanical ventilation,
and femoral arteries, and veins were accessed. Experi-
ments took advantage of a combined interventional car-
diovascular magnetic resonance imaging (MRI) and
biplane X-ray fluoroscopy suite (1.5T Aera and Artis
Zee, Siemens, Erlangen, Germany) for characterization
of pericardial effusion. Pericardial access via RAA
puncture was obtained in a total of 30 Yorkshire swine
with mean weight 48 kg (range 27–66 kg). To test
safety of transatrial pericardial access, 8 animals (4Fr
Puncture group) underwent RAA puncture with a 4Fr
(1.3 mm outer diameter) diagnostic multipurpose cathe-
ter and the back end of a 0.035 inches guidewire and 8
animals (2.8Fr Puncture group) underwent RAA punc-
ture with a 2.8Fr (0.9 mm outer diameter) microcath-
eter (Excelsior, Boston Scientific) and the back end of
a 0.018 inches guidewire (V18, Boston Scientific).
To test CO2 insufflation of the pericardial space to
facilitate sub-xiphoid access, 7 animals (2.8FrþCO2
group) underwent RAA puncture with a 2.8Fr micro-
catheter and the back end of a 0.018 inches guidewire.
The pericardium was then insufflated with CO2 and
sub-xiphoid pericardial access was obtained. To test io-
dinated contrast-facilitated sub-xiphoid access, iopami-
dol (Isovue 300, Bracco) diluted to 25% in normal
saline was infused through a 2.8Fr transatrial micro-
catheter using a power injector in 7 animals
(2.8FrþContrast group). Figure 1 summarizes the ex-
perimental design.
In all animals, a 6Fr diagnostic multipurpose or
angled-tip balloon wedge end-hole catheter was navi-
gated to the RAA from the inferior vena cava using
fluoroscopic guidance (Fig. 2). Position at the tip of
the RAA was confirmed with contrast angiography.
The back end of a guidewire (either 0.035 or 0.018
inches) was used to puncture through the wall of the
RAA into the pericardial space. A catheter (4Fr mul-
tipurpose or 2.8Fr microcatheter) was then advanced
over the wire into the pericardium. To exaggerate
the risk of bleeding, unfractionated heparin (150–200
IU/kg bodyweight) was administered to the first 16
animals to achieve a mean activated clotting time
[16] of 383 sec (range 263–517 sec), before with-
drawal of the transatrial catheter back into the right
atrium.
In the 2.8FrþCO2 group, 100–150 ml of CO2 ("2–
3 ml/kg bodyweight) was delivered into the pericardial
space through the transatrial microcatheter to separate
the visceral and parietal layers (target separation
10 mm). Selective coronary angiography was per-
formed before and after CO2 insufflation to monitor
for coronary artery compression or spasm. Quantitative
2 Rogers et al.
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Figure	  4-­‐1:	  Experimental	  design	  
	   	  
coronary angiography analysis was performed in the
mid left anterior descending artery (LAD) and mid left
circumflex artery (LCx) using Syngo QCA software
(Siemens). Sub-xiphoid access was then obtained using
a 20-gauge micro-puncture needle (0.8 mm outer diam-
eter) and 0.018 inches guidewire using biplane fluoro-
scopic guidance. After sub-xiphoid access was
obtained, the transatrial microcatheter was withdrawn
back into the right atrium.
In the 2.8FrþContrast group, 2–3 ml/kg bodyweight
of iodinated contrast diluted to 25% in normal saline
was infused into the pericardial space through a trans-
atrial microcatheter using a power injector at a rate of
1 ml/sec to minimize microcatheter tip whip. Sub-
xiphoid access was obtained using a 20-gauge micro-
puncture needle and 0.018 inches guidewire.
All animals underwent serial MRI to monitor for
pericardial effusion and/or tamponade after transatrial
catheter withdrawal. We prefer MRI for this purpose
because transthoracic echocardiography is suboptimal
in swine. Contiguous true axial slices were acquired
using a steady-state free precession (SSFP) sequence
with breath hold and ECG gating. Slices were pre-
scribed to include cardiac anatomy from base to
apex to ensure coverage of the entirety of the peri-
cardial space. Acquisition parameters were: repetition
time (TR)/echo time (TE), 2.96/1.25 msec; number
of averages 2; acceleration factor (GRAPPA) 2; flip
angle 80
"
; bandwidth 1157 Hz/pixel; field of view
300 # 300 mm2; matrix 240 # 128 pixels; slice
thickness 6 mm; and slice distance 0 mm. Pericar-
dial and cardiac contours were drawn manually on
each slice and the pericardial effusion volume was
calculated by subtracting the total cardiac volume
from the total pericardial volume using Syngo MR
analysis software (Siemens).
Data were analyzed using SPSS (v19.0, IBM) and
reported as mean6 standard deviation unless otherwise
described. Mean differences were examined by t-test or
one-way repeated measures ANOVA. A P-value $0.05
was considered significant. To estimate the probability
of an adverse event, the binomial confidence interval
was calculated using a one-tailed adjusted Wald inter-
val, and a point estimate using the LaPlace method.
The 95% confidence interval was calculated using an
online tool (http://www.measuringusability.com/wald.
htm). This same method was used to calculate the
number of trials needed to achieve 95% confidence
that the true event rate would be less than 1% and
0.1%, based on the observed event rate.
RESULTS
Pericardial access via RAA puncture was success-
fully obtained in all animals. Once the catheter position
was confirmed in the RAA with angiography, exit into
the pericardium took a few seconds only. The guide-
wire tracked along—but did not puncture—the parietal
pericardium in all animals. In the 4Fr Puncture group
(1.33 mm puncture with 4Fr catheter) small pericardial
effusions were observed in 5/8 anticoagulated animals
with mean volume 18.5 ml (range 7–76 mL) 15 min
after transatrial catheter withdrawal. Effusions did not
enlarge over the following 2 h. There was an insignifi-
cant decline in systolic and diastolic blood pressures
(Fig. 3). There was no change in right atrial pressure.
The largest effusion (76 ml) was observed in one ani-
mal with the highest ACT of 498 sec before transatrial
catheter withdrawal. Otherwise there was no correla-
tion between ACT and effusion volume. In the 2.8Fr
Puncture group, no effusions were observed despite
full anticoagulation.
In the 2.8FrþCO2 group, pericardial CO2 insufflation
effectively separated visceral and parietal layers anteri-
orly to the target separation of 10 mm in all 7 animals.
This separation was highly visible on lateral plane fluo-
roscopy (Fig. 4). A mild transient reduction in systolic
blood pressure and increase in heart rate was observed
during insufflation, but these did not reach statistical
significance (Fig. 3). Selective coronary angiography did
not show any significant coronary artery compression or
vasospasm up to 15 min post-CO2 insufflation (Fig. 2).
Minimum lumen diameters at baseline versus with peri-
cardial CO2 insufflation were 2.8 versus 2.7 mm in the
Fig. 1. Experimental design—4Fr Puncture group: RAA punc-
ture with 4Fr (1.3 mm) catheter then withdrawal after heparin-
ization; 2.8Fr Puncture group: RAA puncture with 2.8Fr
(0.9 mm) microcatheter then withdrawal after heparinization;
2.8Fr1CO2 group: RAA puncture with 2.8Fr microcatheter,
insufflation with CO2, sub-xiphoid access and RAA microcath-
eter withdrawal. 2.8Fr1Contrast group: RAA puncture with
2.8Fr microcatheter, infusion of iodinated contrast, sub-xiph-
oid access and RAA microcatheter withdrawal. RAA: right
atrial appendage.
Intentional Transatrial Pericardial Access 3
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Figure	  4-­‐2:	  Procedural	  steps	  
	   	  
mid LAD and 2.7 versus 2.5 mm in the mid LCx. Sub-
xiphoid access with a micro-puncture needle aiming for
the space created by the CO2 was technically easy, took
under a minute and was successful in all 7 animals
without complication (Fig. 2 and Online Video Support-
ing Information). The separation of pericardial layers
enabled the needle to avoid contact with the myocar-
dium altogether. Serial fluoroscopy after insufflation
with CO2 showed pericardial CO2 spontaneously and
completely resorbed within 15 min in all animals. No
pericardial effusions were observed on MRI after with-
drawal of the transatrial microcatheter.
On the basis of observing 0 effusions out of 15
transatrial access attempts with the 2.8Fr microcatheter
(2.8Fr Puncture and 2.8FrþCO2 groups), the binomial
confidence interval and best point estimate were calcu-
lated to be 0–18% (95% CI) and 6%, respectively. To
achieve 95% confidence that the true incidence of effu-
sion is less than 1% and 0.1%, we would need to per-
form 325 and 3150 observations each without any
effusion, respectively.
In the 2.8FrþContrast group, infusion of dilute io-
dinated contrast effectively separated visceral and pari-
etal pericardial layers posteriorly in all 7 animals. This
separation was highly visible on lateral plane fluoros-
copy (Fig. 4), and created a target for easy and uncom-
plicated subxiphoid posterior pericardial access using a
micro-puncture needle. However, it did not separate
the heart from the sternum for anterior pericardial
access.
Fig. 2. Procedural steps—(A) Right atrial appendage angio-
gram. (B) Transatrial puncture with the back end of a 0.018
inches guidewire. (C) 2.8Fr microcatheter advanced over the
0.018 inches guidewire into the pericardial space. Black
arrows show radiopaque markers on the microcatheter. (D)
Lateral plane fluoroscopy showing close apposition of ante-
rior surface of the myocardium and the sternum (white arrow).
Black arrow shows the sub-xiphoid needle. (E) Pericardial
insufflation with CO2. Black arrow shows the sub-xiphoid nee-
dle. White arrow shows separation of pericardial layers. (F)
Sub-xiphoid needle positioned to enter the pericardial space.
Black arrow marks the tenting of the pericardium. (G) 0.018
inches guidewire (black arrow) introduced through the sub-
xiphoid needle into the pericardium. (H) 0.018 inches guide-
wire (black arrow) tracked along anterior pericardial surface.
(I) Coronary angiogram to assess for coronary artery com-
pression or spasm.
4 Rogers et al.
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Figure	  4-­‐3:	  Haemodynamic	  parameters	  
Figure	  4-­‐4:	  Pericardial	  iodinated	  contrast	  versus	  carbon	  dioxide	  
	   	  
DISCUSSION
Sub-Xiphoid ‘Dry’ Pericardial Access
The commonest complication to arise from sub-
xiphoid ‘dry’ pericardial access is bleeding from right
ventricle (RV) or coronary artery injury [5–7]. This
can lead to tamponade and require surgical interven-
tion. Unusual complications such as RV pseudoaneu-
rysm or hepatic puncture with hematoma or abdominal
bleeding have also been described [17]. Studies have
not suggested an operator learning curve, as the com-
plication rate does not appear to fall with time—even
in expert hands. Strategies to improve the technique
have been proposed and are elegantly summarized in a
recent review article by Lim et al. [10]. These strat-
egies include suspending ventilation during pericardial
puncture to prevent the heart from impaling itself on
the needle, using micro-puncture or blunt scalloped-tip
Tuohy epidural needles to reduce the risk of serious
RV or coronary artery injury, integrating the needle
with an electroanatomic mapping system for better tip
navigation [18], or using live spectral analysis of the
pressure waveform from the sub-xiphoid needle to
detect the higher-frequency phasic signal characteristic
of pericardial entry [19]. Importantly, none of these
strategies specifically separate the heart from the
potentially injurious needle.
The same studies also reported rates of failure to
obtain access of 3–10%, usually because of pericardial
adhesions after prior open chest cardiac surgery or epi-
cardial ablation. It is likely that the risk of RV injury
is higher in these patients because the myocardium is
tethered to the parietal pericardium. Adhesions do not
necessarily preclude access because adhesion disruption
with guidewires or catheters is possible [20].
Interestingly, the rate of RV puncture without bleed-
ing in these studies was high (5–17%) suggesting that
puncturing the myocardium with a needle can be safe.
Another single center study reported inadvertent RV
puncture with an 18-gauge needle in fully anticoagu-
lated patients but no bleeding was observed [4]. These
observations support our hypothesis that puncturing the
substantially lower pressure right atrium with a small
microcatheter is safe and should also be safe in
patients with elevated right atrial pressures. It is
Fig. 4. Pericardial iodinated contrast versus carbon dioxide.
Lateral plane fluoroscopy in a supine animal of (A) iodinated
contrast and (B) CO2 in the pericardium, both introduced
through a transatrial microcatheter. Black arrows show the
separation of the inferior surface of the heart from the peri-
cardium in (A) and of the anterior surface of the heart from
the sternum in (B).
Fig. 3. Hemodynamic parameters—(A) Hemodynamic parameters do not change signifi-
cantly before transatrial pericardial access with 4Fr catheter, and 15, 30, 60, and 120 min af-
ter transatrial catheter withdrawal. (B) Hemodynamic parameters before transatrial
pericardial access with 2.8Fr microcatheter, after pericardial CO2 insufflation, and 30 min af-
ter sub-xiphoid access and transatrial catheter withdrawal. Gray horizontal solid and dashed
lines indicate baseline systolic blood pressure and heart rate respectively. BP: blood pres-
sure.
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important to recognize that many of the serious bleed-
ing complications caused by sub-xiphoid ‘dry’ pericar-
dial access are due to lacerations caused by the heart
beating against the sharp needle tip, rather than from a
direct needle puncture.
Transatrial ‘Dry’ Pericardial Access
In this article, we describe a novel use of intentional
transatrial pericardial access. Our study confirmed the
finding of prior preclinical experiments: that accessing
the pericardium by deliberately exiting through the RAA
with small catheters is easy and safe [11,12]. We found
that a multipurpose diagnostic catheter enabled navigation
to the tip of the RAA in most animals. In animals with
prominent RAA trabeculation, an angled-tip balloon
wedge end-hole catheter was preferred because the bal-
loon prevented the catheter tip from becoming entangled
in the trabeculae. Puncturing the RAA wall with the blunt
back end of a guidewire (either 0.035 or 0.018 inches)
was simple. Advancing a small catheter into the pericar-
dial space over the wire did not meet with resistance.
Even in the presence of full anticoagulation and the
larger 4Fr transatrial catheter, we observed only small
pericardial effusions with no evidence of tamponade
physiology after catheter withdrawal. Spontaneous clo-
sure of small RAA punctures has been described previ-
ously, with small thrombi at the puncture site, focal
inflammatory infiltrates and increased collagen deposi-
tion seen on histology [12]. We therefore tested
whether using a microcatheter could eliminate effu-
sions altogether. With the smaller 2.8Fr microcatheter,
we did not observe any effusions after transatrial
microcatheter withdrawal in any of the 15 animals
(2.8Fr Puncture and 2.8FrþCO2 groups).
We consider these findings, of zero effusions after 15
transatrial access attempts with CO2 insufflation, to be
compelling. However, these data provide 95% confi-
dence only that the true incidence of effusion is 18% or
less. To achieve similar confidence that the true inci-
dence of effusion is less than 1% would require 325
observations of 0 effusions, and if less than 0.1% would
require 3150 such observations. Both are unattainable.
Moreover, we believe even a small pericardial effusion
may be considered clinically acceptable in order to avoid
more serious complications. On the basis of these obser-
vations, we have commenced enrollment in a clinical
trial to test intentional right atrial exit to facilitate sub-
xiphoid access to the anterior pericardial space in
patients undergoing left atrial appendage suture ligation.
Pericardial Contrast Media
Pericardial iodinated contrast has been shown to
facilitate navigation within the pericardial space [21].
Important structures such as atrial appendages, right
ventricular outflow tract or atrioventricular groove can
be delineated. However, contrast is heavier than water
and so preferentially collects behind the heart when the
patient is supine. This separates the layers of pericar-
dium inferiorly and posteriorly and provides a target for
the sub-xiphoid needle for access to the posterior peri-
cardial space (Fig. 4). However, because of its viscosity
it is difficult to aspirate iodinated contrast—even diluted
in normal saline—through the transatrial microcatheter.
Contrast would need to be aspirated through a larger
sheath after sub-xiphoid access is established.
CO2 is much lighter than water so collects anteriorly
between the sternum and the heart when the patient is
supine (Fig. 4). It affords excellent visualization of the
heart contour and provides a space to aim for with the
sub-xiphoid needle. This space enables anterior pericar-
dial access without contacting the anterior surface of
the heart. Anterior access is a prerequisite for certain
interventions such as percutaneous left atrial appendage
suture ligation. The space created by the CO2 reduces
the risk of lacerating the RV free wall or a coronary
artery, usually caused by the heart beating against the
sharp needle tip. An additional advantage of CO2 is
that if, for any reason, sub-xiphoid access cannot be
obtained, then the CO2 introduced does not need to be
aspirated, but instead will resorb spontaneously.
Insufflating body cavities with CO2 is safe. Because
CO2 solubility in blood is high, the reported incidence
of significant CO2 gas embolism from pneumoperito-
neum during laparoscopy is less than 0.002% [22].
Flooding the surgical field with CO2 while coming off
cardiopulmonary bypass has been shown to reduce the
incidence of air embolism [23]. Some studies of lapa-
roscopic abdominal surgery have documented hypercar-
bia, thought to be due to CO2 absorption from the
peritoneal cavity and tissues [24]. However, much of
this effect is likely attributable to hypoventilation
caused by diaphragmatic splinting, which is unlikely to
occur with pericardial CO2 insufflation. In this study,
pericardial CO2 insufflation was very well tolerated. A
transient reduction in systolic blood pressure was seen
(mean decrease from baseline 6 mmHg or 7.7%) but
this was reversible with spontaneous absorption of the
pericardial CO2. We did not observe any evidence of
cardiac tamponade in any animal. Fluid or gas in the
pericardial space can interfere with epicardial interven-
tions, for example by elevating defibrillation thresholds
during electrophysiological interventions [25]. How-
ever, this concern is not relevant to the present tech-
nique because pericardial iodinated contrast or CO2
can be easily aspirated through the sub-xiphoid access
port and moreover, CO2 will resorb rapidly and sponta-
neously.
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CONCLUSION
Intentional right atrial exit to access the ‘dry’ pericar-
dium with small catheters was technically easy and safe
in this preclinical study. Iodinated contrast or CO2 infused
through a transatrial catheter created a target that
enhanced the safety of sub-xiphoid access so large sheaths
could be introduced for electrophysiological or structural
heart interventions. Iodinated contrast collected posteri-
orly, facilitating sub-xiphoid access to the posterior peri-
cardium, whereas CO2 separated the RV free wall from
the sternum facilitating sub-xiphoid access to the anterior
pericardium. This separation should reduce the risk of RV
or coronary artery laceration. Transatrial microcatheters,
which are smaller than 18-gauge needles, were withdrawn
uneventfully despite full anticoagulation. On the basis of
these preclinical findings, we commenced enrollment in a
clinical trial to test this new technique in patients under-
going left atrial appendage suture ligation.
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4.5 Intentional	  right	  atrial	  exit	  and	  CO2	  insufflation	  to	  facilitate	  
subxiphoid	  needle	  entry	  into	  the	  empty	  pericardial	  space:	  first	  
human	  experience	  
An	  original	  research	  manuscript	  accepted	  for	  publication	  in	  the	  ‘Journal	  of	  the	  American	  
College	  of	  Cardiology:	  Clinical	  Electrophysiology’	  in	  2015.	  
4.5.1 Background	  
Subxiphoid	  access	  to	  the	  normal	  or	  “empty”	  pericardial	  space	  is	  required	  for	  therapeutic	  
procedures	  including	  epicardial	  suture	  ligation	  of	  the	  left	  atrial	  appendage136,	  137	  and	  
epicardial	  ablation	  of	  ventricular	  tachycardia138.	  “Dry”	  subxiphoid	  needle	  access	  is	  variably	  
described	  as	  straightforward	  or	  perilous139-­‐142.	  	  Inadvertent	  needle	  entry	  into	  the	  atria	  or	  
ventricles	  is	  seldom	  clinically	  important,	  however	  myocardial	  and	  coronary	  artery	  laceration	  
usually	  causes	  intractable	  haemopericardium	  requiring	  surgical	  repair.	  	  These	  complications	  
continue	  despite	  small-­‐diameter	  needles,	  oblique-­‐endhole	  needles,	  and	  temporary	  
suspension	  of	  respiration,	  because	  of	  the	  small	  distance	  between	  visceral	  and	  parietal	  
pericardial	  walls	  and	  because	  of	  continuous	  cardiac	  motion143.	  In	  many	  cases,	  myocardium	  
lacerates	  as	  the	  heart	  moves	  across	  the	  subxiphoid	  needle	  sharp	  tip.	  	  
Transatrial	  entry	  to	  the	  pericardial	  space	  was	  initially	  described	  in	  animals	  to	  facilitate	  
homogeneous	  epicardial	  drug	  delivery	  144	  or	  chamber	  visualization	  145.	  	  We	  refined	  
transatrial	  pericardial	  entry	  and	  contrast	  infusion	  using	  2.4-­‐2.8Fr	  (0.80	  to	  0.93mm	  outer	  
diameter)	  microcatheters	  in	  animals	  as	  a	  method	  to	  facilitate	  subxiphoid	  needle	  access	  to	  
the	  anterior	  or	  posterior	  pericardial	  spaces146.	  	  Despite	  high-­‐intensity	  anticoagulation,	  we	  
observed	  no	  important	  haemopericardium	  using	  careful	  MRI	  examination	  after	  simple	  
withdrawal	  of	  these	  microcatheters	  from	  across	  the	  wall	  of	  the	  right	  atrial	  appendage.	  
We	  hypothesized	  that	  in	  patients	  the	  right	  atrial	  appendage	  can	  safely	  be	  crossed	  with	  a	  
microcatheter	  and	  that	  the	  microcatheter	  can	  be	  withdrawn	  without	  causing	  clinically	  
important	  pericardial	  haemorrhage.	  We	  further	  hypothesize	  that	  transatrial	  CO2	  insufflation	  
can	  reduce	  the	  risk	  of	  subxiphoid	  pericardial	  needle	  entry	  in	  patients	  undergoing	  epicardial	  
suture	  ligation	  of	  the	  left	  atrial	  appendage,	  by	  separating	  the	  visceral	  and	  parietal	  pericardial	  
walls	  to	  keep	  the	  subxiphoid	  needle	  away	  from	  the	  heart.	  	  We	  describe	  the	  first	  human	  
experience	  with	  intentional	  transcatheter	  right	  atrial	  exit	  and	  pericardial	  CO2	  insufflation.	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4.5.2 Methods	  
Subjects:	  The	  Henry	  Ford	  Health	  System	  Institutional	  Review	  Board	  approved	  this	  protocol.	  	  
From	  June	  2014	  through	  May	  2015,	  consecutive	  candidates	  were	  invited	  to	  participate	  who	  
were	  undergoing	  intrapericardial	  suture	  ligation	  of	  the	  left	  atrial	  appendage	  (Lariat,	  
Sentreheart,	  Redwood	  City,	  CA)	  for	  high	  risk	  of	  thromboembolism	  and	  intolerance	  of	  
anticoagulation	  for	  atrial	  fibrillation.	  All	  subjects	  consented	  in	  writing.	  
Technique	  of	  transatrial	  pericardial	  exit:	  Intentional	  exit	  of	  the	  right	  atrial	  appendage	  was	  
performed	  via	  the	  femoral	  vein.	  	  A	  pulmonary	  artery	  catheter	  was	  placed	  via	  a	  separate	  vein	  
to	  record	  hemodynamics	  solely	  for	  this	  protocol.	  	  The	  right	  atrial	  appendage	  was	  engaged	  
with	  a	  catheter	  (7Fr	  Sones	  in	  the	  first	  subject	  and	  7Fr	  balloon	  wedge	  endhole	  catheter	  the	  
others,	  inside	  a	  transseptal	  introducer	  sheath)	  using	  a	  sweeping	  ascending	  clockwise	  motion	  
from	  the	  lateral	  right	  atrial	  wall.	  	  Right	  atrial	  appendage	  angiography	  was	  performed	  using	  a	  
hand	  injection	  of	  2-­‐5mL	  iodinated	  contrast.	  Through	  the	  guidewire	  lumen,	  a	  2.4Fr	  braided	  
microcatheter	  (Renegade	  STC-­‐18	  150cm,	  Boston	  Scientific)	  was	  positioned	  at	  the	  tip	  of	  the	  
catheter	  and	  the	  back	  end	  of	  a	  guidewire	  (initially	  0.014”	  Balance	  Middleweight,	  Abbott	  and	  
later	  0.018”	  V-­‐18,	  Boston	  Scientific)	  advanced	  into	  the	  pericardial	  space.	  	  	  Next	  the	  
microcatheter	  was	  advanced	  into	  the	  apical	  pericardial	  space	  and	  the	  guidewire	  was	  
withdrawn.	  	  Out	  of	  caution,	  the	  larger	  transfemoral	  catheter	  was	  retracted	  to	  prevent	  
inadvertent	  rail-­‐advancement	  over	  the	  microcatheter	  into	  the	  pericardium,	  which	  might	  
enlarge	  the	  hole.	  	  The	  technique	  was	  further	  refined	  as	  described	  in	  the	  results.	  
After	  refinement,	  we	  used	  SL2	  or	  SL3	  curve	  introducer	  sheaths	  (St	  Jude	  Medical)	  to	  direct	  a	  
curved	  balloon	  wedge	  endhole	  catheter	  (Medtronic	  Pulmonary	  Artery	  Balloon	  or	  Double-­‐
Lumen	  Hi-­‐Shore	  Catheter	  T-­‐Tip,	  Edwards)	  to	  direct	  the	  back-­‐end	  of	  a	  guidewire	  shaft	  known	  
to	  be	  polymer	  coated	  (0.014”	  Runthrough,	  Terumo).	  	  	  
Transatrial	  pericardial	  CO2	  insufflation	  and	  subxiphoid	  needle	  access:	  The	  subxiphoid	  
needle	  trajectory	  was	  planned	  according	  to	  the	  usual	  technique,	  aiming	  towards	  the	  left	  
atrial	  appendage	  shadow	  on	  an	  antero-­‐posterior	  projection.	  A	  coaxial	  long	  21G	  x12	  cm	  
needle	  (Stiffen	  Bariatric,	  Galt,	  Harland,	  TX	  or	  Mak	  NV	  216,	  Merit	  Medical,	  Chester,	  VA)	  was	  
inserted	  alone	  or	  coaxially	  inside	  an	  18G	  x	  9cm	  spinal	  needle	  (Havel,	  Cincinnati,	  OH)	  under	  
the	  skin	  but	  not	  yet	  abutting	  the	  cardiac	  shadow.	  	  	  
For	  CO2	  insufflation,	  a	  closed	  bag	  with	  one-­‐way	  valve	  and	  manifold	  (Figure	  4-­‐5)	  was	  filled	  and	  
purged	  in	  three	  cycles	  using	  filtered	  pure	  CO2	  as	  taught	  by	  Kyung	  Cho	  147.	  The	  system	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stopcock	  was	  connected	  to	  the	  hub	  of	  the	  pericardial	  microcatheter	  and	  serous	  pericardial	  
fluid	  was	  aspirated	  in	  all	  patients	  to	  assure	  an	  air-­‐free	  connection	  and	  proper	  positioning.	  	  	  
Carbon	  dioxide	  was	  injected	  by	  hand	  through	  this	  closed	  system	  until	  adequate	  
(approximately	  5-­‐10mm)	  anterior	  fluoroscopic	  pericardial	  separation	  was	  obtained.	  	  The	  
initial	  gas	  clearance	  of	  the	  microcatheter	  was	  slow	  to	  avoid	  a	  high	  pressure	  “jet	  effect”	  that	  
might	  injure	  soft	  tissue.	  	  Subxiphoid	  needle	  access	  to	  the	  anterior	  pericardium	  was	  obtained	  
in	  the	  lateral	  projection,	  without	  using	  a	  finder	  syringe	  or	  contrast	  injections,	  and	  instead	  
with	  the	  guidewire	  0.018”	  guidewire	  (Steelcore,	  Abbott)	  pre-­‐positioned	  inside	  the	  needle	  to	  
ease	  advancement	  into	  the	  pericardium	  immediately	  upon	  needle	  entry.	  
The	  transatrial	  pericardial	  microcatheter	  was	  withdrawn	  over	  a	  guidewire	  immediately	  after	  
the	  subxiphoid	  Lariat	  SoftTip	  sheath	  was	  advanced	  into	  the	  pericardial	  space.	  	  	  Next	  
transseptal	  access	  was	  obtained	  under	  transesophageal	  echocardiography	  guidance	  and	  
unfractionated	  heparin	  administered	  immediately	  to	  achieve	  an	  activated	  clotting	  time	  >	  
300s.	  	  	  Next	  Lariat	  suture	  ligation	  of	  the	  left	  atrial	  appendage	  was	  performed	  according	  to	  
usual	  methods,	  and	  a	  subxiphoid	  pericardial	  drain	  left	  in	  overnight.	  
Data	  analysis:	  Data	  were	  collected	  using	  REDCap	  (www.project-­‐redcap.org)148,	  and	  analysed	  
using	  Excel	  (v2010,	  Microsoft).	  	  Data	  were	  described	  as	  mean	  	  ±	  standard	  deviation	  if	  they	  
were	  normally	  distributed,	  otherwise	  as	  median	  (first	  quartile,	  third	  quartile).	  Continuous	  
data	  were	  compared	  using	  an	  unpaired	  t-­‐test.	  A	  p<0.05	  was	  considered	  significant.	  	  
4.5.3 Results	  
All	  consecutive	  patients	  undergoing	  Lariat	  suture	  closure	  during	  the	  study	  period	  consented	  
to	  participate.	  	  Of	  the	  13	  subjects	  enrolled	  in	  the	  study,	  the	  mean	  age	  was	  75±8,	  46%	  were	  
women,	  46%	  had	  prior	  TIA	  or	  stroke,	  all	  were	  intolerant	  of	  anticoagulation,	  92%	  used	  aspirin	  
at	  the	  time	  of	  the	  procedure,	  0%	  used	  a	  P2Y12	  blocker,	  85%	  had	  prior	  haemorrhage,	  the	  
average	  CHADS2	  score	  was	  2.8±1.4,	  the	  average	  CHA2DS2-­‐VASc	  score	  was	  4.6±1.6,	  and	  the	  
average	  HAS-­‐BLED	  score	  was	  3.2±1.2.	  	  	  Baseline	  hemodynamics	  under	  general	  anaesthesia	  
were	  heart	  rate,	  70±16	  bpm,	  right	  atrial	  pressure	  7±3	  mmHg,	  mean	  pulmonary	  artery	  23±6,	  
mean	  aortic	  72±17.	  	  Left	  ventricular	  ejection	  fraction	  was	  0.58±0.10,	  and	  31%	  had	  moderate	  
tricuspid	  regurgitation.	  
Right	  atrial	  exit	  was	  successful	  in	  11	  of	  13	  cases,	  and	  required	  2.2±1.7guidewire	  passes.	  
Figure	  4-­‐6	  shows	  a	  representative	  sequence	  of	  right	  atrial	  angiography,	  transatrial	  guidewire	  
exit,	  and	  transatrial	  microcatheter	  advancement	  into	  the	  pericardial	  space.	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After	  pericardial	  insufflation,	  subxiphoid	  needle	  pericardial	  entry	  was	  consistently	  rapid	  and	  
straightforward	  in	  all	  cases	  because	  the	  pericardial	  layers	  clearly	  separated.	  Figure	  4-­‐7	  
shows	  a	  representative	  sequence	  of	  CO2	  insufflation,	  subxiphoid	  needle,	  and	  subxiphoid	  
guidewire	  delivery.	  	  These	  steps	  were	  associated	  with	  no	  change	  in	  heart	  rate,	  central	  aortic	  
blood	  pressure,	  or	  pulmonary	  artery	  pressure.	  The	  mean	  time	  from	  right	  atrial	  angiography	  
to	  right	  atrial	  exit	  was	  1:44±1:16	  minutes,	  and	  from	  right	  atrial	  exit	  to	  subxiphoid	  needle	  
entry	  was	  7:49±2:31	  minutes.	  
The	  right	  atrial	  exit	  angle	  relative	  to	  horizontal,	  in	  the	  antero-­‐posterior	  projection,	  appeared	  
to	  differ	  between	  successful	  and	  unsuccessful	  exits.	  	  	  The	  horizontal	  exit	  angle	  was	  23±12o	  
when	  successful	  compared	  with	  45±14o	  for	  unsuccessful	  exits,	  p=0.01.	  	  An	  average	  of	  
96±22mL	  of	  CO2	  achieved	  12±4mm	  anterior	  pericardial	  separation	  	  
Microcatheters	  were	  withdrawn	  from	  the	  right	  atrial	  appendage	  11:27±5:44	  minutes	  before	  
heparin	  was	  administered	  (during	  which	  time	  transseptal	  access	  was	  obtained)	  to	  raise	  the	  
activated	  clotting	  time	  from	  170±53	  to	  313±14s.	  
The	  equipment	  selected	  for	  right	  atrial	  exit	  evolved	  during	  the	  protocol.	  	  At	  first	  we	  applied	  
standalone	  multi-­‐purpose-­‐type	  catheters	  (Sones,	  multipurpose	  guiding	  catheters,	  balloon-­‐
wedge	  endhole	  catheters).	  	  Then	  we	  used	  standalone	  three-­‐dimensional	  curved	  catheters	  
(heat-­‐gun	  shaped	  sheaths	  and	  MP	  guiding	  catheters.	  	  Ultimately	  we	  settled	  upon	  three-­‐
dimensional	  curve	  introducer	  sheaths	  intended	  for	  atrial	  transseptal	  access	  (SL1	  or	  SL2	  or	  
SL3,	  Daig,	  St	  Jude	  Medical)	  selected	  according	  to	  RA	  size,	  and	  used	  these	  to	  direct	  balloon-­‐
wedge	  endhole	  catheters	  to	  the	  right	  atrial	  appendage.	  	  We	  found	  the	  combination	  achieved	  
a	  helical	  trajectory	  from	  the	  IVC	  along	  the	  lateral	  and	  then	  anterior	  right	  atrial	  and	  
appendage	  wall	  that	  allowed	  backup	  support	  for	  the	  transatrial	  guidewire	  exiting	  
horizontally	  from	  the	  right	  atrial	  appendage.	  	  
One	  patient	  (#8)	  had	  a	  serious	  complication	  of	  left	  atrial	  suture	  ligation	  despite,	  and	  
unrelated	  to,	  successful	  transatrial	  access.	  	  She	  required	  sternotomy	  for	  repair	  of	  visually	  
confirmed	  left	  ventricular	  myocardial	  abrasion	  most	  likely	  attributable	  to	  introducing	  the	  
Sentreheart	  SoftTip	  subxiphoid	  sheath.	  	  	  In	  this	  patient,	  the	  right	  atrial	  appendage	  exit	  site	  
was	  inspected	  directly	  and	  was	  found	  haemostatic	  and	  with	  surrounding	  plethora,	  as	  
expected	  (Figure	  4-­‐8).	  The	  pericardium	  was	  evacuated	  and	  she	  recovered	  uneventfully	  for	  
discharge	  on	  day	  5.	  
One	  patient	  had	  mild	  pericardial	  bleeding	  after	  withdrawal	  of	  the	  transatrial	  microcatheter,	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evident	  on	  angiography	  of	  the	  right	  atrial	  appendage,	  amounting	  to	  125	  mL	  total	  drainage.	  	  
This	  was	  treated	  conservatively	  with	  close	  echocardiographic	  surveillance.	  	  The	  subject	  was	  
discharged	  uneventfully	  on	  day	  2.	  
After	  CO2	  insufflation,	  no	  patient	  suffered	  right	  ventricular	  or	  coronary	  artery	  laceration	  by	  
the	  subxiphoid	  needle,	  or	  even	  inadvertent	  right	  ventricular	  entry.	  	  	  	  
4.5.4 Discussion	  
To	  our	  knowledge	  this	  is	  the	  first	  human	  experience	  intentionally	  exiting	  the	  right	  atrium	  to	  
enter	  the	  pericardial	  space.	  	  We	  found	  that	  a	  catheter	  can	  intentionally	  traverse	  the	  right	  
atrial	  appendage	  wall	  into	  the	  pericardium	  and	  be	  withdrawn	  without	  important	  sequelae	  as	  
part	  of	  a	  therapeutic	  procedure	  that	  requires	  brief	  intensive	  anticoagulation.	  	  	  	  We	  infer	  the	  
small	  0.8mm	  hole	  recoils	  immediately.	  	  This	  should	  come	  as	  no	  surprise,	  since	  transcameral	  
needle	  perforation	  is	  common	  using	  0.6-­‐0.9mm	  outer	  diameter	  needles	  (for	  example,	  18-­‐
21G	  pericardial	  access	  and	  transseptal	  needles)	  and	  usually	  is	  not	  clinically	  significant.	  
Indeed	  intraoperative	  cardiac	  pressures	  are	  often	  recorded	  from	  plunge	  needles	  that	  are	  
withdrawn	  despite	  anticoagulation.	  Transatrial	  CO2	  insufflation	  separated	  the	  anterior	  
pericardial	  walls	  sufficiently	  to	  keep	  a	  subxiphoid	  needle	  far	  from	  the	  epicardial	  surface	  
throughout	  the	  cardiac	  and	  respiratory	  cycles,	  allowing	  safe	  and	  rapid	  subxiphoid	  needle	  
access,	  and	  without	  changing	  hemodynamics.	  
The	  main	  shortcoming	  of	  our	  approach	  was	  failure	  to	  exit	  the	  right	  atrial	  appendage	  in	  two	  
of	  twelve	  subjects	  (fourth	  and	  seventh	  in	  sequence).	  	  We	  attribute	  this	  to	  inexperience,	  to	  
misalignment	  of	  the	  right	  atrial	  catheter	  with	  the	  right	  atrial	  appendage	  and	  intended	  empty	  
pericardial	  space,	  and	  also	  to	  the	  subjectively	  greater	  advancement	  force	  required	  to	  
perforate	  the	  appendage	  in	  humans	  compared	  with	  swine	  146.	  	  We	  believe	  that	  with	  
experience	  our	  success	  rate	  is	  likely	  to	  improve,	  especially	  now	  that	  we	  recognize	  the	  
importance	  of	  good	  backup	  support	  through	  a	  helical	  geometry	  of	  the	  coaxial	  atrial	  catheter	  
system	  (see	  below).	  	  We	  were	  unable	  to	  obtain	  meaningful	  measurements	  of	  thickness	  of	  
the	  right	  atrial	  appendage	  wall	  at	  the	  resolution	  of	  the	  available	  CT	  scans	  to	  determine	  if	  
thickness	  was	  a	  contributing	  factor.	  	  Fortunately,	  all	  transatrial	  exit	  failures	  were	  clinically	  
uneventful,	  and	  were	  addressed	  by	  switching	  to	  conventional	  “dry”	  subxiphoid	  pericardial	  
access.	  
We	  refined	  our	  catheter	  technique	  during	  the	  protocol.	  	  First,	  we	  imparted	  a	  three-­‐
dimensional	  curve	  on	  the	  right	  atrial	  appendage	  catheter	  system,	  extending	  from	  the	  cava	  to	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the	  supero-­‐anterior	  wall	  of	  the	  right	  atrial	  appendage.	  	  This	  afforded	  better	  backup	  support	  
and	  aligned	  the	  catheter	  system	  with	  the	  crest	  of	  the	  appendage	  and	  the	  pericardial	  space.	  	  
Second,	  we	  switched	  to	  a	  balloon	  wedge	  endhole	  catheter,	  which	  in	  a	  cautious	  inflation-­‐
deflation	  manoeuvre	  acted	  to	  separate	  the	  anterior	  and	  posterior	  walls	  of	  the	  right	  atrial	  
appendage	  and	  allowed	  the	  catheter	  tip	  to	  advance	  to	  the	  leftmost	  tip	  of	  the	  appendage	  
despite	  trabeculations.	  	  The	  inflated	  balloon	  tip	  catheter	  may	  also	  protect	  against	  
inadvertent	  advancement	  of	  the	  support	  catheter	  across	  the	  right	  atrial	  appendage	  wall	  
along	  the	  microcatheter.	  	  We	  warn	  that	  incautious	  inflation-­‐deflation	  may	  be	  hazardous	  in	  
the	  right	  atrial	  appendage.	  Third,	  we	  began	  to	  orient	  our	  crossing	  system	  more	  horizontally	  
leftward,	  reasoning	  that	  more	  vertical	  upward	  oriented	  crossing	  may	  contribute	  to	  failure	  
because	  of	  constraint	  from	  cephalad	  pericardial	  reflections	  as	  depicted	  in	  Figure	  4-­‐9.	  We	  
took	  care	  to	  select	  transatrial	  exit	  sites	  near	  the	  cephalad	  extent	  of	  the	  right	  atrial	  
appendage,	  which	  was	  consistently	  far	  from	  the	  right	  coronary	  artery	  on	  CT.	  	  
Important	  limitations	  warrant	  mention.	  	  First,	  pericardial	  fluid	  infusion	  has	  been	  shown	  to	  
increase	  defibrillation	  thresholds	  in	  animals149,	  and	  we	  speculate	  nonconductive	  CO2	  	  may	  
increase	  defibrillation	  thresholds	  by	  surrounding	  the	  heart	  with	  an	  insulator.	  	  We	  found	  the	  
typical	  pericardial	  insufflation	  of	  100	  mL	  (1-­‐1.5mL/kg)	  CO2	  accumulated	  anteriorly	  over	  less	  
than	  10%	  of	  the	  antero-­‐posterior	  dimension	  of	  the	  heart,	  and	  defibrillation	  is	  likely	  
attainable	  using	  laterally	  positioned	  electrodes.	  	  CO2	  need	  only	  be	  insufflated	  a	  few	  seconds	  
before	  the	  subxiphoid	  needle	  is	  advanced	  in	  the	  lateral	  fluoroscopic	  projection.	  In	  our	  
preclinical	  experience,	  much	  larger	  volumes	  (3-­‐5mL/kg)	  of	  CO2	  gas	  spontaneously	  absorb	  in	  
5-­‐10	  minutes.	  	  Overall	  the	  risk	  of	  ventricular	  fibrillation	  during	  subxiphoid	  access	  is	  low.	  
Second,	  transatrial	  access	  requires	  an	  extra	  step	  and	  extra	  equipment	  beyond	  simple	  
subxiphoid	  access.	  This	  is	  offset	  by	  the	  more	  simple	  and	  perhaps	  more	  safe	  subxiphoid	  
needle	  access	  with	  the	  pericardial	  walls	  separated.	  Third,	  transatrial	  separation	  of	  the	  
pericardial	  walls	  does	  not	  address	  all	  the	  risks	  of	  the	  Lariat	  suture	  ligation	  procedure,	  
including	  sheath	  injury	  (which	  required	  surgical	  bailout	  in	  one	  patient	  in	  our	  series),	  
perforation	  of	  the	  LAA	  by	  the	  docking	  magnet	  wires,	  and	  avulsion	  of	  the	  LAA	  by	  the	  suture	  
delivery	  apparatus.	  	  Fourth,	  our	  series	  included	  only	  patients	  with	  relatively	  preserved	  
myocardial	  function	  and	  relatively	  normal	  right	  atrial	  pressure,	  so	  our	  findings	  should	  not	  be	  
extended	  to	  patients	  with	  more	  severe	  cardiomyopathy	  until	  after	  further	  investigation.	  	  
Fifth,	  a	  larger	  clinical	  experience	  obtained	  from	  more	  than	  one	  medical	  centre	  will	  be	  
required	  more	  convincingly	  to	  prove	  the	  safety	  of	  this	  technique	  beyond	  the	  data	  presented	  
here.	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Transatrial	  pericardial	  insufflation	  may	  have	  value	  in	  other	  applications.	  	  These	  include	  
conventional	  applications	  requiring	  subxiphoid	  access	  to	  the	  pericardium,	  such	  as	  epicardial	  
mapping	  and	  ablation	  of	  ventricular	  tachycardia.	  Right	  atrial	  appendage	  exit	  alone	  also	  may	  
have	  value	  in	  more	  novel	  applications,	  such	  as	  transatrial	  intrapericardial	  tricuspid	  
annuloplasty	  150	  and	  emergency	  anterior	  pericardial	  access	  in	  acute	  low-­‐volume	  tamponade	  
when	  conventional	  access	  fails.	  	  Transatrial	  instillation	  of	  iodinated	  radiocontrast	  
accumulates	  in	  the	  posterior	  pericardium	  and	  may	  enhance	  the	  safety	  of	  subxiphoid	  
posterior	  pericardial	  access146	  if	  desired,	  although	  this	  was	  not	  tested	  in	  this	  protocol.	  
4.5.5 Conclusions	  
We	  report	  the	  first	  human	  intentional	  transatrial	  exit	  procedure.	  Transatrial	  access	  to	  the	  
pericardium	  can	  be	  achieved	  safely.	  	  Pericardial	  insufflation	  with	  CO2	  makes	  subxiphoid	  
access	  to	  the	  empty	  anterior	  pericardium	  rapid	  and	  safe.	  With	  further	  experience	  this	  
technique	  might	  prevent	  life-­‐threatening	  complications	  of	  “dry”	  subxiphoid	  pericardial	  
access.	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Figure	  4-­‐5:	  CO2	  setup	  for	  transatrial	  pericardial	  insufflation	  
The	  connection	  to	  the	  CO2	  tank	  should	  be	  detached	  before	  use	  in	  a	  patient;	  crossed	  
stopcocks	  allow	  air	  to	  be	  purged	  after	  it	  the	  syringe	  is	  reattached	  for	  refilling.	  The	  system	  is	  
filled	  and	  purged	  at	  least	  three	  times	  before	  use.	  The	  syringe	  has	  a	  one-­‐way	  valve	  that	  
allows	  it	  to	  fill	  with	  CO2	  from	  the	  bag	  and	  to	  eject	  into	  a	  stopcock	  connected	  to	  the	  
transatrial	  microcatheter.	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Figure	  4-­‐6:	  An	  example	  of	  transatrial	  guidewire	  exit	  
Antero-­‐posterior	  (A)	  and	  lateral	  (B)	  contrast	  angiogram	  of	  the	  R	  atrial	  appendage	  from	  a	  
catheter	  positioned	  at	  its	  crest.	  	  (C)	  The	  back-­‐end	  of	  an	  0.014”	  guidewire	  crosses	  the	  R	  atrial	  
appendage.	  	  (D)	  A	  microcatheter	  is	  advanced	  over	  the	  guidewire	  into	  the	  pericardial	  space.	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Figure	  4-­‐7:	  Subxiphoid	  access	  
After	  the	  transatrial	  pericardial	  microcatheter	  is	  placed,	  the	  subxiphoid	  needle	  is	  positioned	  
outside	  the	  heart	  (A).	  	  In	  the	  lateral	  fluoroscopic	  projection,	  the	  pericardium	  is	  filled	  with	  
1.0-­‐1.5mL/kg	  of	  CO2	  to	  displace	  the	  heart	  posteriorly	  (B).	  	  The	  gas	  clearly	  visualizes	  the	  
anterior	  wall	  of	  the	  heart	  to	  allow	  needle	  entry	  without	  cardiac	  contact.	  (C)	  The	  subxiphoid	  
guidewire	  is	  then	  advanced	  through	  the	  needle	  and	  the	  procedure	  continues	  as	  usual.	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Figure	  4-­‐8:	  Operative	  inspection	  of	  a	  transatrial	  exit	  site	  
This	  patient	  required	  surgical	  repair	  of	  left	  ventricular	  abrasion	  attributed	  to	  the	  suture	  
delivery	  sheath.	  	  Incidental	  inspection	  of	  the	  right	  atrial	  appendage	  (asterisk)	  showed	  
plethora	  and	  inflammation	  but	  no	  bleeding	  or	  discrete	  hole	  at	  the	  site	  of	  right	  atrial	  exit	  
from	  the	  crest	  of	  the	  right	  atrial	  appendage	  (dotted	  circle).	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Figure	  4-­‐9:	  Exit	  angle	  and	  success	  
In	  this	  contrast	  pericardiogram	  from	  another	  patient,	  the	  right	  atrial	  appendage	  border	  
(dotted	  red	  line)	  is	  depicted	  along	  with	  two	  theoretical	  wire	  exit	  trajectories.	  	  	  Trajectory	  1	  
(orange)	  is	  aligned	  with	  the	  main	  axis	  of	  the	  right	  atrial	  appendage	  and	  oriented	  superiorly;	  
failed	  right	  atrial	  exit	  along	  this	  trajectory	  may	  be	  related	  to	  the	  superior	  pericardial	  
reflection.	  	  By	  contrast,	  trajectory	  2	  (green)	  is	  oriented	  more	  horizontally	  and	  leftwards.	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Chapter	  5. Fully	  percutaneous	  transthoracic	  left	  atrial	  access	  
and	  closure	  as	  a	  potential	  access	  route	  for	  mitral	  valve	  
interventions	  (publication)	  
5.1 Introduction	  
A	  number	  of	  transcatheter	  mitral	  valve	  prostheses	  have	  been	  tested	  in	  early	  human	  studies.	  
However,	  because	  the	  mitral	  annulus	  is	  much	  larger	  than	  the	  aortic,	  and	  because	  these	  
devices	  must	  incorporate	  fixation	  components	  to	  anchor	  them	  in	  the	  mitral	  annulus,	  they	  all	  
require	  wide-­‐bore	  access	  ports	  (≥10mm	  internal	  diameter).	  The	  obvious	  approach	  is	  
transapical	  because	  it	  affords	  direct	  and	  coaxial	  access	  to	  the	  mitral.	  Achieving	  coaxiality	  
with	  alternative	  approaches	  such	  as	  trans-­‐septal	  is	  much	  more	  difficult.	  However,	  there	  is	  
evidence	  from	  transcatheter	  aortic	  valve	  implantation	  studies	  that	  transapical	  access	  causes	  
local	  scar	  formation,	  which	  can	  negatively	  impact	  LV	  function.	  LV	  morphology	  and	  function	  
in	  patients	  with	  severe	  mitral	  regurgitation	  are	  very	  different	  and	  it	  likely	  that	  transapical	  
access	  in	  these	  patients	  may	  affect	  LV	  function	  to	  a	  much	  greater	  degree.	  
Direct	  left	  atrial	  needle	  access	  through	  the	  right	  thoracic	  cavity	  was	  demonstrated	  in	  the	  
1950s,	  before	  the	  advent	  of	  cardiac	  catheterization.	  We	  explored	  whether	  this	  approach	  
could	  be	  re-­‐visited	  to	  deliver	  large	  transcatheter	  mitral	  valve	  devices.	  
5.2 The	  role	  of	  CMR	  
Direct	  left	  atrial	  access	  through	  the	  posterior	  chest	  wall	  and	  right	  thoracic	  cavity	  requires	  
crossing	  a	  variety	  of	  anatomic	  boundaries	  and	  avoiding	  a	  number	  of	  critical	  structures.	  
Visualization	  of	  each	  structure	  and	  determination	  of	  optimal	  trajectory	  is	  therefore	  
important.	  For	  this	  reason,	  we	  developed	  the	  procedure	  using	  real-­‐time	  CMR	  guidance.	  CMR	  
allowed	  us	  to	  learn	  how	  single	  lung	  deflation	  affects	  the	  geometry	  of	  the	  heart	  and	  
mediastinum	  and	  to	  correct	  the	  trajectory	  in	  real-­‐time	  because	  all	  soft	  tissue	  structures	  are	  
visible	  at	  all	  times.	  This	  would	  not	  be	  feasible	  using	  X-­‐ray	  fluoroscopy	  and	  echocardiography.	  
CMR	  also	  permits	  early	  identification	  and	  management	  of	  complications,	  such	  as	  pericardial	  
or	  pleural	  bleeding.	  Once	  we	  gained	  a	  clear	  understanding	  of	  these	  dynamic	  anatomical	  
parameters,	  we	  were	  able	  to	  replicate	  the	  technique	  using	  X-­‐ray	  fluoroscopy	  and	  adjunctive	  
rotational	  angiography	  imaging	  so	  that	  the	  intervention	  could	  be	  translated	  to	  clinic	  without	  
needing	  a	  dedicated	  interventional	  CMR	  catheterization	  laboratory.	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5.3 Candidate’s	  contribution	  
I	  performed	  all	  the	  pre-­‐clinical	  experiments	  (under	  MRI	  and	  X-­‐ray	  imaging	  guidance).	  I	  
collected	  the	  pre-­‐clinical	  data	  and	  performed	  the	  statistical	  analysis.	  I	  also	  analysed	  the	  
human	  CT	  studies.	  I	  drafted	  the	  manuscript	  and	  prepared	  the	  figures,	  tables	  and	  
supplementary	  materials.	  
5.4 Fully	  percutaneous	  transthoracic	  left	  atrial	  access	  and	  closure	  as	  a	  
potential	  access	  route	  for	  mitral	  valve	  interventions	  
An	  original	  manuscript	  published	  in	  the	  journal	  ‘Circulations:	  Cardiovascular	  Interventions’	  in	  
2015.	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Transcatheter mitral valve-in-valve or valve-in-ring implantation is feasible using prostheses designed for 
the aortic valve.1,2 Implantation in the native mitral annulus 
presents distinct challenges: available aortic prostheses are too 
small, valve fixation is difficult because the annulus is elastic, 
and the subvalvular apparatus, which plays an important role 
in left ventricular function, should not be disrupted. At least 
4 dedicated devices have undergone early human testing.3–5 
These are bulky and require large caliber access ports (up to 
32F), mostly transapical.
Whether transapical access is associated with higher mor-
tality than transfemoral remains unclear.6–8 The higher mortal-
ity reported in some studies may reflect inclusion of higher risk 
patients or operator experience. Nonetheless, magnetic resonance 
imaging (MRI) and echocardiography detect apical wall motion 
abnormalities after transapical access, particularly in patients 
with increased left ventricle (LV) diameter, which can lead to 
long-term reduction in global LV function.9–11 In the Placement 
of Aortic Transcatheter Valves (PARTNER) trial quality-of-life 
assessment, transcatheter aortic valve replacement via transapi-
cal approach demonstrated no benefit compared with conven-
tional surgery.12 Morbidity and mortality are likely even higher 
in patients with mitral valve disease because of preexisting LV 
dysfunction. Truly percutaneous transapical access using niti-
nol devices for closure is possible,13 but complications do occur 
including pneumothorax, cardiac tamponade, LV pseudoaneu-
rysm, and hemothorax related to coronary or intercostal vessel 
laceration or bleeding from the LV puncture site.14
Alternative approaches have been explored for mitral 
valve interventions: direct transatrial via minithoracotomy,15 
Background—Percutaneous access for mitral interventions is currently limited to transapical and transseptal routes, both 
of which have shortcomings. We hypothesized that the left atrium could be accessed directly through the posterior chest 
wall under imaging guidance.
Methods and Results—We tested percutaneous transthoracic left atrial access in 12 animals (10 pigs and 2 sheep) under real-
time magnetic resonance imaging or x-ray fluoroscopy plus C-arm computed tomographic guidance. The pleural space was 
insufflated with CO2 to displace the lung, an 18F sheath was delivered to the left atrium, and the left atrial port was closed using 
an off-the-shelf nitinol cardiac occluder. Animals were survived for a minimum of 7 days. The left atrial was accessed, and the 
port was closed successfully in 12/12 animals. There was no procedural mortality and only 1 hemodynamically insignificant 
pericardial effusion was observed at follow-up. We also successfully performed the procedure on 3 human cadavers. A simulated 
trajectory to the left atrium was present in all of 10 human cardiac computed tomographic angiograms analyzed.
Conclusions—Percutaneous transthoracic left atrial access is feasible without instrumenting the left ventricular myocardium. 
In our experience, magnetic resonance imaging offers superb visualization of anatomic structures with the ability to 
monitor and address complications in real-time, although x-ray guidance seems feasible. Clinical translation seems 
realistic based on human cardiac computed tomographic analysis and cadaver testing. This technique could provide a 
direct nonsurgical access route for future transcatheter mitral implantation.  (Circ Cardiovasc Interv. 2015;8:e002538. 
DOI: 10.1161/CIRCINTERVENTIONS.114.002538.)
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transjugular transseptal,16,17 and transfemoral transseptal.18 
However, a minithoracotomy still confers surgical morbidity. 
Transseptal delivery of large mitral implants has been dem-
onstrated, but achieving coaxiality with the mitral valve can 
remain challenging. A straight shot to the mitral valve that 
permits large sheath access but does not violate the LV myo-
cardium would be desirable and could reduce the engineering 
constraints of miniaturization, reduce procedural complexity, 
and improve patient outcomes.
Percutaneous left atrial (LA) access was first performed in 
the 1950s using long needles through the posterior chest wall 
to sample pressure.19,20 At first glance, delivering large sheaths 
via this approach seems challenging because of interposed 
lung, but there is extensive surgical evidence that temporarily 
collapsing a lung to perform an intrathoracic intervention is 
safe.21 In fact, diagnostic thoracoscopy with iatrogenic lung 
deflation is commonly performed in awake patients and con-
fers extremely low morbidity and mortality.22 Percutaneous 
transthoracic cardiac catheterization has also been performed 
in children with no alternative access, through the anterior 
chest into the pulmonary venous atrium and through the lower 
back into the inferior vena cava.23,24
We hypothesized that with imaging guidance and percu-
taneous techniques, it is possible to access the LA directly 
through the posterior chest wall by first displacing a lung 
with gas, then delivering a large sheath, and finally clos-
ing the LA port using off-the-shelf nitinol cardiac occluder 
devices. Compared with percutaneous transapical LV clo-
sure, we think that closing a port in the lower pressure LA 
may be preferable. Because of anatomic differences between 
large mammals and human, we tested this hypothesis in 
2 different large animal models (porcine and ovine) and 
then explored feasibility of clinical translation with human 
cardiac computed tomographic (CT) analysis and human 
cadaver testing. We also explored different image guidance 




The institutional animal care and use committee approved all pro-
cedures, which were performed according to contemporary National 
Institutes of Health guidelines. Animals were anesthetized with ket-
amine (25 mg/kg), midazolam (15 mg/kg), and glycopyrrolate (0.01 
mg/kg) and maintained on sevoflurane (1%–4%) and mechanical 
ventilation. Femoral arterial and venous access was obtained with 
ultrasound guidance with animals supine.
The technique was developed in nonsurvival experiments on 10 
naïve Yorkshire swine, not further described here. Subsequently, sur-
vival experiments were performed in 10 naïve Yorkshire swine with 
median bodyweight 51 kg (47–54 kg) and 2 naïve Dorset sheep (28 
and 36 kg), all of which were survived for at least 7 days before eu-
thanasia and necropsy.
Imaging
Experiments were performed first using MRI at 1.5T (Aera, Siemens) 
and later using biplane x-ray fluoroscopy enhanced by C-arm CT 
(Artis Zee and DynaCT, Siemens). Experiments are summarized in 
Figure 1. For MRI, trajectories were planned on isotropic 3-dimen-
sional images, and the procedure was performed using custom MRI-
antenna needles25 and real-time MRI at frame rates ≤15 fps. MRI 
parameters and devices are provided in the Data Supplement.
Pericardial Autotransfusion Catheter Placement
An 8.3F multi-sidehole subxiphoid pericardial drain was placed af-
ter transatrial microcatheter CO2 insufflation as described26 and con-
nected to the femoral vein to facilitate immediate autotransfusion for 
blood salvage. Unfractionated heparin (500–1000 IU) was infused 
into the pericardial space to prevent in situ thrombus.
Pleural CO2 Insufflation to Displace Lung
A needle was advanced through the left lateral chest wall during small 
puffs of iodinated or gadolinium contrast (for x-ray or MRI visualiza-
tion, respectively) until the pleural space was entered (Figure 2). This 
was exchanged for an 8.3F multi-sidehole pleural drain positioned 
in a dependent position to aspirate fluid but not CO2. As with the 
pericardium, 500 to 1000 IU of unfractionated heparin was infused 
into the pleural space to prevent in situ thrombus formation and fa-
cilitate autotransfusion. The pleural space was insufflated with CO2 
titrated to displace lung sufficiently to allow a clear trajectory to the 
WHAT IS KNOWN
??Transcatheter mitral valve replacement requires a 
large caliber sheath and coaxiality between the de-
livery system and the mitral valve.
??Transapical access may not be an option in all pa-
tients, so alternative approaches are needed.
WHAT THE STUDY ADDS
??Fully percutaneous transthoracic left atrial access 
and closure is feasible in large animal models and 
affords superb coaxiality with the mitral valve.
??The procedure can be guided using x-ray fluoros-
copy or real-time MRI.
??Cardiac computed tomographic analysis and hu-
man cadaver feasibility testing indicate that the left 
atrium can be accessed with a large caliber sheath 
through the posterior chest wall in humans.
Figure 1. Experiment design. LA indicates left atrial.
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LA. After insufflation, the ventilation rate was increased and tidal 
volumes reduced to keep airway pressure low.
Transthoracic LA Trajectory Planning and Access
Three-dimensional MRI or x-ray (C-arm CT and biplane fluoroscopy 
contrast angiograms) of the LA was acquired at baseline and after 
pleural insufflation. For x-ray guidance, we used a superimposed 
C-arm CT of LA and LV angiograms (syngo InSpace EP, Siemens). 
Swine and sheep were positioned respectively on the right side or 
prone to optimize working angles. A 20-cm needle was used to 
puncture through the posterior or lateral chest wall, pass through the 
empty pleural space, and enter the LA posteriorly (Figures 3 and 4). 
Needle tip position was confirmed by atrial pressure waveform and 
contrast injection. A stiff nitinol guidewire (Nitrex, Covidien) was 
introduced through the mitral valve to the LV apex, over which a 18F 
sheath (outer diameter, 7 mm; Large Check-Flo, Cook) and a custom-
shortened dilator were advanced into the LA without predilatation. 
Sheath position and relation to the mitral valve were confirmed using 
MRI or biplane contrast angiography.
LA Closure
The LA port was closed with an off-the-shelf 5- or 6-mm nitinol 
atrial septal occluder (St Jude Medical, MN; Lepu Medical, Beijing, 
China). The distal disc was deployed within the LA, and the sheath 
and delivery catheter were withdrawn in tandem until the disc was in 
apposition with the LA wall. The proximal disc was deployed outside 
the heart within the pleural space, and the device was released.
Human Cadaver Study and Human CT Analysis
To explore feasibility for humans, we tested percutaneous transtho-
racic LA access and closure in 3 human cadavers (1 under MR and 2 
under x-ray guidance). After femoral access, the cadavers were rolled 
prone and all procedural steps were identical to those previously 
described for animal procedures, using a larger sheath (Ascendra, 
Edwards Lifesciences, 26F/30F inner/outer diameter).
We also examined 10 random cardiac CT angiograms having full 
chest wall coverage among patients with mitral valve disease, dilated 
LA, or previous sternotomy in the National Heart, Lung, and Blood 
Institute anonymized and delinked database. This does not constitute 
human subjects research under US 45CFR§46.102(f). Each CT was 
examined for potential trajectories to the LA.
Statistical Analysis
Hemodynamic data are reported in the Table as median with first and 
third quartiles (Q1–Q3). Each hemodynamic parameter was analyzed in 
a linear mixed model with autoregressive–moving-average (1,1) corre-
lation structure assumed within each animal. The model fit mean levels 
of each parameter at each of the 4 postbaseline follow-up measurements 
with baseline as the reference. Because there were 4 follow-up measures 
for each of 3 hemodynamic parameters, we used a Bonferroni correction 
factor of 12 to account for multiple comparisons. A multiplicity cor-
rected P value ≤0.05 was considered statistically significant.
Results
Pericardial Access for Autotransfusion Catheter 
Placement
Transatrial pericardial access with a 2.8F microcatheter, 
insufflation of the pericardial space with CO2, placement of 
a subxiphoid 8.3F drain, and withdrawal of the transatrial 
microcatheter was uncomplicated in all 12 animals.
Pleural Insufflation
Pleural access and left lung deflation with CO2 was uncompli-
cated in all 12 animals. 600 to 900 mL of CO2 was required to 
displace the lung sufficiently to establish an unobstructed tra-
jectory to the LA in both species. Pleural pressures remained 
low (8–10 mm Hg) and, despite lung displacement, ventila-
tion was well tolerated with no increase in expired CO2 or 
evidence of hemodynamic compromise (Table). Reductions 
in mean arterial pressure and heart rate were observed after 
pleural insufflation, which were likely caused by an increase 
in the inhaled anesthetic agent concentration required to allow 
for the reduction in ventilator tidal volumes. However, these 
changes were not statistically significant.
Figure 2. Magnetic resonance imaging (MRI)-guided pleural insufflation to displace lung. A, Needle (arrow) is advanced through the chest 
wall toward the pleura. B, Saturation mode MRI darkens tissue to enhance visibility of gadolinium contrast. Small aliquots of contrast injected 
through the needle (arrow) show that the tip is still within the chest wall. C, After advancing the needle further, contrast flows freely around 
the lung in the pleural space (arrows). Saturation mode MRI is then toggled off. D–F, After insertion of a drain, the pleural space is insufflated 
with CO2 to deflate the lung despite positive pressure ventilation. Arrows indicate lung margin during progressive pleural insufflation.
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Trajectory Planning
In swine, pleural insufflation caused the heart to rotate, dis-
placing the long axis of the LV by 7° (6°–14°) compared with 
baseline. A direct trajectory to the LA, avoiding important 
anatomic structures was achievable in all animals. Distance 
from skin to LA was 10 cm (9–11 cm) in swine and 11 cm in 
both sheep.
Transthoracic LA Access and Closure
The LA was successfully accessed in 10/10 swine, including 
8 under MR guidance (Figure 3; Movie I in the Data Supple-
ment) and 2 under x-ray guidance (Figure 4; Movie II in the 
Data Supplement). All succeeded in a single needle pass except 
in 1, wherein a custom needle that had become dull required a 
second pass. The stiff nitinol guidewire was positioned in the 
LV apex, over which the 18F sheath was advanced without 
predilation. Sheath advancement displaced the LA wall by 25 
mm (20–30 mm; under x-ray guidance), but the wall recoiled 
as soon as the sheath tip entered the LA. No pericardial or 
pleural effusions developed during LA puncture or while the 
large sheath remained in place. Three-dimensional and cine 
MRI confirmed that the sheath trajectory was offset relative 
to the long axis of the LV by an angle α of ≤30° (Figure 3). 
The LA port was successfully closed with a single nitinol car-
diac occluder device in all animals. During sheath withdrawal 
and LA port closure, accumulated blood was autotransfused 
intermittently using the prepositioned pericardial and pleu-
ral drains. Median pericardial and pleural autotransfusion 
volumes were 55 mL (40–73 mL) and 10 mL (10–75 mL), 
respectively. Animals were stable hemodynamically through-
out, and no arrhythmias were observed (Table).
The LA was successfully accessed with a single pass and 
closed under MRI guidance in 2/2 sheep. One animal had mini-
mal pericardial effusion (50 mL). The second required higher 
than expected intraprocedural autotransfusion (300 mL) with-
out any hemodynamic compromise. Pleural effusion was neg-
ligible in both animals (10 and 20 mL).
There was no procedural mortality and all animals recov-
ered uneventfully. At the end of the procedure, the pericardial 
and pleural spaces were aspirated to dryness, any remaining 
pleural CO2 was aspirated, and the drains were withdrawn.
Figure 4. X-ray fluoroscopy and C-arm CT–guided left atrial (LA) 
access and closure in swine. A, A pigtail catheter is positioned in 
the LA via transseptal puncture. Contrast-enhanced cone-beam 
angiography is performed, and LA and left ventricle (LV) are seg-
mented and overlaid on the fluoroscopic images. The needle tip 
(arrow) for LA puncture is positioned against the posterior wall of 
the LA. B, The needle (arrow) is advanced into the LA. C, A stiff 
wire is introduced through the mitral valve into the LV apex.  
D, A large sheath is advanced over the wire into the heart. E, 
After withdrawing the sheath dilator, the sheath tip is confirmed 
within the LA. F, The LA port is closed with a nitinol cardiac 
occluder device (arrow).
Figure 3. Real-time magnetic resonance imaging (MRI)–guided 
left atrial (LA) access and closure in swine. A, An active visualiza-
tion MRI needle incorporating MRI electronics for enhanced vis-
ibility is introduced through the chest wall into the empty pleural 
space. The tip is positioned against the posterior LA wall (arrow). 
B, LA puncture: the active needle tip is clearly seen within the LA 
(arrow). C, Delivery of a large 18F sheath into the LA. The guide-
wire is visible in the apex of the left ventricle (LV; arrow).  
D, Filled with gadolinium contrast, the sheath trajectory to the 
LA is apparent. There is a passive marker at the tip of the sheath 
(arrow). The angle α represents the offset between the sheath 
trajectory and the long axis of the LV (dotted red line). E, A nitinol 
cardiac occluder device is loaded onto an active delivery cable, 
which incorporates MRI electronics for visualization. The distal 
disk is deployed within the LA and pulled back against the poste-
rior wall (arrow). The proximal disk is deployed outside the heart. 
F, Seven days later, the nitinol cardiac occluder device remains in 
the intended position with no pericardial effusion.
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Follow-Up
No complications were observed during the follow-up 
period of 7.5 days (7–8.5 days). Follow-up MRI confirmed 
stable position of the LA occluder device in all animals. 
Twelve of 12 animals had no pleural effusion. Eleven of 
12 animals had no detectable or trace pericardial effusion 
0 mL (0–6 mL). One pig, in which the LA was punctured 
twice, had a large but hemodynamically insignificant peri-
cardial effusion (660 mL) at 7 days follow-up. No other 
complications were observed in any animal and all skin 
incisions healed well. On necropsy, the nitinol cardiac 
occluder device was well seated and fibrosed to the LA wall 
in all animals (data not shown).
Human CT Analysis
Cardiac CT angiograms from 10 patients (age 68years [59–
73 years], 8/10 male) with full chest wall coverage were 
examined. A direct trajectory to the LA through the right 
posterior chest wall was achievable in all (Figure 5; Movie 
III in the Data Supplement). The right lung would need to be 
displaced by pleural insufflation, but the trajectory avoided 
important structures, including descending aorta and esoph-
agus. The mean angle α between the achievable trajectory 
and the true long axis of the LV was 5° (4°–7°). Mean inter-
costal distance at the point of entry through the chest wall 
was 12 mm (11–15 mm).
We also tested whether there was a trajectory to the mitral 
valve from a right minithoracotomy incision, entering the right 
atrium, and passing through the interatrial septum. In all 10 
patients this was achievable, but the offset angle between the 
trajectory and the true long axis of the LV was 56° (51°–58°).
Human Cadaver Study
In the prone position, right pleural insufflation and deflation 
of the right lung were straightforward whether under MR or 
x-ray guidance. This exposed a direct trajectory to the poste-
rior wall of the LA avoiding other important structures, such 
as aorta and esophagus, in all 3 cadavers. The LA was suc-
cessfully entered and a large 26F sheath was delivered. Pleural 
insufflation did not cause the heart to shift orientation within 
the thorax. As a result, the sheath trajectory remained well 
aligned with the long axis of the LV. The LA port was closed 
using a nitinol cardiac occluder device, and the right lung was 
reinflated by aspirating the pleural CO2 (Figure 6; Movie IV 
in the Data Supplement).
Discussion
We describe a novel percutaneous technique to access the 
left heart to deliver interventional devices. The technique 
combines several innovations: (1) fully percutaneous trans-
thoracic LA access with a needle followed by a large sheath; 
(2) pericardial autotransfusion catheter placement; (3) pleural 
Table.  Hemodynamics—MAP, HR, and Expired CO2 in Swine (n=10) Undergoing 
Fully Percutaneous Transthoracic Left Atrial Access and Closure
Swine (n=10) MAP, mm Hg HR, bpm Expired CO2, mm Hg
Baseline 61 (53–74) 96 (77–102) 29 (27–32)
After lung deflation 57 (46–66) 88 (72–98) 28 (26–29)
After insertion of left atrial sheath 52 (45–64) 87 (69–97) 29 (27–31)
After closure 50 (47–59) 81 (67–91) 31 (29–33)
Follow-up 56 (48–72) 102 (84–113) 30 (30–33)
The 2 sheep were smaller animals with lower baseline blood pressure so were excluded from the 
analysis of hemodynamics. No differences retained statistical significance after correction for multiplicity. 
Data are presented as median (Q1–Q3). HR indicates heart rate; and MAP, mean arterial blood pressure.
Figure 5. Human cardiac computed 
tomography (CT) angiography analysis. 
Axial (A) and sagittal (B) CT cross-sections 
showing simulated trajectory to the left 
atrium (LA; red line). The angle α represents 
the offset between the simulated trajectory 
and the true long axis of the left ventricle. 
C, Three-dimensional reconstruction show-
ing skin entry point (yellow arrow). The LA 
is highlighted in green and the esophagus 
in purple.
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insufflation and lung displacement to create an unobstructed 
trajectory to the LA; and (4) closure of the LA port using off-
the-shelf nitinol cardiac occluder devices. We demonstrated 
preclinical feasibility in 2 large animal models (porcine and 
ovine) and feasibility of clinical translation through perform-
ing the procedure in human cadavers and simulating on human 
cardiac CT images. Real-time MRI provided optimum usabil-
ity, for example, continuous depiction of the deflated lung, but 
x-ray fluoroscopy assisted by C-arm CT provided adequate 
confirmation of lung displacement during sheath traversal of 
the pleural space for LA entry.
Pleural Insufflation to Create Unobstructed 
Trajectory to LA
Thoracoscopy to inspect the pleura, perform biopsy, or deliver 
therapy is an established technique usually performed under 
moderate sedation.27 More advanced procedures, for example, 
lobectomy or management of spontaneous pneumothorax, 
are typically performed under general anesthesia with dual-
lumen endotracheal tube to facilitate single lung ventilation and 
have excellent perioperative outcomes.21,28,29 However, there is 
evidence that such interventions can be well tolerated in con-
scious nonintubated patients30 even for long procedures and in 
older sicker patients.31 Based on this extensive clinical experi-
ence, there is reason to expect that single lung deflation for the 
purpose of transthoracic LA access may be tolerated in patients.
Choice of Imaging Modality to Guide LA Access
The superior soft tissue visualization and multiplanar viewing 
capabilities of MRI are appealing to guide minimally invasive 
interventions, particularly interventions that violate vascular 
boundaries, in which every anatomic structure traversed must 
be visualized. MRI provides this capability. In this study, we 
demonstrated that LA access and closure could be safely per-
formed using real-time MRI guidance. MRI also permitted 
easy access to the pleural space and titration of pleural insuf-
flation to displace lung. Crucially, MRI afforded continuous 
monitoring for development of pericardial and pleural effu-
sions during LA puncture and closure. Any accumulation of 
blood in the pericardial or pleural space was immediately 
identified and autotransfused.
Nonetheless, we explored whether the procedure could be 
performed using x-ray fluoroscopy. A transseptal pigtail cath-
eter was positioned in the LA. Biplane contrast angiography 
and intrapericardial iodinated contrast delineated LA anatomy 
adequately. This enabled a trajectory to the LA to be planned 
in orthogonal x-ray projections. It was difficult to definitely 
establish adequate lung displacement using fluoroscopy only, 
but C-arm CT provided clear visualization of lung tissue and 
assurance of satisfactory lung displacement. In humans, where 
the preferred LA puncture site should be posterior and midway 
between left and right pulmonary vein ostia, dual transseptal 
guidewires in left and right pulmonary veins could offer a pre-
cise fluoroscopic target for LA puncture. Echocardiography 
could provide a substitute for real-time MRI to monitor for 
pericardial blood accumulation and guide autotransfusion.
We also explored using color overlays of the LA and LV, 
segmented from contrast-enhanced C-arm CT using software 
designed to guide electrophysiology procedures. The fusion 
images enhanced our ability to predict trajectories and deter-
mine optimal LA puncture location (Figure 4). In addition, 
the overlays aided in selecting optimal x-ray projection angles 
and may have reduced overall iodinated contrast usage.
Closure of LA Port
There is clinical precedent for the use of off-label nitinol car-
diac occluder devices to seal large holes in vascular structures, 
including the LV apex or abdominal aorta.13,32 Even in the 
high-pressure LV, hemostasis was rapidly achieved with rever-
sal of anticoagulation. Hemostasis should be easier to achieve 
in the LA because the pressure is much lower than in the LV or 
systemic arteries, even in patients with mitral valve disease. In 
some animals, blood did accumulate in the pericardial or pleu-
ral space, but was easily managed by aspiration and autotrans-
fusion, akin to standard surgical blood salvage technique. After 
aspirating to dryness, all drains were removed post procedure 
for animal comfort—although in humans they would be left 
in overnight. Only 1 large but hemodynamically insignificant 
pericardial effusion was observed at follow-up, in the 1 animal 
in which 2 LA punctures were made because a custom needle 
Figure 6. Real-time magnetic resonance imaging (MRI)–guided 
left atrial (LA) access and closure in a human cadaver. A, Axial 
MRI before lung deflation. B, MRI in the same plane after right 
lung deflation. An unobstructed trajectory to the LA is apparent. 
C, Axial MRI of large sheath filled with gadolinium contrast in the 
LA. D, Sagittal MRI of sheath in the LA. E, Deployment of a nitinol 
cardiac occluder device (arrow). The delivery cable incorporates 
MRI electronics to enhance device visualization. F, After lung 
reinflation, the device can be clearly seen across the posterior 
wall of the LA (arrow).
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had become dull. The animal recovered uneventfully and the 
effusion would not have accumulated had the pericardial drain 
remained in place post procedure.
Feasibility of Clinical Translation
We tested LA access and closure in 2 large animal models to 
determine whether the approach was feasible in different anat-
omies. The trajectories for unobstructed access to the LA were 
different in the 2 species but easily achievable by deflating 
the left lung. Importantly, all animals were hemodynamically 
stable with a large sheath in the LA. This approach could cir-
cumvent many of the risks associated with transapical access 
in patients with advanced mitral valve disease, in particular, 
acute hemodynamic instability and late LV pseudoaneurysm, 
ventricular arrhythmias, and decrement in LV function.
Human cardiac CT angiogram analysis confirmed that 
a theoretical trajectory exists in humans. In swine, pleural 
insufflation rotated the heart in the thorax, which resulted in 
an offset between the long axis of the heart and the achieved 
trajectory (Figure 3). Because the orientation of the heart in 
the human mediastinum is different, the trajectory is different 
from that in swine or sheep. In humans, the right lung would 
be deflated to puncture the LA posteriorly between the pulmo-
nary veins (Figure 5). In this configuration, right lung defla-
tion would deflect the right pulmonary veins away from the 
needle trajectory, exposing the posterior wall of the LA. This 
trajectory avoids other important structures, such as the aorta 
and esophagus. The mean intercostal distance at the point of 
entry through the chest wall was sufficient to accommodate a 
sheath 32F or larger.
To demonstrate that this trajectory was feasible, we 
accessed the LA in human cadavers and delivered a large 
sheath under either MRI or x-ray guidance (Figure 6). Pleural 
insufflation did not shift the orientation of the heart within the 
thorax in cadavers. We then closed the LA port with a nitinol 
cardiac occluder device and re-expanded the right lung.
Limitations
There are anatomic differences between humans and swine. 
For example, the descending aorta and esophagus vary in 
position within the thorax. Procedural tomography (such as 
C-arm CT and real-time MRI) is therefore recommended for 
trajectory planning. Pulmonary disease or chronic heart fail-
ure could increase the risk of single lung ventilation. Clotting 
disorders could increase bleeding. Off-label nitinol cardiac 
occluder devices may not assure hemostasis. Prior cardio-
thoracic surgery may cause pleural adhesions, which could 
impede lung displacement. Because our technique involves 2 
points of fixation (chest wall and LA wall), sheath maneuver-
ability is constrained. However, because excellent alignment 
with the LV long axis can be achieved by careful trajectory 
planning, we do not anticipate that excessive sheath manipu-
lation would be required to achieve coaxial alignment to per-
form a mitral valve intervention.
Technical Considerations for Clinical Translation
To perform this procedure in patients under x-ray fluoroscopy 
guidance, we envision the following provisions: (1) The proce-
dure would be performed under general anesthesia with a dual 
lumen endotracheal tube and bronchial blockers to facilitate 
intentional right lung collapse and single lung ventilation. (2) 
The patient would be positioned initially supine for standard 
percutaneous access and then rolled prone for transthoracic 
atrial access. (3) A temperature or transesophageal echocar-
diography probe would be used to identify the esophagus. (4) 
A pericardial drain may not be required in patients with prior 
sternotomy and pericardial adhesions. (5) Respiration would 
be suspended during LA puncture. (6) The guidewire would 
be advanced through the mitral valve into the LV over a bal-
loon catheter to prevent chordal entrapment. (7) Anticoagu-
lation would be reversed with protamine immediately before 
cardiac occluder device deployment. (8) A coaxial buddy wire 
would be used during LA port closure to allow LA access to 
be reestablished rapidly in case of inadvertent pull through of 
the nitinol cardiac occluder device. (9) Pleural and pericardial 
drains would be left in place for a short period after the proce-
dure to drain any effusions.
Conclusions
Fully percutaneous transthoracic LA access is feasible to 
deliver large interventional devices to the mitral valve without 
violating the LV myocardium. The procedure can be guided 
by a variety of imaging modalities, although in our experience 
MRI guidance offers the greatest visualization of anatomic 
structures with the ability to monitor and address complica-
tions in real-time, for example, pericardial effusion. Clinical 
translation seems feasible based on human cardiac CT analy-
sis and human cadaver testing. This technique could provide 
a direct and coaxial access route for transcatheter mitral valve 
interventions in the future.
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5.5 Supplemental	  materials	  
5.5.1 MR	  imaging	  parameters	  
Steady-­‐state	  free	  precession	  (SSFP)	  imaging	  followed	  usual	  parameters:	  repetition	  time	  
(TR)/echo	  time	  (TE)	  2.9/1.2ms;	  flip	  angle	  57°;	  bandwidth	  930Hz/pixel;	  field	  of	  view	  (FOV)	  
340x340mm;	  matrix	  256x256pixels;	  slice	  thickness	  6mm.	  Three-­‐dimensional	  radial	  SSFP	  non-­‐
contrast	  whole	  heart	  parameters	  were	  TR/TE	  3.1/1.56ms;	  flip	  angle	  115°;	  bandwidth,	  
898Hz/pixel;	  FOV	  220x220mm;	  voxel	  size	  1.1x1.1x1.1mm;	  base	  resolution	  192;	  radial	  views	  
12360.	  Real-­‐time	  imaging	  used	  SSFP	  (TR/TE	  2.9/1.4ms;	  flip	  angle	  45°;	  bandwidth	  
1000Hz/pixel;	  matrix	  192x108;	  FOV	  300x300mm;	  GRAPPA	  Factor	  2-­‐4)	  or	  gradient	  echo	  
(TR/TE	  4.2/1.9ms;	  flip	  angle	  15°;	  bandwidth	  500Hz/pixel;	  matrix	  192x144;	  FOV	  300x300mm;	  
GRAPPA	  Factor	  2-­‐4).	  
To	  assess	  for	  and	  quantify	  volume	  of	  pericardial	  effusion,	  contiguous	  true	  axial	  slices	  were	  
acquired	  using	  a	  steady-­‐state	  free	  precession	  (SSFP)	  sequence	  with	  breath	  hold	  and	  ECG	  
gating.	  Slices	  were	  prescribed	  to	  include	  cardiac	  anatomy	  from	  base	  to	  apex	  to	  ensure	  
coverage	  of	  the	  entirety	  of	  the	  pericardial	  space.	  Acquisition	  parameters	  were:	  repetition	  
time	  (TR)/echo	  time	  (TE),	  2.96/1.25msec;	  number	  of	  averages	  2;	  acceleration	  factor	  
(GRAPPA)	  2;	  flip	  angle	  80°;	  bandwidth	  1157Hz/pixel;	  field	  of	  view	  300x300mm;	  matrix	  
240x128	  pixels;	  slice	  thickness	  6mm;	  and	  slice	  distance	  0mm.	  Pericardial	  and	  cardiac	  
contours	  were	  drawn	  manually	  on	  each	  slice	  and	  the	  pericardial	  effusion	  volume	  was	  
calculated	  by	  subtracting	  the	  total	  cardiac	  volume	  from	  the	  total	  pericardial	  volume	  using	  
Syngo	  Argus	  MR	  analysis	  software	  (Siemens).	  
5.5.2 Interventional	  devices	  used	  in	  MR	  
We	  used	  a	  custom	  needle	  and	  closure	  device	  delivery	  cable,	  each	  incorporating	  a	  loop	  
antenna	  for	  active	  visualization.	  This	  enables	  the	  devices	  to	  appear	  highlighted	  in	  colour	  in	  
the	  real-­‐time	  MR	  images.	  To	  visualize	  the	  18Fr	  sheath	  in	  MR,	  a	  passive	  marker	  containing	  
iron	  oxide	  particles	  was	  added	  to	  the	  tip,	  which	  appears	  as	  a	  dark	  artefact	  on	  the	  real-­‐time	  
MR	  images.	  
5.5.3 DynaCT	  imaging	  parameters	  
ECG	  triggered	  with	  breath	  hold,	  4	  sweeps	  with	  5	  second	  scan	  time/sweep,	  90	  kV,	  0.80	  
degrees/frame,	  total	  of	  4	  sweeps.	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Chapter	  6. Transcatheter	  myocardial	  needle	  chemoablation	  
under	  realtime	  MRI	  guidance	  
6.1 Introduction	  
Radiofrequency	  ablation	  for	  rhythm	  disorders	  is	  limited	  by	  the	  inability	  to	  instantaneously	  
visualize	  and	  monitor	  ablation	  lesions,	  and	  by	  the	  mismatch	  between	  immediate	  injury	  and	  
irreversible	  conduction	  block151.	  Magnetic	  resonance	  imaging	  (MRI)	  thermometry	  has	  shown	  
potential	  for	  monitoring	  the	  effect	  of	  radiofrequency	  energy	  but	  only	  approximates	  the	  
extent	  of	  irreversible	  lesions	  152.	  Late	  gadolinium	  enhancement	  MRI	  (LGE)	  correlates	  with	  
histological	  lesion	  volume	  153	  but	  can	  only	  be	  performed	  once	  per	  procedure	  and	  is	  not	  a	  
surrogate	  for	  real-­‐time	  lesion	  monitoring	  during	  ablation.	  Furthermore,	  scar	  size	  by	  LGE	  
several	  months	  post-­‐ablation	  is	  up	  to	  50%	  smaller	  than	  that	  measured	  acutely	  immediately	  
post-­‐ablation	  154.	  This	  could	  be	  explained	  by	  lesion	  contraction	  during	  fibrotic	  healing	  and	  by	  
enhancement	  with	  LGE	  of	  both	  radiofrequency	  energy	  induced	  oedematous	  penumbra	  and	  
the	  true	  necrotic	  core.	  
Radiofrequency	  ablation	  for	  ventricular	  tachycardia	  (VT)	  is	  further	  limited	  by	  the	  mismatch	  
between	  thickness	  of	  left	  ventricular	  (LV)	  myocardium	  and	  shallowness	  of	  radiofrequency	  
lesions155.	  Critical	  peri-­‐infarct	  substrate	  can	  be	  deep	  within	  the	  myocardium	  and	  difficult	  to	  
ablate	  via	  endocardial	  or	  epicardial	  approaches156.	  Failure	  to	  achieve	  permanent	  transmural	  
tissue	  destruction	  is	  a	  common	  cause	  of	  therapeutic	  failure.	  MRI	  tissue	  characterization	  
techniques	  can	  identify	  pathologic	  rhythm	  substrate	  tissues	  such	  as	  a	  critical	  re-­‐entrant	  
isthmus	  or	  a	  peri-­‐infarct	  slow-­‐conduction	  heterogeneous	  zone157.	  Areas	  of	  scar	  tissue	  by	  LGE	  
have	  in	  animals	  shown	  close	  similarity	  to	  electroanatomic	  voltage	  maps93.	  Trans-­‐catheter	  
MRI	  guided	  radiofrequency	  ablation	  of	  atrial	  tissue	  has	  been	  reported	  in	  early	  human	  
studies123.	  	  
Chemoablation	  is	  already	  used	  for	  trans-­‐coronary	  interventricular	  septal	  ablation	  in	  patients	  
with	  hypertrophic	  cardiomyopathy	  158,	  in	  the	  viscera	  for	  tumour	  ablation159,	  and	  through	  the	  
vein	  of	  Marshall	  for	  atrial	  fibrillation160.	  Caustic	  agents	  such	  as	  ethanol	  or	  acetic	  acid	  cause	  
early	  coagulative	  necrosis,	  followed	  by	  late	  fibrosis	  and	  scarring	  161.	  These	  agents	  are	  
considered	  safe,	  because	  if	  small	  quantities	  reach	  the	  blood	  pool	  they	  are	  immediately	  
diluted	  down	  to	  a	  harmless	  concentration.	  Transarterial	  162,	  163	  or	  retrograde	  transvenous	  164	  
chemoablation	  may	  allow	  deeper	  endocardial	  lesion	  creation	  compared	  with	  radiofrequency	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ablation,	  but	  are	  constrained	  by	  the	  myocardial	  territories	  incidentally	  subtended	  by	  the	  
injected	  vessels	  and	  may	  lead	  to	  the	  destruction	  of	  excess	  tissue.	  Chemoablation	  for	  
ventricular	  arrhythmias	  by	  direct	  endomyocardial	  injection	  may	  overcome	  these	  anatomic	  
constraints	  and	  may	  allow	  more	  targeted	  tissue	  ablation.	  Pre-­‐clinical	  feasibility	  of	  
fluoroscopic	  or	  intracardiac	  echocardiography	  guided	  subendocardial	  ablation	  with	  ethanol	  
has	  been	  demonstrated	  165,	  although	  we	  are	  not	  aware	  of	  acetic	  acid	  chemoablation	  in	  the	  
heart.	  These	  techniques	  remain	  limited	  because	  they	  do	  not	  allow	  differentiation	  of	  target	  
tissues	  or	  real-­‐time	  lesion	  monitoring.	  
We	  hypothesized	  that	  real-­‐time	  MRI	  would	  enable	  substrate-­‐guided	  myocardial	  
chemoablation.	  We	  propose	  to	  use	  MRI	  to	  instantaneously	  visualize	  arrhythmia	  substrate	  
and	  ablative	  agents	  doped	  with	  gadolinium-­‐based	  contrast	  agents.	  In	  this	  report	  we	  
demonstrate	  for	  the	  first	  time	  (1)	  feasibility	  of	  real-­‐time	  MRI	  guided	  myocardial	  
chemoablation	  in	  swine;	  (2)	  MRI	  characteristics,	  macroscopic	  appearance	  and	  
histopathology	  of	  acute	  and	  chronic	  chemoablation	  lesions;	  (3)	  superior	  circumscription	  of	  
myocardial	  acetic	  acid	  chemoablation	  lesions	  compared	  with	  ethanol	  lesions;	  and	  (4)	  
anatomical	  and	  electrical	  interruption	  of	  a	  conductive	  isthmus	  in	  an	  animal	  model	  of	  
ischemic	  cardiomyopathy.	  
6.2 Candidate’s	  contribution	  
I	  created	  the	  animal	  model	  if	  ischaemic	  cardiomyopathy	  and	  performed	  all	  MRI-­‐guided	  
chemoablation	  experiments.	  Except	  for	  the	  first	  animal,	  I	  personally	  performed	  all	  
subsequent	  endocardial	  and	  epicardial	  mapping	  experiments.	  I	  received	  assistance	  from	  St	  
Jude	  Medical	  to	  analyse	  the	  electroanatomic	  maps	  but	  I	  collected	  all	  other	  data.	  I	  assisted	  
with	  all	  necropsy,	  histological	  specimen	  collection	  and	  preparation,	  and	  participated	  in	  all	  
histology	  review	  sessions.	  I	  drafted	  the	  manuscript	  and	  prepared	  the	  figures,	  tables	  and	  
supplementary	  materials.	  
6.3 Methods	  
The	  institutional	  animal	  care	  and	  use	  committee	  approved	  all	  procedures,	  which	  were	  
performed	  according	  to	  contemporary	  NIH	  guidelines.	  18	  Yorkshire	  swine	  with	  mean	  
bodyweight	  54(46-­‐57)kg	  were	  anesthetized	  with	  mechanical	  ventilation.	  Chemoablation	  
experiments	  were	  performed	  in	  a	  clinical	  MRI	  catheterization	  suite,	  equipped	  with	  sound-­‐
suppression	  communication	  headsets	  and	  with	  LCD	  projectors	  to	  display	  hemodynamics	  and	  
real-­‐time	  MRI	  images	  at	  the	  bedside	  (Figure	  6-­‐1)15.	  Electroanatomic	  mapping	  was	  performed	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under	  X-­‐ray	  guidance.	  
6.3.1 Evaluation	  of	  chemoablation	  agents	  
Gadolinium-­‐based	  contrast	  agents	  can	  release	  free	  gadolinium	  (Gd3+)	  in	  solutions	  with	  low	  
pH.	  We	  therefore	  tested	  whether	  50%	  acetic	  acid	  (pH	  1.9)	  caused	  release	  of	  free	  gadolinium	  
from	  three	  different	  commercially	  available	  gadolinium-­‐based	  contrast	  agents	  
(gadopentetate	  dimeglumine,	  Magnevist,	  Bayer	  Healthcare;	  gadofosveset	  trisodium,	  
Ablavar,	  Lantheus	  Medical	  Imaging;	  and	  gadoterate	  meglumine,	  Dotarem,	  Guerbet).	  
The	  amount	  of	  Gd3+	  was	  quantified	  using	  Arsenazo	  III,	  which	  binds	  to	  gadolinium	  ions	  to	  
form	  a	  complex	  that	  can	  be	  quantified	  with	  a	  colorimetric	  assay166.	  The	  amount	  of	  free	  
gadolinium	  was	  quantified	  by	  using	  Arsenazo	  III.	  Arsenazo	  III	  binds	  to	  gadolinium	  ions	  to	  
form	  a	  complex,	  which	  can	  be	  quantified	  with	  a	  colorimetric	  assay.	  	  Standards	  at	  
concentrations	  of	  0	  –	  50	  μg/ml	  Gd3+	  were	  prepared	  with	  gadolinium	  (III)	  chloride	  
hexahydrate	  (Alfa	  Aesar)	  prepared	  in	  50%	  acetic	  acid	  (Mallinckrodt	  Baker).	  	  An	  ultraviolet-­‐
visible	  spectrophotometer	  (Shimadzu)	  was	  used	  to	  read	  absorbance	  values	  at	  652	  nm	  to	  
form	  a	  linear	  calibration	  curve.	  	  Samples	  of	  MRI	  contrast	  agents	  (Magnevist	  500mM	  Gd,	  
Ablavar	  250mM	  Gd,	  and	  Dotarem	  500mM	  Gd)	  were	  prepared	  in	  50%	  acetic	  acid	  (pH	  1.9)	  at	  
concentrations	  of	  2%	  and	  5%	  Gd3+,	  and	  samples	  were	  incubated	  for	  15	  minutes	  before	  
absorbance	  values	  at	  652	  nm	  were	  recorded.	  For	  Dotarem,	  values	  were	  also	  recorded	  after	  
30	  minutes	  and	  60	  minutes	  of	  incubation	  time.	  
We	  characterized	  ethanol	  or	  acetic	  acid	  chemoablation	  lesions	  in	  experiments	  in	  8	  naïve	  
swine.	  4	  animals	  were	  euthanized	  immediately	  and	  4	  were	  survived	  for	  at	  least	  7	  days.	  70%	  
ethanol	  and	  50%	  acetic	  acid	  were	  doped	  with	  gadolinium-­‐based	  contrast	  agent	  for	  MRI	  
conspicuity	  (2%	  gadolinium	  by	  total	  volume).	  Pure	  ethanol	  was	  pre-­‐diluted	  to	  70%	  with	  
sterile	  water	  because	  in	  higher	  concentrations	  gadopentetate	  can	  precipitate.	  50%	  acetic	  
acid	  is	  the	  optimal	  concentration	  for	  solid	  organ	  tumour	  ablation	  167.	  Small	  aliquots	  (0.1-­‐
0.6mL)	  of	  these	  two	  solutions	  were	  injected	  into	  the	  LV	  myocardium	  under	  real-­‐time	  MRI	  
guidance.	  Venous	  blood	  was	  collected	  before	  and	  immediately	  after	  chemoablation	  with	  
acetic	  acid	  to	  assess	  for	  any	  effect	  on	  systemic	  pH	  and	  anion	  gap.	  	  
6.3.2 MRI	  guided	  chemoablation	  
Injections	  into	  the	  LV	  myocardium	  were	  delivered	  using	  a	  MRI-­‐conditional	  deflectable	  
sheath	  (Imricor	  and	  Innotom)	  with	  a	  passive	  marker	  tip	  and	  a	  custom	  injection	  needle	  
catheter	  incorporating	  electronics	  for	  active	  visualization.	  The	  needle	  catheter	  appeared	  in	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colour	  on	  real-­‐time	  MRI.	  The	  sheath	  was	  introduced	  to	  the	  LV	  cavity	  via	  transarterial	  
retrograde	  approach	  over	  a	  Nitinol	  guidewire	  (Nitrex)	  under	  interactive	  real-­‐time	  MRI	  
guidance168.	  The	  needle	  was	  navigated	  to	  the	  target	  myocardium,	  positioned	  orthogonally	  to	  
the	  endocardial	  surface	  (Figure	  6-­‐2)	  and	  deployed	  to	  a	  depth	  of	  4mm.	  The	  chemoablation	  
agent	  was	  injected	  slowly	  in	  aliquots	  of	  0.1-­‐0.6mL	  and	  the	  needle	  was	  withdrawn	  after	  
30sec.	  Chemoablation	  lesions	  appeared	  bright	  in	  real-­‐time	  inversion-­‐recovery	  MRI	  as	  the	  
chemoablation	  agent	  doped	  with	  gadolinium	  contrast	  was	  injected.	  
6.3.3 MRI	  scanning	  parameters	  
Steady-­‐state	  free	  precession	  (SSFP)	  cine	  imaging:	  Repetition	  time	  (TR)/echo	  time	  (TE)	  
3.1/1.3ms;	  flip	  angle	  57°;	  bandwidth	  930Hz/pixel;	  field	  of	  view	  (FOV)	  300mmx300mm;	  
matrix	  256x256pixels;	  slice	  thickness	  8mm.	  
Three-­‐dimensional	  radial	  SSFP	  non-­‐contrast	  whole	  heart:	  TR/TE	  3.1/1.5ms;	  flip	  angle	  115°;	  
bandwidth,	  898Hz/pixel;	  FOV	  220x220mm;	  voxel	  size	  1.1x1.1x1.1mm;	  base	  resolution	  192;	  
radial	  views	  12360.	  
Realtime	  MRI:	  TR/TE	  2.9/1.4ms;	  flip	  angle	  45°;	  bandwidth	  1000Hz/pixel;	  matrix	  192x108;	  
FOV	  300x300mm;	  GRAPPA	  Factor	  2-­‐4)	  or	  gradient	  echo	  (TR/TE	  4.2/1.9ms;	  flip	  angle	  15°;	  
bandwidth	  500Hz/pixel;	  matrix	  192x144;	  FOV	  300x300mm;	  GRAPPA	  Factor	  2-­‐4.	  A	  real-­‐time	  
inversion	  recovery	  sequence	  could	  be	  toggled	  on	  to	  highlight	  gadolinium	  enhancement	  of	  
injection	  sites,	  relative	  to	  normal	  myocardium	  and	  areas	  of	  prior	  infarction.	  A	  non-­‐selective	  
inversion	  pre-­‐pulse	  was	  performed	  before	  every	  bSSFP	  image	  acquisition	  with	  an	  interactive	  
inversion	  time	  (TI).	  The	  next	  inversion	  pulse	  immediately	  followed	  the	  image	  acquisition,	  
with	  no	  additional	  time	  for	  signal	  recovery.	  Typical	  imaging	  parameters	  were	  TI	  417ms,	  
TR/TE	  2.54/1.27ms,	  flip	  angle	  45°,	  FOV	  300mm,	  slice	  thickness	  6	  mm,	  matrix	  128x128,	  
GRAPPA	  factor	  2	  and	  frame	  rate	  2	  frames/second.	  The	  real-­‐time	  MRI	  user	  interface	  
(Interactive	  Front	  End,	  Siemens)	  enabled	  control	  of	  slice	  plane	  and	  thickness,	  and	  toggling	  
between	  rapid	  imaging	  for	  catheter	  navigation	  and	  high	  contrast	  real-­‐time	  inversion-­‐
recovery	  MRI	  during	  injection.	  
Ex-­‐Vivo	  3D	  Hi-­‐Res	  Isotropic	  T1-­‐W	  SPGR:	  TR/TE	  10/5.4ms;	  flip	  angle	  20°;	  bandwidth	  
210Hz/pixel;	  matrix	  320x320;	  FOV	  180x180mm;	  voxel	  size	  0.6x0.6x0.6mm;	  slab	  thickness	  
72mm;	  120	  slices	  per	  slab.	  
LGE	  PSIR	  segmented	  FLASH	  724:	  TR/TE	  8.2/3.2ms;	  flip	  angle	  25°;	  bandwidth	  140Hz/pixel;	  
matrix	  256x144;	  FOV	  360x270mm;	  slice	  thickness	  8mm.	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MRI	  post-­‐processing	  and	  image	  analysis:	  Images	  were	  analysed	  using	  QMass	  MR	  (Medis).	  
Acutely,	  infarct	  and	  lesion	  could	  be	  differentiated	  by	  relative	  signal	  intensity	  on	  phase	  
sensitive	  inversions	  recovery	  LGE	  (3	  and	  10	  standard	  deviations	  above	  mean	  respectively).	  
Chronically,	  lesion	  signal	  intensity	  was	  similar	  to	  infarct	  (3	  standard	  deviations	  above	  mean).	  
6.3.4 Animal	  model	  of	  ischemic	  cardiomyopathy	  
10	  pigs	  were	  pre-­‐treated	  with	  amiodarone,	  aspirin	  and	  heparin,	  and	  underwent	  X-­‐ray	  guided	  
left	  coronary	  artery	  branch	  balloon	  occlusion.	  Obtuse	  marginal	  and	  diagonal	  arteries	  were	  
selected	  for	  ethanol	  infarction	  ensuring	  that	  at	  least	  one	  interposed	  branch	  (e.g.	  first	  
diagonal,	  first	  obtuse	  marginal	  or	  ramus	  intermedius)	  remained	  intact	  to	  provide	  a	  simulated	  
VT	  isthmus.	  1-­‐2mL	  of	  70%	  ethanol	  /	  30%	  iopamidol	  contrast	  was	  infused	  through	  the	  balloon	  
guidewire	  lumen	  to	  create	  infarcts.	  No	  sustained	  arrhythmias	  were	  observed	  and	  there	  was	  
no	  mortality	  from	  this	  procedure.	  Animals	  were	  survived	  for	  12(8-­‐15)	  days	  before	  MRI	  
guided	  isthmus	  chemoablation.	  
6.3.5 Real-­‐time	  MRI	  guided	  isthmus	  chemoablation	  
0.2mmol/kg	  gadopentetate	  dimeglumine	  (Bayer	  Healthcare)	  was	  administered	  
intravenously	  to	  the	  ischemic	  cardiomyopathy	  animals.	  Real-­‐time	  inversion-­‐recovery	  MRI	  
identified	  areas	  of	  infarction	  containing	  gadolinium	  contrast.	  Firstly,	  to	  test	  feasibility	  of	  
targeted	  isthmus	  chemoablation	  under	  MRI	  guidance,	  we	  ablated	  the	  normal	  myocardium	  
interposed	  between	  the	  infarcted	  regions	  in	  5	  animals.	  
In	  the	  other	  5	  animals,	  we	  performed	  pre-­‐and	  post-­‐chemoablation	  electroanatomic	  mapping	  
of	  the	  LV	  endocardium	  ±	  epicardium	  using	  a	  commercial	  system	  and	  catheters	  under	  X-­‐ray	  
guidance	  (NavX	  and	  EnSite	  Velocity;	  duo-­‐decapolar	  Livewire	  and	  FlexAbility,	  St	  Jude	  
Medical).	  Pericardial	  access	  for	  epicardial	  mapping	  was	  obtained	  via	  right	  atrial	  appendage	  
exit169.	  Isthmus	  chemoablation	  was	  performed	  under	  real-­‐time	  MRI	  guidance.	  
6.3.6 Ex-­‐vivo	  MRI	  and	  histology	  
After	  euthanasia	  hearts	  were	  explanted	  and	  suspended	  in	  agar	  for	  ex-­‐vivo	  high-­‐resolution	  
MRI.	  Specimens	  were	  fixed	  in	  10%	  formalin,	  then	  sectioned	  and	  stained	  with	  hematoxylin	  
and	  eosin	  (H&E)	  and	  Masson	  trichrome	  stains.	  
6.3.7 Statistics	  
Data	  were	  analysed	  using	  SPSS	  (v19.0,	  IBM)	  and	  are	  described	  as	  mean	  ±	  standard	  deviation	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if	  normally	  distributed,	  otherwise	  as	  median	  (first	  and	  third	  quartile).	  Acute	  and	  chronic	  
lesion	  volumes	  were	  tested	  for	  correlation	  using	  Pearson’s	  correlation	  coefficient.	  Anion	  gap	  
and	  pH	  pre-­‐and	  post-­‐chemoablation	  were	  compared	  using	  a	  paired	  t-­‐test.	  A	  p	  value	  <0.05	  
was	  considered	  significant.	  
6.4 Results	  
6.4.1 Chemoablation	  lesion	  histology	  
In	  the	  8	  naïve	  animals,	  ethanol	  lesions	  exhibited	  stellate	  geometry	  with	  patchy	  areas	  of	  
viable	  myocardium	  histologically,	  whereas	  acetic	  acid	  lesions,	  exhibited	  greater	  
homogeneity	  and	  more	  circumscribed	  borders	  (Figure	  6-­‐3).	  Acetic	  acid	  lesions	  were	  46%	  
larger	  than	  ethanol	  lesions	  for	  the	  same	  injection	  volume.	  Based	  on	  these	  findings,	  we	  
elected	  to	  perform	  chronic	  experiments	  with	  acetic	  acid.	  Acute	  lesions	  with	  either	  agent	  had	  
a	  macroscopic	  area	  of	  discoloration	  with	  a	  haemorrhagic	  centre.	  H&E	  of	  acute	  lesion	  
revealed	  hypereosinophilia	  of	  affected	  myocardial	  fibres	  with	  mild	  to	  moderately	  pyknotic	  
nuclei	  and	  indistinct	  cross	  striations,	  consistent	  with	  cellular	  destruction	  	  (Figure	  6-­‐2).	  
H&E	  of	  chronic	  lesions	  revealed	  typical	  features	  of	  fibrosis	  and	  replacement	  of	  normal	  
myocardial	  architecture.	  Masson	  trichrome	  stain	  revealed	  a	  zone	  of	  fibroplasia	  and	  fibrosis	  
with	  collagen	  stained	  blue,	  normal	  myocardial	  fibres	  stained	  red	  and	  necrotic	  myocardial	  
fibres	  stained	  purple	  (Figure	  6-­‐2).	  Chronic	  acetic	  acid	  lesions	  were	  well	  circumscribed	  with	  
distinct	  margins	  between	  lesion	  and	  normal	  myocardium.	  	  
6.4.2 Chemoablation	  lesion	  appearances	  by	  MRI	  
As	  gadolinium-­‐doped	  chemoablation	  agent	  was	  injected	  into	  the	  myocardium,	  the	  evolving	  
lesion	  was	  visualized	  in	  real-­‐time	  using	  real-­‐time	  inversion-­‐recovery	  MRI	  (Figure	  6-­‐2).	  12(7-­‐
17)days	  after	  chemoablation,	  lesions	  enhanced	  using	  LGE	  after	  systemic	  gadolinium	  contrast	  
administration	  (Figure	  6-­‐2).	  Volume	  of	  acute	  acetic	  acid	  chemoablation	  lesions	  correlated	  
with	  volume	  of	  chronic	  lesions	  on	  LGE	  (0.78±0.39mL	  vs.	  0.75±0.34mL,	  r=0.71,	  n=34,	  
p<0.001).	  
6.4.3 Ischemic	  cardiomyopathy	  isthmus	  chemoablation	  
All	  10	  animals	  developed	  cardiomyopathy	  (left	  ventricular	  end-­‐diastolic	  volume	  index	  
136±17mL/m2;	  end-­‐systolic	  volume	  index	  83±13mL/m2;	  ejection	  fraction	  39±5%).	  After	  
systemic	  gadolinium	  contrast	  administration,	  infarcts	  were	  distinguishable	  from	  normal	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myocardium	  by	  LGE	  or	  real-­‐time	  inversion-­‐recovery	  MRI.	  Successful	  transcatheter	  
chemoablation	  of	  the	  isthmus	  between	  infarcts	  was	  defined	  as	  presence	  of	  a	  confluent	  
chemoablation	  lesion	  spanning	  the	  gap	  between	  infarcts	  and	  was	  achieved	  in	  all	  10	  animals	  
with	  2-­‐5	  injections	  (Figure	  6-­‐1).	  We	  mapped	  LV	  endocardial	  ±	  epicardial	  voltages	  before	  and	  
after	  MRI	  guided	  chemoablation	  in	  5	  of	  these	  animals.	  Voltage	  maps	  confirmed	  that	  a	  
functional	  ablation	  line	  through	  the	  isthmus	  of	  normal	  myocardium	  was	  successfully	  created	  
in	  all	  5	  animals	  (Figure	  6-­‐1	  and	  Figure	  6-­‐4).	  Voltages	  over	  infarcts	  were	  low	  (0.5-­‐1.5mV),	  but	  
voltages	  over	  chemoablation	  lesions	  were	  even	  lower	  (<0.5mV)	  with	  clearly	  defined	  borders	  
(Figure	  6-­‐5).	  Local	  abnormal	  voltage	  activities	  with	  fragmented	  slow	  conduction	  were	  
abolished	  with	  chemoablation	  (Figure	  6-­‐6).	  	  
6.4.4 Safety	  considerations	  
Chemoablation	  did	  not	  cause	  any	  conduction	  system	  disease	  or	  tachyarrhythmias	  in	  the	  
early	  post-­‐ablation	  period.	  No	  intramyocardial	  hematoma,	  myocardial	  perforation	  or	  
rupture,	  pericardial	  effusion	  or	  tamponade	  occurred.	  Linear	  gadolinium-­‐based	  contrast	  
agents	  (Magnevist	  and	  Ablavar)	  released	  free	  gadolinium	  in	  50%	  acetic	  acid	  solution	  (pH	  1.9)	  
within	  minutes,	  but	  did	  not	  in	  70%	  ethanol	  (pH	  7).	  A	  macrocyclic	  gadolinium-­‐based	  contrast	  
agent	  (gadoterate)	  did	  not	  release	  any	  free	  gadolinium	  after	  60mins	  incubation	  in	  50%	  acetic	  
acid	  (Table	  6-­‐1).	  Chemoablation	  with	  acetic	  acid	  did	  not	  alter	  serum	  pH	  (pre-­‐	  vs.	  post-­‐
procedure,	  7.52	  vs.	  7.57,	  p=0.34)	  or	  anion	  gap	  (15.8	  vs.	  15.1,	  p=24;	  normal	  range	  in	  swine	  
10-­‐25mEq/L).	  
6.5 Discussion	  
In	  this	  study,	  we	  demonstrate	  for	  the	  first	  time	  feasibility	  of	  real-­‐time	  MRI	  guided	  
transcatheter	  myocardial	  chemoablation.	  We	  show	  that	  gadolinium	  doping	  of	  
chemoablative	  agents	  provides	  immediate	  visualization	  of	  lesion	  extent	  and	  continuity.	  
Chemoablation	  lesions	  correlate	  with	  irreversible	  myocardial	  injury	  as	  evidenced	  by	  chronic	  
LGE	  and	  histological	  tissue	  necrosis.	  Acetic	  acid	  creates	  homogeneous	  and	  well-­‐
circumscribed	  lesions	  compared	  with	  ethanol.	  In	  an	  animal	  model	  of	  ischemic	  
cardiomyopathy	  we	  demonstrate	  successful	  substrate-­‐guided	  chemoablation	  of	  a	  
conductive	  isthmus	  between	  two	  infarcts,	  with	  functional	  ablation	  confirmed	  by	  endocardial	  
and	  epicardial	  voltage	  mapping,	  and	  abolition	  of	  local	  abnormal	  voltage	  activities	  in	  areas	  of	  
heterogeneous	  scar.	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6.5.1 Substrate-­‐guided	  ablation	  
Conventional	  electroanatomic	  mapping	  relies	  on	  surface	  voltage	  and	  activation	  maps	  to	  
locate	  arrhythmia	  substrate,	  which	  can	  be	  challenging	  in	  the	  thick-­‐walled	  LV.	  In	  contrast,	  
LGE	  could	  afford	  direct	  visualization	  of	  culprit	  diseased	  myocardium	  for	  targeted	  anatomic	  
substrate-­‐guided	  ablation.	  Areas	  of	  LGE	  correspond	  with	  areas	  of	  low	  endocardial	  voltage	  in	  
patients	  with	  ischemic	  cardiomyopathy170.	  Heterogeneous	  zones,	  which	  are	  a	  complex	  
mixture	  of	  scar	  and	  viable	  myocardium,	  exhibit	  abnormal	  potentials	  more	  frequently	  than	  
dense	  scar	  or	  normal	  myocardium171,	  and	  commonly	  represent	  the	  arrhythmic	  substrate	  in	  
patients	  with	  scar-­‐related	  VT157.	  MRI-­‐based	  computational	  simulation	  with	  identification	  of	  
heterogeneous	  zones	  can	  accurately	  determine	  ablation	  targets172	  and	  may	  be	  used	  to	  
predict	  the	  risk	  of	  VT	  for	  an	  individual	  patient173.	  These	  may	  enable	  entirely	  substrate-­‐guided	  
ablation	  in	  the	  future.	  MRI	  guided	  chemoablation	  could	  also	  be	  used	  to	  ablate	  different	  
structures,	  for	  example	  the	  interventricular	  septum	  in	  patients	  with	  LV	  outflow	  tract	  
obstruction.	  
6.5.2 Endocardial	  vs.	  epicardial	  ablation	  
Endocardial	  radiofrequency	  ablation	  fails	  to	  eliminate	  LV	  epicardial	  arrhythmia	  substrate	  in	  
many	  patients	  174.	  Consequently,	  epicardial	  ablation	  is	  often	  required.	  Sub-­‐xiphoid	  access	  to	  
the	  naïve	  pericardium	  and	  epicardial	  ablation	  cause	  serious	  complications,	  including	  
tamponade,	  abdominal	  haemorrhage	  and	  coronary	  artery	  occlusion	  in	  over	  5%	  of	  patients	  
139.	  Pericardial	  adhesions	  and	  epicardial	  fat	  can	  prevent	  effective	  ablation	  or	  mislead	  the	  
operator	  to	  believe	  that	  effective	  ablation	  has	  been	  achieved	  175.	  In	  contrast,	  transcatheter	  
needle	  chemoablation	  achieves	  full-­‐thickness	  ablation	  from	  the	  endocardial	  surface,	  
avoiding	  the	  need	  for	  epicardial	  access.	  Needle	  catheters	  have	  also	  been	  used	  to	  deliver	  
radiofrequency	  energy	  deeper	  into	  the	  myocardium176.	  
Chemoablation	  is	  not	  dependent	  on	  catheter	  tip	  contact	  force,	  and	  is	  not	  subject	  to	  steam	  
pop	  and	  coagulum	  embolization,	  though	  these	  problems	  appear	  less	  common	  with	  modern	  
irrigated	  radiofrequency	  ablation	  catheters.	  Chemoablation	  is	  unlikely	  to	  be	  subject	  to	  the	  
phenomenon	  of	  reversible	  conduction	  block	  after	  radiofrequency	  ablation,	  because	  it	  does	  
not	  appear	  to	  cause	  an	  oedematous	  penumbra.	  
6.5.3 Choice	  of	  chemoablation	  agent	  
Bioenzymatic	  myocardial	  ablation	  through	  topical	  epicardial	  application	  of	  a	  cellulose	  
sponge	  soaked	  in	  collagenase	  to	  homogenize	  patchy	  scar	  tissue	  has	  been	  described,	  but	  the	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result	  is	  not	  instantaneous	  and	  it	  is	  not	  clear	  whether	  transmural	  penetration	  of	  the	  enzyme	  
is	  achievable177.	  We	  tested	  ethanol	  and	  acetic	  acid,	  the	  two	  most	  commonly	  used	  agents	  for	  
tumour	  chemoablation	  in	  other	  organs.	  Based	  on	  our	  bench	  top	  and	  pre-­‐clinical	  
experiments,	  we	  favoured	  acetic	  acid	  for	  the	  following	  reasons:	  (1)	  it	  has	  been	  used	  safely	  in	  
humans;	  (2)	  it	  achieved	  tissue	  necrosis	  with	  smaller	  injectate	  volumes	  compared	  with	  
ethanol,	  reducing	  the	  risk	  of	  extravasation;	  (3)	  lesions	  within	  the	  myocardium	  were	  more	  
homogenous,	  well-­‐circumscribed	  and	  without	  patchy	  areas	  of	  viable	  tissue,	  an	  observation	  
that	  corroborates	  prior	  reports	  using	  ethanol	  in	  the	  heart165	  and	  other	  organs	  178;	  and	  (4)	  we	  
did	  not	  observe	  a	  change	  in	  serum	  pH	  or	  anion	  gap	  with	  acetic	  acid	  in	  swine.	  We	  confirmed	  
in	  a	  bench	  top	  assay	  that	  a	  macrocyclic	  gadolinium-­‐based	  contrast	  agent	  does	  not	  release	  
free	  gadolinium	  after	  60mins	  incubation	  in	  50%	  acetic	  acid,	  whereas	  a	  linear	  agent	  does	  
within	  minutes.	  Based	  on	  the	  dissociation	  half-­‐lives	  (T1/2)	  at	  low	  pH	  of	  the	  available	  
macrocyclic	  contrast	  agents179,	  we	  recommend	  gadoterate	  (T1/2	  26.4hrs	  at	  pH	  1)	  be	  the	  
contrast	  of	  choice	  for	  chemoablation	  using	  acetic	  acid.	  
6.5.4 Realtime	  MRI	  guided	  catheter	  navigation	  
Co-­‐registration	  of	  previously	  acquired	  computed	  tomography	  or	  MRI	  three-­‐dimensional	  
volumes	  and/or	  electroanatomic	  maps	  can	  be	  used	  to	  enhance	  catheter	  positioning.	  But	  co-­‐
registration	  is	  subject	  to	  errors	  from	  respiration	  and	  cardiac	  motion,	  does	  not	  permit	  real-­‐
time	  monitoring	  of	  lesions,	  and	  cannot	  accommodate	  for	  geometric	  changes	  imparted	  by	  
catheters	  and	  guidewires.	  
For	  device	  visualization	  in	  MRI,	  we	  relied	  on	  passive	  markers	  on	  the	  deflectable	  sheath	  and	  
active	  visualization	  of	  the	  needle	  catheter	  to	  navigate	  and	  target	  chemoablation.	  Using	  real-­‐
time	  MRI,	  needle	  position	  was	  confirmed	  on	  orthogonal	  short	  and	  long	  axis	  planes	  through	  
the	  LV.	  Future	  integration	  of	  needle	  catheters	  with	  MRI-­‐conditional	  electroanatomic	  
mapping	  systems	  that	  track	  catheter	  position	  may	  simplify	  this	  task.	  
6.5.5 Chemoablation	  lesion	  imaging	  
Correlation	  between	  lesion	  volumes	  by	  MRI	  and	  macroscopic	  volumes	  of	  injury	  has	  been	  
evaluated	  for	  radiofrequency	  catheter	  153.	  LGE	  best	  approximates	  macroscopic	  volumes	  of	  
injury,	  but	  T2-­‐weighted	  MRI	  overestimates	  and	  underestimates	  acute	  and	  chronic	  lesion	  
volumes	  respectively.	  Although	  LGE	  may	  enable	  identification	  of	  radiofrequency	  lesions,	  it	  
can	  only	  be	  performed	  once	  per	  procedure	  due	  to	  limitations	  in	  total	  gadolinium	  dose	  and	  
cannot	  distinguish	  between	  true	  necrotic	  core	  and	  oedematous	  penumbra.	  Insufficient	  or	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incomplete	  radiofrequency	  ablation	  likely	  explains	  current	  high	  recurrence	  rates	  after	  VT	  
ablation.	  
Small	  volumes	  of	  solution	  containing	  gadolinium	  injected	  into	  the	  myocardium	  using	  needle	  
catheters	  can	  be	  visualized	  in	  real-­‐time.	  In	  this	  study,	  the	  volume	  of	  lesions	  immediately	  
post-­‐ablation	  correlated	  with	  the	  volume	  of	  LGE	  chronically.	  Extent	  of	  LGE	  correlates	  closely	  
with	  volume	  of	  necrosis180.	  Chemoablation	  lesions	  that	  enhance	  on	  LGE	  imaging	  correspond	  
to	  areas	  of	  myocardial	  necrosis	  and	  fibrosis	  histologically.	  Radiofrequency	  lesion	  size	  can	  
shrink	  by	  up	  to	  50%	  chronically	  compared	  to	  immediately	  post-­‐ablation154.	  This	  
phenomenon	  is	  likely	  caused	  by	  the	  reversible	  radiofrequency-­‐induced	  oedematous	  
penumbra	  around	  the	  true	  necrotic	  core.	  We	  did	  not	  observe	  this	  phenomenon	  with	  acetic	  
acid	  lesions.	  
6.5.6 Isthmus	  ablation	  
Clinical	  usefulness	  of	  this	  technique	  depends	  on	  the	  ability	  to	  target	  specific	  tissues	  that	  can	  
support	  VT.	  We	  demonstrate	  that	  real-­‐time	  MRI	  permits	  precise	  targeting	  of	  chemoablation	  
in	  an	  animal	  model	  of	  ischemic	  cardiomyopathy	  with	  an	  isthmus	  of	  normal	  myocardium	  
between	  two	  areas	  of	  infarction.	  We	  demonstrate	  the	  ability	  to	  create	  chemoablation	  
lesions	  confluent	  with	  the	  two	  infarcts,	  resulting	  in	  electroanatomic	  mapping	  confirmed	  
disruption	  of	  the	  conductive	  isthmus.	  
6.5.7 Limitations	  
This	  was	  a	  preclinical	  feasibility	  study	  and	  we	  did	  not	  perform	  a	  head-­‐to-­‐head	  comparison	  of	  
chemo	  versus	  radiofrequency	  ablation.	  However,	  the	  limitations	  of	  radiofrequency	  ablation	  
in	  the	  thick-­‐walled	  LV	  are	  well	  recognized.	  Despite	  the	  advent	  of	  irrigation-­‐tip	  catheters	  to	  
enable	  longer	  ablations,	  needle-­‐tip	  electrodes	  to	  facilitate	  deeper	  delivery	  of	  radiofrequency	  
energy176	  or	  contact	  force-­‐sensing	  catheters	  to	  improve	  delivery	  of	  radiofrequency	  energy	  to	  
the	  myocardium181,	  procedural	  success	  rates	  remain	  low	  –	  almost	  certainly	  due	  to	  
incomplete	  ablation.	  Porcine	  models	  of	  hemodynamically	  stable	  VT	  are	  difficult	  to	  create	  
and	  for	  this	  reason	  we	  did	  not	  test	  ability	  of	  chemoablation	  to	  terminate	  arrhythmia.	  
However,	  chemoablation	  did	  abolish	  late	  and	  fractionated	  electrograms	  within	  and	  around	  
infarcted	  areas	  suggesting	  that	  critical	  substrate	  was	  eliminated.	  Recent	  data	  suggests	  that	  
elimination	  of	  late	  potentials	  is	  at	  least	  as	  strong	  a	  predictor	  of	  freedom	  from	  VT	  in	  patients	  
as	  non-­‐inducibility	  182,	  183.	  
Equipping	  an	  MRI	  suite	  for	  interventional	  procedures	  require	  additional	  infrastructure,	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including	  communication	  headsets,	  video	  projectors,	  and	  hemodynamic	  monitoring	  
system15.	  Although	  there	  are	  no	  commercially	  available	  injection	  catheters	  for	  use	  in	  MRI,	  
these	  are	  currently	  in	  development.	  Although	  we	  selected	  acetic	  acid,	  we	  recognize	  that	  
alternative	  agents	  may	  be	  suitable	  for	  clinical	  use.	  We	  anticipate	  that	  if	  a	  small	  quantity	  of	  
acetic	  acid	  reaches	  the	  blood	  pool	  (e.g.	  by	  tracking	  along	  the	  needle	  tract),	  it	  will	  be	  
immediately	  diluted	  and	  metabolized.	  
Many	  patients	  with	  VT	  have	  implantable	  cardioverter	  defibrillators	  that	  usually	  would	  
disqualify	  them	  from	  undergoing	  a	  MRI	  scan.	  MRI-­‐conditional	  devices	  are	  increasingly	  
common	  and	  patients	  with	  these	  newer	  devices	  would	  be	  eligible	  for	  MRI	  guided	  
chemoablation.	  Nevertheless,	  implanted	  devices	  and	  leads	  can	  cause	  imaging	  artefacts,	  
which	  could	  obscure	  target	  tissue	  and	  ablation	  lesions.	  
6.6 Conclusion	  
This	  is	  the	  first	  report	  of	  real-­‐time	  MRI	  guided	  transcatheter	  myocardial	  chemoablation.	  MRI	  
enables	  instantaneous	  visualization	  of	  arrhythmic	  substrate	  and	  real-­‐time	  monitoring	  of	  
irreversible	  ablation	  lesions.	  Acetic	  acid	  creates	  more	  homogenous	  and	  well-­‐circumscribed	  
ablation	  lesions	  compared	  with	  ethanol.	  Unlike	  radiofrequency	  energy,	  endocardial	  needle	  
chemoablation	  achieves	  fully	  transmural	  and	  irreversible	  ablation	  lesions.	  We	  demonstrate	  
feasibility	  of	  conductive	  isthmus	  ablation	  with	  abolition	  of	  local	  abnormal	  voltage	  activities	  
in	  an	  animal	  model	  of	  ischemic	  cardiomyopathy.	  MRI	  guided	  chemoablation	  could	  improve	  
procedural	  success	  of	  VT	  ablation.	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6.7 Figures	  
	  
Figure	  6-­‐1:	  MRI	  guided	  chemoablation	  of	  a	  conductive	  isthmus	  
(A)	  Baseline	  LGE	  showing	  two	  infarcts	  (green	  arrows)	  with	  isthmus	  of	  normal	  myocardium	  
(black	  arrow).	  (B)	  Real-­‐time	  MRI	  guided	  chemoablation.	  The	  active	  visualization	  injection	  
needle	  appears	  in	  green.	  (C)	  LGE	  after	  chemoablation	  showing	  infarcts	  (green	  arrows)	  and	  
transmural	  chemoablation	  lesion	  (red	  arrow).	  (D)	  After	  7	  days,	  ex-­‐vivo	  high-­‐resolution	  MRI	  
confirms	  transmural	  chemoablation	  lesion	  (red	  arrow)	  confluent	  with	  both	  infarcts	  (green	  
arrows).	  (E)	  Wide-­‐field	  Masson	  trichrome	  stain	  of	  a	  section	  through	  the	  heart	  in	  the	  same	  
orientation	  as	  panels	  A,	  C	  and	  D.	  Normal	  myocardium	  appears	  pink,	  necrotic	  myocardium	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appears	  purple	  and	  fibrotic	  tissue	  appears	  blue.	  (F)	  The	  operator	  wears	  a	  noise-­‐cancelling	  
headset	  for	  communication	  with	  staff	  in	  the	  control	  room.	  Real-­‐time	  magnetic	  resonance	  
images	  and	  hemodynamics	  are	  displayed	  in	  the	  room.	  (G)	  Endocardial	  voltage	  maps	  at	  
baseline	  showing	  normal	  amplitude	  electrograms	  throughout	  the	  conductive	  isthmus.	  (H)	  
Post-­‐chemoablation,	  a	  band	  of	  very	  low	  (<0.5mV	  white	  box)	  voltages	  interrupts	  the	  isthmus.	  
Black	  lines	  represent	  the	  margins	  of	  the	  original	  infarcts.	  LGE:	  late	  gadolinium	  enhancement;	  
MRI:	  magnetic	  resonance	  imaging.	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Figure	  6-­‐2:	  Ablation	  imaging	  and	  histology	  
(A)	  Real-­‐time	  MRI	  during	  chemoablation.	  The	  active	  visualization	  injection	  needle	  appears	  
green	  (arrow).	  (B)	  Real-­‐time	  inversion-­‐recovery	  MRI	  reduces	  signal	  from	  normal	  tissue,	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highlighting	  chemoablation	  lesions	  containing	  gadolinium	  contrast	  (arrow).	  (C)	  Macroscopic	  
appearance	  of	  an	  acute	  lesion,	  which	  has	  been	  butterflied	  open.	  The	  dotted	  line	  marks	  
lesion	  margins.	  (D)	  Histology	  of	  acute	  lesion	  with	  H&E	  stains	  (400x	  and	  600x	  magnification).	  
Affected	  myocardial	  fibres	  are	  hypereosinophilic	  with	  mild	  to	  moderately	  pyknotic	  nuclei	  
(black	  arrows).	  Dotted	  line	  marks	  border	  between	  chemoablation	  lesion	  and	  normal	  
myocardium.	  (E)	  LGE	  and	  (F)	  ex	  vivo	  high	  resolution	  MRI	  of	  a	  chronic	  lesion	  after	  systemic	  
gadolinium	  contrast	  administration.	  (G)	  Macroscopically,	  chronic	  lesions	  have	  well	  
circumscribed	  margins	  (marked	  with	  dotted	  line).	  (H)	  Histology	  of	  a	  chronic	  lesion	  with	  
trichrome	  stain	  (20x	  and	  200x	  magnification).	  Collagen	  stains	  blue,	  normal	  myocardial	  fibres	  
stain	  red	  and	  necrotic	  myocardial	  fibres	  stain	  purple.	  LGE:	  late	  gadolinium	  enhancement;	  
MRI:	  magnetic	  resonance	  imaging.	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Figure	  6-­‐3:	  Ethanol	  vs.	  acetic	  acid	  
(A)	  Macroscopic	  appearance	  after	  fixing	  in	  formalin	  of	  70%	  ethanol	  0.2mL(*),	  0.4mL(**)	  and	  
0.6mL(***)	  injections.	  (B)	  Trichrome	  stain	  of	  0.6mL	  ethanol	  lesion	  (20x	  magnification).	  
Lesion	  has	  stellate	  geometry	  with	  patchy	  areas	  of	  normal	  myocardium	  within	  the	  ablation	  
field	  (black	  arrows).	  (C)	  Macroscopic	  appearance	  of	  50%	  acetic	  acid	  0.2mL(*),	  0.4mL(**)	  and	  
0.6mL(***)	  injections.	  (D)	  Trichrome	  stain	  of	  0.4mL	  acetic	  acid	  lesion	  (20x	  magnification).	  
Lesion	  is	  homogeneous	  with	  well-­‐circumscribed	  border	  and	  no	  patchy	  areas	  of	  normal	  
myocardium	  are	  seen	  within	  the	  ablation	  field.	   	  
Page	  124	  of	  242	  
	  
Figure	  6-­‐4:	  Left	  ventricular	  endocardial	  electroanatomic	  mapping	  before	  and	  after	  
chemoablation	  in	  an	  animal	  model	  of	  ischemic	  cardiomyopathy	  
(A)	  Baseline	  endocardial	  voltage	  map	  demonstrates	  low	  voltages	  corresponding	  with	  the	  
diagonal	  infarct	  (Diag)	  and	  an	  adjacent	  heterogeneous	  area	  corresponding	  with	  the	  obtuse	  
marginal	  infarct	  (OM).	  Purple	  represents	  normal	  voltages	  (>1.5mV)	  and	  grey	  represents	  very	  
low	  voltages	  (<0.5mV).	  (B)	  Baseline	  epicardial	  map	  demonstrates	  two	  distinct	  areas	  of	  low	  
voltage	  separated	  by	  an	  isthmus	  of	  normal	  conduction.	  (C)	  Baseline	  three-­‐dimensional	  scar	  
map	  derived	  from	  high-­‐resolution	  ex-­‐vivo	  MRI	  shows	  infarct	  (pink).	  The	  LV	  cavity	  appears	  in	  
purple	  and	  the	  left	  atrium	  in	  green.	  (D)	  Post-­‐chemoablation	  endocardial	  voltage	  map	  
demonstrates	  low	  voltages	  with	  abolition	  of	  the	  heterogeneous	  area	  between	  the	  two	  
infarcts.	  (E)	  Post-­‐chemoablation	  epicardial	  map	  confirmed	  interruption	  of	  the	  conductive	  
isthmus.	  (F)	  The	  chemoablation	  lesion	  (arrow)	  appears	  in	  red	  and	  is	  confluent	  with	  the	  
infarcts.	  LGE:	  late	  gadolinium	  enhancement;	  MRI:	  magnetic	  resonance	  imaging.	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Figure	  6-­‐5:	  Scar	  border	  geometry	  
(A)	  Epicardial	  voltage	  map	  showing	  the	  duo-­‐decapolar	  mapping	  catheter	  spanning	  the	  
chemoablation	  lesion.	  (B)	  Three-­‐dimensional	  scar	  map	  derived	  from	  high-­‐resolution	  ex-­‐vivo	  
MRI	  showing	  catheter	  position	  relative	  to	  pre-­‐existing	  infarct	  (pink)	  and	  chemoablation	  
lesion	  (red).	  The	  left	  ventricular	  cavity	  appears	  in	  purple	  and	  the	  left	  atrium	  in	  green.	  (C)	  
Electrograms	  from	  individual	  catheter	  electrodes	  demonstrate	  low	  voltages	  (0.5-­‐1.5mV)	  
over	  the	  pre-­‐existing	  infarct	  borders	  (white	  boxes),	  and	  (D)	  extremely	  low	  voltages	  (<0.5mV)	  
over	  the	  chemoablation	  lesion	  (white	  box).	  LGE:	  late	  gadolinium	  enhancement;	  MRI:	  
magnetic	  resonance	  imaging.	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Figure	  6-­‐6:	  Abolition	  of	  abnormal	  electrocardiograms	  with	  chemoablation	  
(A-­‐B)	  At	  baseline,	  endocardial	  and	  epicardial	  mapping	  demonstrates	  local	  abnormal	  voltage	  
activities	  (LAVA)	  with	  fragmented	  slow	  conduction	  between	  the	  infarcts.	  (C-­‐D)	  After	  
chemoablation,	  LAVA	  are	  abolished.	  Very	  low	  amplitude	  and	  complete	  absence	  of	  far-­‐field	  
electrograms	  remain	  on	  endocardial	  and	  epicardial	  mapping	  respectively.	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   15	   20	  
Gadopentatate	   2%	   15	   40	  
5%	   15	   42	  
Gadoterate	   2%	   15	   <LOD	  
5%	   15	   <LOD	  
2%	   30	   <LOD	  
5%	   30	   <LOD	  
2%	   60	   <LOD	  
5%	   60	   <LOD	  
Table	  6-­‐1:	  Concentration	  of	  free	  Gd3+	  in	  50%	  acetic	  acid	  solution	  with	  2%	  or	  5%	  
gadolinium-­‐based	  contrast	  agent	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Chapter	  7. Conclusions	  and	  future	  directions	  
7.1 Conclusions	  
Diagnostic	  cardiac	  catheterization	  using	  only	  CMR	  guidance	  is	  a	  clinical	  reality	  in	  a	  small	  but	  
growing	  number	  of	  institutions.	  Now	  that	  good	  solutions	  for	  hemodynamic	  monitoring,	  
communication	  between	  staff,	  and	  interactive	  manipulation	  of	  real-­‐time	  images	  are	  
available	  commercially,	  it	  is	  relatively	  straightforward	  to	  equip	  a	  standard	  MRI	  scanner	  for	  
invasive	  procedures.	  A	  number	  of	  simple	  cardiovascular	  interventions	  have	  been	  
demonstrated	  in	  early	  clinical	  trials	  over	  the	  last	  decade.	  The	  main	  limitation	  to	  widespread	  
adoption	  remains	  paucity	  of	  available	  devices	  and	  in	  particular	  guidewires,	  without	  which	  
interventions	  are	  not	  feasible.	  However,	  a	  number	  of	  MRI-­‐conditional	  guidewires	  are	  in	  
development	  or	  are	  already	  in	  early	  clinical	  trials	  in	  Europe.	  If	  they	  prove	  safe,	  MRI	  
conspicuous	  and	  have	  the	  required	  mechanical	  properties,	  then	  cautious	  introduction	  of	  
increasingly	  complex	  CMR	  guided	  cardiovascular	  interventions	  should	  be	  possible	  in	  the	  
near	  future.	  
It	  would	  be	  wrong	  to	  suggest	  that	  CMR	  should	  replace	  all	  other	  imaging	  modalities	  for	  all	  
applications.	  CMR	  guided	  coronary	  interventions	  for	  example,	  are	  not	  realistic	  because	  the	  
spatial	  resolution	  of	  real-­‐time	  CMR	  is	  insufficient	  and	  vastly	  inferior	  to	  fluoroscopy.	  Rather,	  
the	  focus	  of	  interventional	  CMR	  research	  should	  be	  on	  two	  fronts:	  (1)	  improving	  safety	  and	  
efficacy	  of	  existing	  interventions	  for	  which	  current	  imaging	  is	  inadequate;	  and	  (2)	  developing	  
new	  interventions	  that	  are	  not	  feasible	  using	  X-­‐ray	  or	  echocardiography.	  The	  novel	  
interventions	  described	  in	  this	  thesis	  address	  both	  of	  these	  objectives.	  Intentional	  right	  atrial	  
exit	  and	  CO2	  insufflation	  reduces	  complication	  from	  sub-­‐xiphoid	  access	  to	  the	  naïve	  
pericardium.	  Transthoracic	  direct	  left	  atrial	  access	  enables	  delivery	  of	  large	  mitral	  valve	  
implants	  without	  injuring	  the	  left	  ventricular	  myocardium.	  Real-­‐time	  CMR	  guided	  myocardial	  
needle	  chemoablation	  is	  a	  completely	  new	  approach	  to	  arrhythmia	  substrate	  ablation	  in	  the	  
ventricle	  and	  could	  be	  used	  to	  ablate	  other	  structures	  (e.g.	  the	  interventricular	  septum	  or	  
intracardiac	  tumours	  causing	  obstruction	  to	  blood	  flow).	  Transatrial	  intrapericardial	  tricuspid	  
annuloplasty	  is	  a	  much-­‐needed	  therapy	  for	  a	  clinical	  problem	  for	  which	  there	  is	  currently	  no	  
solution	  other	  than	  open	  chest	  surgery.	  
The	  value	  of	  CMR	  in	  the	  development	  process	  does	  not	  mean	  that	  CMR	  will	  necessarily	  be	  
the	  preferred	  imaging	  guidance	  modality	  for	  clinical	  translation	  of	  these	  novel	  interventions.	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X-­‐ray	  fluoroscopy	  and	  echocardiography	  are	  widely	  available	  in	  most	  cardiac	  catheterization	  
laboratories,	  whereas	  very	  few	  hospitals	  currently	  have	  interventional	  CMR	  capability.	  The	  
investment	  to	  build	  interventional	  CMR	  cath	  labs	  is	  substantial	  and	  many	  of	  the	  simple	  tools	  
we	  take	  for	  granted	  in	  the	  X-­‐ray	  cath	  lab	  (e.g.	  commodity	  guidewires	  and	  catheters)	  are	  not	  
yet	  commercially	  available.	  For	  this	  reason,	  we	  tested	  whether	  transatrial	  intrapericardial	  
tricuspid	  annuloplasty	  (TRAIPTA),	  intentional	  right	  atrial	  exit	  and	  CO2	  insufflation,	  and	  
transthoracic	  direct	  left	  atrial	  access	  could	  be	  performed	  using	  a	  combination	  of	  X-­‐ray	  
fluoroscopy,	  echocardiography,	  rotational	  angiography,	  or	  fusion	  imaging,	  and	  without	  the	  
need	  for	  CMR.	  Indeed,	  whereas	  we	  used	  real-­‐time	  MRI	  to	  titrate	  TRAIPTA	  implant	  tension	  in	  
the	  animal	  experiments,	  in	  clinic	  we	  would	  expect	  tensioning	  to	  be	  performed	  under	  3D	  
echocardiography	  guidance	  and	  titrated	  to	  reduce	  tricuspid	  regurgitation.	  Measuring	  the	  
volume	  of	  pericardial	  effusion	  with	  MRI	  after	  withdrawal	  of	  a	  right	  atrial	  appendage	  catheter	  
would	  be	  unnecessary	  in	  clinic,	  as	  a	  sub-­‐xiphoid	  drain	  would	  evacuate	  accumulating	  
pericardial	  fluid.	  Rotational	  angiography	  could	  confirm	  lung	  displacement	  prior	  to	  direct	  left	  
atrial	  needle	  entry	  and	  fusion	  imaging	  could	  provide	  sufficient	  anatomical	  landmarks	  to	  plan	  
optimal	  trajectories.	  
Nonetheless,	  CMR	  played	  a	  critical	  role	  in	  the	  development	  process	  for	  these	  novel	  
interventions.	  Assessing	  the	  dynamic	  impact	  of	  TRAIPTA	  tension	  on	  atrioventricular	  
geometry	  would	  have	  been	  difficult	  –	  if	  not	  impossible	  –	  without	  the	  cross-­‐sectional	  
capability	  of	  real-­‐time	  MRI.	  Accurately	  measuring	  pericardial	  effusion	  volume	  serially	  and	  
non-­‐invasively	  for	  intentional	  right	  atrial	  exit	  would	  have	  been	  equally	  challenging.	  Without	  
the	  ability	  to	  characterize	  the	  geometric	  impact	  of	  single	  lung	  deflation	  and	  determine	  the	  
optimal	  trajectories	  for	  transthoracic	  left	  atrial	  access,	  it	  would	  not	  have	  been	  possible	  to	  
refine	  this	  procedure.	  More	  than	  any	  other,	  transthoracic	  direct	  left	  atrial	  access	  illustrates	  
the	  value	  of	  CMR	  in	  the	  development	  process.	  The	  complexity	  of	  this	  procedure,	  with	  a	  
needle	  trajectory	  that	  crosses	  and	  passes	  by	  a	  number	  of	  critical	  anatomic	  structures,	  
required	  imaging	  in	  multiple	  planes	  with	  clear	  soft	  tissue	  depiction.	  Neither	  X-­‐ray	  
fluoroscopy	  nor	  echocardiography	  can	  provide	  this,	  and	  so	  there	  is	  no	  doubt	  in	  my	  mind	  that	  
this	  intervention	  would	  not	  have	  been	  conceivable	  without	  CMR	  guidance.	  However,	  once	  
we	  had	  tested	  and	  refined	  the	  procedural	  steps	  using	  CMR,	  it	  was	  then	  possible	  to	  replicate	  
the	  intervention	  using	  X-­‐ray	  with	  augmented	  imaging	  (e.g.	  rotational	  angiography).	  In	  a	  way,	  
CMR	  served	  as	  the	  testing	  and	  training	  ground	  so	  that	  we	  could	  determine	  how	  to	  perform	  
the	  procedure	  using	  more	  conventional	  and	  widely	  available	  imaging	  modalities.	  In	  contrast,	  
MRI-­‐guided	  myocardial	  chemoablation	  is	  a	  clear	  example	  where	  CMR	  is	  a	  truly	  disruptive	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technology.	  It	  is	  not	  conceivable	  to	  perform	  this	  procedure	  using	  X-­‐ray	  or	  echocardiography	  
because	  neither	  affords	  the	  soft	  tissue	  characterization	  capability	  of	  MRI.	  
The	  interventions	  described	  in	  this	  thesis	  therefore	  illustrate	  how	  CMR	  can	  add	  value	  to	  
different	  stages	  of	  the	  innovation	  process.	  While	  some	  of	  these	  novel	  interventions	  should	  
be	  performed	  from	  start	  to	  finish	  using	  CMR	  guidance,	  others	  are	  better	  suited	  to	  clinical	  
translation	  using	  more	  conventional	  imaging	  modalities.	  For	  these	  interventions,	  CMR	  
served	  mainly	  to	  support	  device	  development,	  testing	  and	  technical	  refinement.	  An	  
underutilized	  tool	  in	  interventional	  cardiology,	  I	  hope	  that	  this	  thesis	  will	  encourage	  others	  
to	  embrace	  this	  powerful	  and	  enabling	  imaging	  tool	  to	  develop	  novel	  cardiovascular	  
interventions	  in	  the	  future.	  
7.2 Future	  directions	  
Translating	  these	  novel	  cardiovascular	  interventions	  into	  humans	  requires	  a	  number	  of	  
steps.	  Most	  importantly,	  clinical	  grade	  MRI-­‐conditional	  or	  MRI-­‐safe	  devices	  are	  needed.	  This	  
requires	  engagement	  of	  industry	  and	  regulatory	  agencies.	  In	  the	  last	  decade,	  a	  number	  of	  
medical	  device	  manufacturers	  specialising	  in	  interventional	  MRI	  applications	  have	  emerged	  
and	  have	  built	  fruitful	  collaborations	  with	  academic	  institutions	  in	  Europe	  and	  the	  United	  
States.	  
Transatrial	  intrapericardial	  tricuspid	  annuloplasty	  is	  currently	  the	  subject	  of	  a	  collaborative	  
research	  and	  development	  contract	  between	  the	  National	  Institutes	  of	  Health	  and	  Cook	  
Medical	  in	  the	  United	  States.	  The	  goal	  of	  this	  collaboration	  is	  to	  develop	  a	  clinical	  grade	  
device	  for	  first-­‐in-­‐man	  testing.	  
Intentional	  right	  atrial	  exit	  and	  CO2	  insufflation	  has	  already	  been	  tested	  in	  humans	  
undergoing	  left	  atrial	  appendage	  ligation.	  We	  are	  collaborating	  with	  several	  
electrophysiologists	  in	  the	  United	  States	  to	  use	  this	  technique	  to	  facilitate	  pericardial	  access	  
for	  ventricular	  tachycardia	  epicardial	  ablation.	  
Since	  publication	  of	  the	  manuscript,	  we	  have	  tested	  transthoracic	  left	  atrial	  access	  using	  X-­‐
ray	  fluoroscopy	  guidance	  in	  human	  cadavers	  in	  collaboration	  with	  the	  structural	  heart	  team	  
at	  Henry	  Ford	  Hospital	  in	  Detroit,	  Michigan.	  The	  focus	  of	  these	  subsequent	  experiments	  was	  
firstly	  to	  learn	  to	  perform	  the	  procedure	  using	  X-­‐ray	  projection	  imaging,	  and	  secondly	  to	  
determine	  the	  optimal	  approach	  for	  surgical	  bailout	  in	  case	  a	  complication	  occurs	  during	  the	  
percutaneous	  intervention.	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Real-­‐time	  MRI	  guided	  myocardial	  chemoablation	  was	  developed	  in	  collaboration	  with	  St	  
Jude	  Medical,	  who	  provided	  support	  for	  electroanatomic	  mapping.	  Two	  medical	  device	  
manufacturers	  have	  been	  awarded	  contracts	  by	  the	  National	  Institutes	  of	  Health	  in	  the	  
United	  States	  to	  build	  clinical	  needle	  injection	  catheters	  for	  first-­‐in-­‐man	  testing	  under	  an	  
Investigational	  Device	  Exemption	  (IDE)	  clinical	  protocol.	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Chapter	  8. Appendices	  
8.1 Patent	  applications	  
8.1.1 Devices	  and	  methods	  for	  treating	  functional	  tricuspid	  regurgitation	  
International	  patent	  application	  published	  on	  2nd	  October	  2014.	  
Inventors:	  Robert	  J.	  Lederman,	  Kanishka	  Ratnayaka	  and	  Toby	  Rogers.	  
Describes	  devices	  and	  methods	  for	  treating	  functional	  tricuspid	  regurgitation	  through	  
transcatheter	  delivery	  of	  circumferential	  devices	  that	  lie	  along	  the	  atrioventricular	  groove,	  
imparting	  selective	  compression	  to	  the	  tricuspid	  annulus.	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8.1.2 Encircling	  implant	  delivery	  systems	  and	  methods	  
International	  patent	  application	  published	  on	  the	  18th	  December	  2014.	  
Inventors:	  Toby	  Rogers,	  Robert	  J.	  Lederman,	  Merdim	  Sonmez,	  Dominique	  N.	  Franson	  and	  
Ozgur	  Kocaturk.	  
Describes	  transcatheter	  devices	  and	  methods	  to	  encircle	  an	  anatomic	  structure	  (e.g.	  the	  
heart)	  and	  deliver	  a	  circumferential	  device	  that	  can	  be	  tightened	  to	  impart	  compression	  to	  
the	  anatomic	  structure	  resulting	  in	  geometric	  change.	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8.2 Transatrial	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